
<html lang="en"     class="pb-page"  data-request-id="db00a294-62ea-438d-993a-4b857d8463ec"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-3;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.7b01598;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases" /></meta><meta name="dc.Creator" content="Michael L.  Vazquez" /></meta><meta name="dc.Creator" content="Neelu  Kaila" /></meta><meta name="dc.Creator" content="Joseph W.  Strohbach" /></meta><meta name="dc.Creator" content="John D.  Trzupek" /></meta><meta name="dc.Creator" content="Matthew F.  Brown" /></meta><meta name="dc.Creator" content="Mark E.  Flanagan" /></meta><meta name="dc.Creator" content="Mark J.  Mitton-Fry" /></meta><meta name="dc.Creator" content="Timothy A.  Johnson" /></meta><meta name="dc.Creator" content="Ruth E.  TenBrink" /></meta><meta name="dc.Creator" content="Eric P.  Arnold" /></meta><meta name="dc.Creator" content="Arindrajit  Basak" /></meta><meta name="dc.Creator" content="Steven E.  Heasley" /></meta><meta name="dc.Creator" content="Soojin  Kwon" /></meta><meta name="dc.Creator" content="Jonathan  Langille" /></meta><meta name="dc.Creator" content="Mihir D.  Parikh" /></meta><meta name="dc.Creator" content="Sarah H.  Griffin" /></meta><meta name="dc.Creator" content="Jeffrey M.  Casavant" /></meta><meta name="dc.Creator" content="Brian A.  Duclos" /></meta><meta name="dc.Creator" content="Ashley E.  Fenwick" /></meta><meta name="dc.Creator" content="Thomas M.  Harris" /></meta><meta name="dc.Creator" content="Seungil  Han" /></meta><meta name="dc.Creator" content="Nicole  Caspers" /></meta><meta name="dc.Creator" content="Martin E.  Dowty" /></meta><meta name="dc.Creator" content="Xin  Yang" /></meta><meta name="dc.Creator" content="Mary Ellen  Banker" /></meta><meta name="dc.Creator" content="Martin  Hegen" /></meta><meta name="dc.Creator" content="Peter T.  Symanowicz" /></meta><meta name="dc.Creator" content="Li  Li" /></meta><meta name="dc.Creator" content="Lu  Wang" /></meta><meta name="dc.Creator" content="Tsung H.  Lin" /></meta><meta name="dc.Creator" content="Jason  Jussif" /></meta><meta name="dc.Creator" content="James D.  Clark" /></meta><meta name="dc.Creator" content="Jean-Baptiste  Telliez" /></meta><meta name="dc.Creator" content="Ralph P.  Robinson" /></meta><meta name="dc.Creator" content="Ray  Unwalla" /></meta><meta name="dc.Description" content="Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis. ..." /></meta><meta name="Description" content="Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis. ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 23, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01598" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01598" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01598" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01598" /></link>
        
    
    

<title>Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01598" /></meta><meta property="og:title" content="Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0017.jpeg" /></meta><meta property="og:description" content="Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis. As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling. Our efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis. Through modification of the 3-aminopiperidine linker in tofacitinib, we discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay. Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by X-ray crystallographic analysis. After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clinical candidate for the treatment of JAK1-mediated autoimmune diseases." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis. As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling. Our efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis. Through modification of the 3-aminopiperidine linker in tofacitinib, we discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay. Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by X-ray crystallographic analysis. After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clinical candidate for the treatment of JAK1-mediated autoimmune diseases." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0017.jpeg" /></meta><meta name="twitter:title" content="Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01598"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01598">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01598&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01598&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01598&amp;href=/doi/10.1021/acs.jmedchem.7b01598" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 1130-1152</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01558" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01630" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+L.++Vazquez">Michael L. Vazquez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-6244-6540" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neelu++Kaila">Neelu Kaila</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+W.++Strohbach">Joseph W. Strohbach</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+D.++Trzupek">John D. Trzupek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+F.++Brown">Matthew F. Brown</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+E.++Flanagan">Mark E. Flanagan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+J.++Mitton-Fry">Mark J. Mitton-Fry</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+A.++Johnson">Timothy A. Johnson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ruth+E.++TenBrink">Ruth E. TenBrink</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â¶</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eric+P.++Arnold">Eric P. Arnold</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arindrajit++Basak">Arindrajit Basak</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven+E.++Heasley">Steven E. Heasley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Soojin++Kwon">Soojin Kwon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan++Langille">Jonathan Langille</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mihir+D.++Parikh">Mihir D. Parikh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+H.++Griffin">Sarah H. Griffin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+M.++Casavant">Jeffrey M. Casavant</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+A.++Duclos">Brian A. Duclos</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ashley+E.++Fenwick">Ashley E. Fenwick</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+M.++Harris">Thomas M. Harris</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Seungil++Han">Seungil Han</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicole++Caspers">Nicole Caspers</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+E.++Dowty">Martin E. Dowty</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Yang">Xin Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary+Ellen++Banker">Mary Ellen Banker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Hegen">Martin Hegen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter+T.++Symanowicz">Peter T. Symanowicz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Li">Li Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lu++Wang">Lu Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tsung+H.++Lin">Tsung H. Lin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Jussif">Jason Jussif</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+D.++Clark">James D. Clark</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Baptiste++Telliez">Jean-Baptiste Telliez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ralph+P.++Robinson">Ralph P. Robinson</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-4066-5299" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ray++Unwalla">Ray Unwalla</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-5789-7336" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Medicine Design, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Medicine Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">Â§</span> <span class="aff-text">Chemical Research Development, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">â¥</span> <span class="aff-text">Medicine Design, Pfizer Inc, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">#</span> <span class="aff-text">Inflammation and Immunology, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">â¥</span> <span class="aff-text">Veterinary Medicine Research and Development, Pfizer Inc, 333 Portage Street, Kalamazoo, Michigan 49007, United States</span></div><div class="aff-info" id="aff7"><span class="aff-symbol">Â¶</span> <span class="aff-text">Medicinal Chemistry, Pfizer Inc, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#1765767b677f3967396578757e796478795767717e6d72653974787a"><span class="__cf_email__" data-cfemail="e391828f938bcd93cd918c818a8d908c8da393858a998691cd808c8e">[emailÂ protected]</span></a></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#87f5e6fea9f2e9f0e6ebebe6c7f7e1eefde2f5a9e4e8ea"><span class="__cf_email__" data-cfemail="384a5941164d564f5954545978485e51425d4a165b5755">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01598&amp;href=/doi/10.1021%2Facs.jmedchem.7b01598" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 1130â1152</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 3, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 October 2017</li><li><span class="item_label"><b>Published</b> online</span>23 January 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 February 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01598" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01598</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1130%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMichael%2BL.%2BVazquez%252C%2BNeelu%2BKaila%252C%2BJoseph%2BW.%2BStrohbach%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D3%26contentID%3Dacs.jmedchem.7b01598%26title%3DIdentification%2Bof%2BN-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2B%2528PF-04965842%2529%253A%2BA%2BSelective%2BJAK1%2BClinical%2BCandidate%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1152%26publicationDate%3DFebruary%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01598"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5381</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">35</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01598" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;L. Vazquez&quot;},{&quot;first_name&quot;:&quot;Neelu&quot;,&quot;last_name&quot;:&quot;Kaila&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;W. Strohbach&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;D. Trzupek&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;F. Brown&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;E. Flanagan&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;J. Mitton-Fry&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;A. Johnson&quot;},{&quot;first_name&quot;:&quot;Ruth&quot;,&quot;last_name&quot;:&quot;E. TenBrink&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;P. Arnold&quot;},{&quot;first_name&quot;:&quot;Arindrajit&quot;,&quot;last_name&quot;:&quot;Basak&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;E. Heasley&quot;},{&quot;first_name&quot;:&quot;Soojin&quot;,&quot;last_name&quot;:&quot;Kwon&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;Langille&quot;},{&quot;first_name&quot;:&quot;Mihir&quot;,&quot;last_name&quot;:&quot;D. Parikh&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;H. Griffin&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;M. Casavant&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;A. Duclos&quot;},{&quot;first_name&quot;:&quot;Ashley&quot;,&quot;last_name&quot;:&quot;E. Fenwick&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;M. Harris&quot;},{&quot;first_name&quot;:&quot;Seungil&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Nicole&quot;,&quot;last_name&quot;:&quot;Caspers&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;E. Dowty&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Ellen Banker&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Hegen&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;T. Symanowicz&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Lu&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Tsung&quot;,&quot;last_name&quot;:&quot;H. Lin&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Jussif&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;D. Clark&quot;},{&quot;first_name&quot;:&quot;Jean-Baptiste&quot;,&quot;last_name&quot;:&quot;Telliez&quot;},{&quot;first_name&quot;:&quot;Ralph&quot;,&quot;last_name&quot;:&quot;P. Robinson&quot;},{&quot;first_name&quot;:&quot;Ray&quot;,&quot;last_name&quot;:&quot;Unwalla&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;1130-1152&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01598&quot;},&quot;abstract&quot;:&quot;Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis. As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling. Our efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis. Through modification of the 3-aminopiperidine linker in tofacitinib, we discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay. Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by X-ray crystallographic analysis. After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clinical candidate for the treatment o&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01598&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01598" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01598&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01598" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01598&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01598" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01598&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01598&amp;href=/doi/10.1021/acs.jmedchem.7b01598" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01598" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01598" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26pmid%3D29298069%26genre%3Darticle%26aulast%3DVazquez%26date%3D2018%26atitle%3DIdentification%2Bof%2BN-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2B%2528PF-04965842%2529%253A%2BA%2BSelective%2BJAK1%2BClinical%2BCandidate%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D3%26spage%3D1130%26epage%3D1152%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290716" title="Sulfones">Sulfones</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/3" title="Go to Volume 61, Issue 3"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/jmcmar.2018.61.issue-3/20180208/jmcmar.2018.61.issue-3.largecover.jpg" alt="Go to Volume 61, Issue 3"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis. As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling. Our efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis. Through modification of the 3-aminopiperidine linker in tofacitinib, we discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay. Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by X-ray crystallographic analysis. After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (<b>25</b>) was nominated as a clinical candidate for the treatment of JAK1-mediated autoimmune diseases.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22540" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22540" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> There are four members of the Janus kinase family: JAK1, JAK2, JAK3, and TYK2. A cytokine binding to its receptor initiates the dimerization or multimerization of receptor units. JAKs associated with the receptor subunits are brought into proximity, resulting in their phosphorylation and activation. The activated JAKs in turn phosphorylate specific tyrosine residues within the intracellular domain of the cytokine receptor. These phosphorylated tyrosine residues create docking sites for the recruitment and phosphorylation of signal transducers and activators of transcription (STAT) proteins. Subsequently, the STATs dimerize and translocate to the cell nucleus where they modulate gene expression.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">JAK1 has the broadest cytokine signaling profile among the JAK family members and is the only isoform that pairs with the other three JAKs. In combination with JAK3, which pairs only with JAK1, it regulates the signaling of the gamma common (Î³<sub>c</sub>) cytokines. JAK1 pairing specifically with JAK2 regulates signaling of type II interferon (IFNÎ³). JAK1 paired with TYK2 regulates signaling of type I interferons (IFNÎ±, IFNÎ²) and the IL-10 family of cytokines.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Additionally, when paired with JAK2 or TYK2, JAK1 regulates signaling of gp130-containing receptors (including the prototypic cytokine IL-6 receptor) as well as signaling through the granulocyte macrophage colony-stimulating factor (GM-CSF) receptor.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> JAK1-independent cytokines include IL-12 and IL-23, whose receptors signal via JAK2 and TYK2. JAK2 is the only member of the family that pairs with itself, regulating signals for various cytokines and growth factors including IL-3, IL-5, GM-CSF, EPO, and TPO.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> There are no redundant pathways known for cytokines that signal through the JAKs, and many of these cytokines have been implicated in a number of autoimmune diseases, making them attractive drug targets.<a onclick="showRef(event, 'cit1e ref6'); return false;" href="javascript:void(0);" class="ref cit1e ref6">(1e, 6)</a></div><div class="NLM_p">Tofacitinib (<b>1</b>) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), a JAK1/JAK3 inhibitor with moderate activity on JAK2, and baricitinib (<b>2</b>), a JAK1/JAK2 inhibitor, are approved for the treatment of rheumatoid arthritis (RA).<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Ruxolitinib (<b>3</b>), which inhibits both JAK1 and JAK2, is approved for the treatment of primary myelofibrosis (PMF).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Tofacitinib and baricitinib are also in clinical trials for other autoimmune indications.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Because these compounds have activity against JAK2, the potential for anemia and thrombocytopenia exists because of interference with EPO and TPO signaling. In phase 2 dose ranging studies, reduction in hemoglobin was observed in patients treated with baricitinib and tofacitinib.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Tofacitinib (<b>1</b>), baricitinib (<b>2</b>), and ruxolitinib (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On the basis of human genetic data, the loss of JAK3 function through mutation results in severe combined immunodeficiency (SCID) due to the loss in signaling of the Î³<sub>c</sub> cytokines.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The SCID clinical phenotype resulting from JAK3 inactivating mutations is essentially identical to the X-linked SCID phenotype resulting from inactivating mutations in the Î³<sub>c</sub> receptor chain.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> As such, JAK3 has been a target of interest for the treatment of transplant rejection and other immune disorders including RA. Because inhibition of transplant rejection was a focus during the initial drug discovery program leading to the discovery of tofacitinib, JAK3 was of particular interest because of its role in controlling common Î³-chain cytokine signaling and because of its known expression, which is restricted to lymphoid cells.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> However, with the development of improved kinase assays, the pan-JAK (i.e., nonselective) inhibitory nature of tofacitinib within the JAK family was ultimately revealed and with it the recognition that JAK1 inhibition is a major contributor to its pharmacology.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In light of these findings, we initiated a program to discover and develop a potent and selective JAK1 inhibitor.<a onclick="showRef(event, 'ref2 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref2 ref15 ref16">(2, 15, 16)</a> As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding the inhibition of the JAK2 homodimer regulating EPO and TPO signaling and other cytokines.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Herein we describe the identification and characterization of a novel series of potent and orally bioavailable small molecule inhibitors of JAK1, along with our efforts at achieving the desired JAK1/JAK2 selectivity that allowed identification of a clinical candidate.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18833" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18833" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Screening Strategy</h3><div class="NLM_p">Literature accounts reporting kinase selectivity typically use the ratio of biochemical IC<sub>50</sub>âs determined at the <i>K</i><sub>m</sub> for ATP. These selectivity ratios are misleading for kinases with dissimilar ATP <i>K</i><sub>m</sub> values and when extrapolating data to cellular settings.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> JAK1 (<i>K</i><sub>m</sub> = 40 Î¼M) has a <i>K</i><sub>m</sub> for ATP about 10-fold higher than that for JAK2 (4 Î¼M) and JAK3 (4 Î¼M) and about 3-fold higher than that for TYK2 (12 Î¼M). When tofacitinib is assayed at a physiologically relevant concentration of ATP (1 mM), JAK1 and JAK2 potencies are decreased when compared to data obtained at ATP concentrations equal to their respective <i>K</i><sub>m</sub>âs. Because of these differences in <i>K</i><sub>m</sub> for ATP, there is a greater potency reduction for JAK2 with its higher affinity for ATP and, as a result, tofacitinib becomes 5-fold more potent for JAK1 than JAK2 at physiological ATP levels. Importantly, the higher potency of tofacitinib inhibition of JAK1 over JAK2 also translates into more potent inhibition of cytokines such as IFNÎ±, which are JAK1-dependent and JAK2-independent, over cytokines such as EPO that are solely JAK2-dependent.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Differences in the <i>K</i><sub>m</sub> for ATP may also come into play when assessing selectivity across the kinome as kinases with lower <i>K</i><sub>m</sub> values may appear to have greater activity (biochemical) but may not translate into functional (cellular) assays which are determined at physiologic ATP levels.</div><div class="NLM_p">When assessing JAK selectivity, the human cytokine inhibition profile in patients is most relevant. However, determination of this required modeling of human whole blood (HWB) potencies onto projected human pharmacokinetics, not a quick and inexpensive analysis to routinely conduct on all project compounds. Clinical data suggested that maximizing JAK1 selectivity over JAK2 in HWB is required to reduce the risk of hematopoietic effects.<a onclick="showRef(event, 'ref16 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref19">(16, 19)</a> Thus, we routinely generated IC<sub>50</sub>âs for IFNÎ± stimulation in HWB (JAK1) and CD34+ cells spiked into HWB (JAK2) and measured the inhibition of phosphorylation of various STATs following stimulation. These values correlated well with the biochemical enzyme assays conducted at 1 mM ATP.</div><div class="NLM_p last">To identify compounds with a high probability of demonstrating in vivo selectivity for JAK1 versus JAK2, we aimed for an in vitro selectivity window (biochemical or HWB) of â¼25-fold and human liver microsome (HLM) stability of â¼8 Î¼L/min/mg or lower for desirable in vitro clearance.<a onclick="showRef(event, 'cit20a'); return false;" href="javascript:void(0);" class="ref cit20a">(20a)</a> These values were chosen to allow for uncertainties in the cellular assays and in the translation of the dynamic range of HLM measurements to in vivo clearance. Compounds which met these criteria were selected for advancement into pharmacokinetic and efficacy studies.</div></div><div id="sec2-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Lead Analogs: Replacing the Tofacitinib 3-Aminopiperidine Group</h3><div class="NLM_p">In our efforts to develop highly selective JAK1 inhibitors, we noted that tofacitinib (<b>1</b>) has excellent overall kinome selectivity<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and attributed much of this beneficial characteristic to the pyrrolopyrimidine hinge-binding motif. Therefore, we opted to retain the pyrrolopyrimidine while a variety of diamine linkers were systematically evaluated as alternatives to the tofacitinib 3-aminopiperidine group. The terminal amino group was capped to obtain a variety of amide and sulfonamide derivatives. As a consequence of this survey, we observed that sulfonamides bearing a <i>cis</i>-1,3-cyclobutane diamine linker tended to confer not only excellent potency in the low nanomolar range but more importantly excellent selectivity within the JAK family. Interestingly, unlike the 3-aminopiperidine group in <b>1</b>, capping the <i>cis</i>-1,3-cyclobutane diamine with an amide group resulted in compounds possessing JAK1 activity in the micromolar range (data not shown), significantly less active than the sulfonamide analogs. One of the hits, phenylsulfonamide <b>4</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), possessed remarkable potency (JAK1 IC<sub>50</sub> = 6 nM) and selectivity (69-fold over JAK2) when assayed at an ATP concentration of 1 mM. Although HLM clearance of this compound was high (58 Î¼L/min/mg), we felt that we would be able to improve metabolic stability by appropriate substitution and reduction of lipophilicity (logâ¯<i>D</i>). The initial cohort of alkyl sulfonamides <b>5</b>â<b>8</b> demonstrated potency and, importantly, a concomitant increase in JAK1 selectivity as the sulfonamide alkyl group increased in size. Even the simple methanesulfonamide <b>5</b> possessed good potency and selectivity for JAK1 (IC<sub>50</sub> = 90 nM; 14-fold selective over JAK2), suggesting that the sulfonamide series has an inherent potency and selectivity advantage for JAK1. Additionally, the alkyl sulfonamides <b>5</b>â<b>8</b> possessed reasonable metabolic stability as measured by HLM. The trifluoroethyl analog <b>8</b> was interesting in that JAK1 potency was â¼8-fold higher than the ethyl analog <b>6</b>, but selectivity over JAK2 was not improved. Analog <b>9</b>, bearing a <i>p</i>-fluorophenyl sulfonamide, exhibited high JAK1 potency and selectivity versus JAK2 (JAK1 IC<sub>50</sub> = 3 nM; 80-fold selectivity over JAK2), but unfortunately, like <b>4</b>, metabolic stability (39 Î¼L/min/mg) was poor. Potency was somewhat reduced for the benzylsulfonamide <b>10</b> (JAK1 IC<sub>50</sub> = 92 nM) and, like the phenyl sulfonamides, this compound suffered from high HLM (24 Î¼L/min/mg) clearance.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Biological and Physical Properties of Sulfonamide Pyrrolopyrimidine Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0013.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All compounds were assayed at 1 mM ATP at least twice, and the IC<sub>50</sub> values were averaged, with the exception of compound <b>10</b> (<i>n</i> = 1).</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">All compounds were assayed at least twice, and the IC<sub>50</sub> values were averaged.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">In vitro stability in cyropreserved human liver microsomes.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Logâ¯<i>D</i> measured between octanol/water phosphate buffered to pH 7.4.</p></div></div><div></div></div><div class="NLM_p">On the basis of their excellent potency and high selectivity, further optimization efforts focused on the phenylsulfonamides. However, in spite of their impressive activity, extensive modifications to the aryl ring did not result in analogs with acceptable clearance, and they were not pursued further (data not shown). All compounds were assessed against JAK3 and TYK2 in a biochemical assay. The majority of the sulfonamide analogs did not possess significant activity for JAK3 (IC<sub>50</sub>âs â¼ 8 uM to >10 uM) and showed only modest activity against TYK2 (IC<sub>50</sub>âs > 200 nM) (Table S1 in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p">Analogs <b>4</b>â<b>10</b> were evaluated in a HWB assay using IFNÎ± as stimulant to assess JAK1 potency in a cellular system. We also evaluated <b>5</b>â<b>9</b> in a HWB assay to which we added CD34<sup>+</sup> cells and used EPO as stimulant to assess JAK2 potency.<a onclick="showRef(event, 'ref14 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref18">(14, 18)</a> A general observation was made that the HWB potency was right-shifted 5- to 35-fold from the biochemical assay and the shift roughly correlated with logâ¯<i>D</i> of the compounds. In general, we attributed this to plasma protein binding (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_001.pdf" class="ext-link">Figure S2</a>). In addition, the JAK2/JAK1 selectivity ratios in HWB were similar to those derived from the biochemical assays, but with a trend toward being slightly more JAK1-selective. Also potentially contributing to the potency shift was use of the truncated kinase domain in the biochemical assay, whereas in the HWB assay, the full length kinase is present in its native cellular environment at physiologic ATP levels. For these reasons we recognized that the HWB assays were most relevant for translating selectivity from in vitro to in vivo.</div><div class="NLM_p last">With these results and the initial evaluation of sulfonamides <b>4</b>â<b>10</b> in hand, it became apparent that smaller, lower logâ¯<i>D</i> compounds would be more likely to possess all of the properties required to advance a molecule to the clinic, and we therefore focused our efforts on analogs with small alkyl analogs in place of the aryl group in <b>10.</b></div></div><div id="sec2-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Sulfonamide Replacements</h3><div class="NLM_p">Beyond exploration of different sulfonamide derivatives, we also evaluated variants of the sulfonyl-containing linker, namely sulfamides, sulfones, and âreverse sulfonamidesâ (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Biological and Physical Properties of Sulfamide, Sulfone, and Reverse Sulfonamide Pyrrolopyrimidine Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0014.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All compounds were assayed at 1 mM ATP at least twice, and the IC<sub>50</sub> were averaged.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">All compounds were assayed at least twice, and the IC<sub>50</sub> values were averaged.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">In vitro stability in cyropreserved human liver microsomes.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Logâ¯<i>D</i> measured between octanol/water phosphate buffered to pH 7.4.</p></div></div><div></div></div><div class="NLM_p">Sulfamide analogs <b>11</b>â<b>15</b> possessed small alkyl groups and exhibited JAK1 potencies (IC<sub>50</sub>âs) ranging from 51 to 144 nM with 8â24-fold selectivity over JAK2. The ethyl (<b>11</b>), propyl (<b>12</b>), and cyclopropyl (<b>13</b>) analogs had modest potency, but their selectivities were lower, suggesting that shorter alkyl groups in sulfamides do not make efficient interactions with JAK1. Extending the cyclopropyl group by a methylene gave <b>14</b>, which improved the JAK1 potency (IC<sub>50</sub> = 51 nM) and increased JAK2 selectivity to 21-fold. HLM clearances for <b>12</b> and <b>14</b> were good, but reduced metabolic stability was noted when larger, more lipophilic alkyl groups were employed to increase potency and selectivity. Thus, analog <b>15</b> incorporating a nitrile was prepared to introduce polarity into the alkyl chain and lower logâ¯<i>D</i>. The choice of nitrile as a polar function was based on the reported favorable interaction of the nitrile in <b>1</b> with the backbone atoms of the residues of the P-loop, i.e. Gly831, Gly834 of JAK3.<a onclick="showRef(event, 'cit20b'); return false;" href="javascript:void(0);" class="ref cit20b">(20b)</a> However, although <b>15</b> exhibited a good metabolic stability and selectivity profile, no enhancement in JAK1 potency was observed.</div><div class="NLM_p">Sulfones <b>16</b>â<b>20</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) exhibited improved JAK1 potencies relative to the sulfamides; however, selectivities against JAK2 were not improved. The ethyl analog <b>16</b> (JAK1 IC<sub>50</sub> = 57 nM) was approximately 3-fold more potent than the related sulfamide <b>11</b> and about equipotent to the cyclopropyl analog <b>17</b>. While an improvement in potency was observed with the <i>n</i>-propyl analog <b>18</b>, a more significant increase in potency was observed with the longer <i>n</i>-butyl analog <b>19</b> (IC<sub>50</sub> = 9 nM), which possessed an improved JAK2 selectivity of 24-fold. This was the first analog to show significant JAK1 selectivity while also having high potency and modest HLM clearance (14 Î¼L/min/mg). We assessed the potency of the sulfones in the HWB assays, and although there was some variability in the right shift, HWB activities were largely in line with biochemical activity. The <i>n</i>-butyl analog <b>19</b> displayed excellent activity against IFNÎ± (IC<sub>50</sub> = 155 nM) and good selectivity versus EPO (IC<sub>50</sub> = 4089 nM). We prepared phenyl analog <b>20</b> to assess potency and clearance within an aryl sulfone motif. As previously noted with phenylsulfonamide <b>4</b>, the JAK1 potency was exceptional (10 nM), but HLM clearance was high (20 Î¼L/min/mg). Unlike <b>4</b>, which showed good selectivity over JAK2 (69-fold), <b>20</b> displayed no advantage in terms of selectivity, which was reduced to 16-fold.</div><div class="NLM_p">The low nanomolar potency previously observed with the sulfonamides and sulfones was again observed with reverse sulfonamides <b>21</b>â<b>24</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). For a similar logâ¯<i>D</i> range, the clearance was comparable to that of the other analogs. However, desirable potency and selectivity levels required introduction of larger alkyl groups as in <b>23</b> for which HLM clearance increased from moderate to a high level.</div><div class="NLM_p">Observations from compounds <b>4</b>â<b>24</b> indicated that, for all variants of the sulfonyl-containing linker, selectivity generally improved as the side chains grew larger. Although based on a limited number of examples, the sulfamide subset was of lower interest as these compounds possessed the poorest overall JAK1 potency. A comparison of the JAK1/JAK2 selectivity ratios of sulfonamides to sulfones and reverse sulfonamides suggested that the sulfonamides were capable of achieving the best selectivities for JAK1: 39-fold for isobutyl analog <b>7</b> and 80-fold for <i>p</i>-fluorophenyl analog <b>9</b>. Selectivity peaked at about 24-fold for the other series containing similar alkyl and aryl groups. We also observed a trend that suggested HLM clearance values were often >8.0 Î¼L/min/mg when logâ¯<i>D</i><sub>7.4</sub> exceeded 2.0. On the basis of these observations, the alkyl sulfonamide series appeared to provide the best balance of potency and clearance. We thus prepared an additional cohort of alkyl sulfonamides (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Biological and Physical Properties of Sulfonamide Pyrrolopyrimidine Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0015.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">All compounds were assayed at 1 mM ATP least twice, and the IC<sub>50</sub> values were averaged.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">All compounds were assayed at least twice, and the IC<sub>50</sub> values were averaged.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">In vitro stability in cyropreserved human liver microsomes.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Logâ¯<i>D</i> measured between octanol/water phosphate buffered to pH 7.4.</p></div></div><div></div></div><div class="NLM_p">In order to determine the impact of stereochemistry on potency and selectivity, the 1,3-<i>trans</i>-cyclobutyl analog of <b>25</b> was prepared and evaluated. Whereas the <i>cis</i>-configured isomer <b>25</b> showed good potency (JAK1 IC<sub>50</sub> = 29 nM), the <i>trans</i> isomer <b>26</b> suffered a â¼20-fold loss in potency. Because the JAK2 IC<sub>50</sub> of <b>26</b> was greater than that of the top screening concentration, we were unable to determine its JAK2/JAK1 selectivity ratio.</div><div class="NLM_p">The addition of a methyl to give <i>n</i>-butyl analog <b>27</b> resulted in a â¼3-fold increase in potency relative to <b>25</b>, the expected increase for a nonspecific hydrophobic interaction of methyl with a protein.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> However, this addition increased logâ¯<i>D</i> to 2.4, resulting in a concomitant increase in HLM clearance to 17 Î¼L/min/mg. The incorporation of cyclopropyl rings as in <b>28</b> and <b>29</b> did not afford an improvement in potency or selectivity over the simple linear analogs <b>25</b> and <b>27</b>, but the reduced logâ¯<i>D</i> of the cyclopropyl group did improve HLM clearance. In contrast, cyclobutylmethyl analog <b>30</b>, which did not afford a reduction in logâ¯<i>D</i>, demonstrated improved potency and selectivity but displayed higher clearance. The incorporation of trifluoromethyl within the side chain to improve metabolic stability was successful as analogs <b>31</b> and <b>32</b> maintained JAK1 potency and low clearance (<8.0 Î¼L/min/mg) while displaying increased selectivity (54-fold and 61-fold, respectively). The ether analogs <b>33</b> and <b>34</b> were weaker in potency but retained low clearance when compared to the trifluoromethyl analogs.</div><div class="NLM_p">In the HWB assays, the simple alkyl analogs <b>25</b>â<b>30</b> had potency shifts in the biochemical assay similar to the earlier sulfonamide cohort, while the groups containing heteroatoms <b>31</b>â<b>34</b> appeared to have greater right shifts than would be expected based on logâ¯<i>D</i> alone. For example, compound <b>31</b>, which has a similar logâ¯<i>D</i> value and JAK1 biochemical potency comparable to that of <b>30</b>, shows a larger right shift (63- vs 20-fold for <b>30</b>) in the HWB IFNÎ± assay. The right shift in the HWB CD34+ EPO assay was more variable but generally agreed with the magnitude of the right shift observed in the IFNÎ± assay.</div><div class="NLM_p last">At this stage we were pleased that several compounds, especially sulfonamides <b>25</b>, <b>28</b>, and <b>29</b>, exhibited promising overall profiles including good JAK1 potency (biochemical and HWB INFÎ± IC<sub>50</sub> â¤ 0.05 Î¼M and â¤0.3 Î¼M respectively), good JAK1/JAK2 selectivity (â¥25-fold), and high in vitro metabolic stability (HLM â¤ 9 Î¼L/min/mg). Although HLM clearance for sulfone <b>19</b> was somewhat higher (â¼14 Î¼L/min/mg), its profile was also attractive in terms of potency (JAK1 IC<sub>50</sub> = 9 nM) and selectivity (24-fold). When sulfonamides <b>25</b>, <b>28</b>, and <b>29</b> were compared, compound <b>25</b> was the most selective based on ratios determined using HWB IC<sub>50</sub> values (38-fold vs 22- and 29-fold for <b>28</b> and <b>29</b>, respectively). Thus, representing two structural series (sulfones and sulfonamides), compounds <b>19</b> and <b>25</b> were selected for further profiling from among the analogs shown in <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>â<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> (vide infra).</div></div><div id="sec2-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> X-ray Crystallographic Studies: Understanding JAK1/JAK2 Selectivity</h3><div class="NLM_p">While initial compound synthesis and evaluation was in progress, we developed a robust crystallographic soaking method enabling the routine determination of JAK1 inhibitor structures.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Notably, we determined the X-ray structure of compound <b>25</b> in complex with the kinase domains of JAK1 (2.1 Ã) and JAK2 (1.8 Ã). This effort built upon our knowledge of these important tyrosine kinases and provided invaluable insight into the observed JAK1/JAK2 selectivity (28-fold) of compound <b>25</b>.</div><div class="NLM_p">The overall folds of the two kinase domains are similar to those previously reported<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (RMSD â¼ 0.80 Ã). Although the JAK1 kinase domain shares only 53% overall sequence identity with JAK2, most of the residues in the ATP-binding site are conserved between the two enzymes. The residue differences (within 5 Ã radius from the ligand) are located in the hinge region, phosphate-binding region, i.e., P-loop (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) and in the solvent exposed regions toward the periphery of the binding site. While at first these differences may seem sufficient for a ligand to achieve a high level of selectivity, these residues point away from the ligand; hence, they are not amenable for direct hydrogen bonding contacts with the ligand. There is one exception, the Glu966(JAK1)/Asp939(JAK2) residue difference that lies toward the solvent-exposed region of the binding site (<a class="ref internalNav" href="#fig2" aria-label="Figures 2">Figures 2</a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). This difference has been specifically targeted in the literature for a differential hydrogen bonding interaction with favorable improvement in JAK1 selectivity (36-fold).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> This observation was supported by cocrystal structures of both JAK1 and JAK2 that indeed revealed differential interaction between the two isoforms. Additionally, Vasbinder and co-workers observed water-mediated hydrogen bonds between Glu966 and a potent JAK1-selective inhibitor.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Residues Differences with Their Location in the Kinase Domain of JAK1 and JAK2 Structures</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">location in the kinase domain</th><th class="colsep0 rowsep0" align="center">JAK1</th><th class="colsep0 rowsep0" align="center">JAK2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hinge</td><td class="colsep0 rowsep0" align="left">Phe958</td><td class="colsep0 rowsep0" align="left">Tyr931</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hinge</td><td class="colsep0 rowsep0" align="left">Ser961</td><td class="colsep0 rowsep0" align="left">Tyr934</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hinge</td><td class="colsep0 rowsep0" align="left">Lys965</td><td class="colsep0 rowsep0" align="left">Arg938</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hinge</td><td class="colsep0 rowsep0" align="left">Glu966</td><td class="colsep0 rowsep0" align="left">Asp939</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-loop</td><td class="colsep0 rowsep0" align="left">Glu883</td><td class="colsep0 rowsep0" align="left">Lys857</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-loop</td><td class="colsep0 rowsep0" align="left">His885</td><td class="colsep0 rowsep0" align="left">Asn859</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-loop</td><td class="colsep0 rowsep0" align="left">Lys888</td><td class="colsep0 rowsep0" align="left">Ser862</td></tr></tbody></table></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure of <b>25</b> in complex with JAK1. The ligand <b>25</b> is shown in yellow. Hydrogen bond interactions of the core pyrrolopyrimidine ring with hinge residues Leu959, Glu957, and the NH group with Asn1008 are highlighted in red. The structure is of sufficient resolution (2.1 Ã) to observe a bound water molecule (light pink) hydrogen bonded to N-3 of the core ring and in position to form hydrogen bond with Glu966 residue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of <b>25</b> in complex with JAK2. The ligand <b>25</b> is shown in magenta. Hydrogen bond interactions of the core pyrrolopyrimidine ring with hinge residues Leu932, Glu930, and the NH group with Asn981 and Arg980 are highlighted in red. The structure is of sufficient resolution (1.8 Ã) to observe a bound water molecule (light pink) hydrogen bonded to N-3 of the core ring and in position to form hydrogen bond to Asp939 through a network of water molecules. For clarity, the network of water molecules is not depicted. Another water molecule is also observed forming hydrogen bond interaction with the sulfur atom of the ligand and the NH backbone of the Lys857 residue in the P-loop.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Comparison of the crystal structures of <b>25</b> bound to both JAK1 and JAK2 showed that although the ligand binding mode is similar in both cases, there are subtle differences in hydrogen bonding pattern with residues within the binding site and in the orientation of the propyl tail group in the P-loop region that could contribute to the JAK1 selectivity. The core pyrrolopyrimidine ring of the ligand in both structures makes two critical hinge binding interactions, the pyrrole NH with the carbonyl backbone of Glu957(JAK1)/Glu930(JAK2) and the pyrimidine N1 nitrogen with the NH backbone of Leu959(JAK1)/Leu932(JAK2) residues.</div><div class="NLM_p">There are other differences in the structures that we believe contribute to overall ligand selectivity, for example, a water molecule is in position to bridge a hydrogen bond interaction between the N3 of the pyrimidine ring and the side chain Glu966 residue in JAK1. In JAK2, because of the shorter Asp939 residue at this position, a direct water-mediated bridge interaction is not possible and requires an extended network of water molecules in the solvent-exposed region to make interaction with the N3 atom. Although the extent to which this differential interaction contributes to selectivity is difficult to predict, these differences in the hydrogen bonding pattern could have influence on the JAK1 selectivity of <b>25</b>.</div><div class="NLM_p">In both structures, the observed conformation of the sulfonamide group has the HâNâSâO dihedral at 1â10Â°. A search of this fragment in the Cambridge Crystallographic Database<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> indicated that this is a preferred conformation for this group. It is believed that this conformation allows the nitrogen lone pair to favorably interact with the sulfur d-orbitals. The <i>cis</i> configuration of the puckered cyclobutyl ring allows the NH of the sulfonamide to be in a position to pick up hydrogen bond interactions with both the backbone carbonyl of Arg1007(JAK1)/Arg980(JAK2) and also the side chain of Asn1008(JAK1)/Asn981(JAK2) in both structures. We did observe differences in the rotamer states of the Arg residue, for example, in the JAK2 X-ray structure, a single rotamer was observed for the Arg980 residue which allows a hydrogen bond from the side chain of Arg980 to the SO<sub>2</sub> group of the ligand. In JAK1, this particular rotamer is observed only as a minor state. Additionally in JAK2, there is a water-mediated hydrogen bond observed between oxygen of the SO<sub>2</sub> group and NH backbone of the Lys857 residue in the P-loop which could influence the flexibility of the P-loop. This will be discussed in detail below.</div><div class="NLM_p">A difference in the orientation of the <i>n</i>-propyl group of the ligand toward the P-loop region was observed when comparing the two JAK structures. In both structures the electron densities of the P-loop and ligand were well-resolved, which aided general conclusions on the origin of ligand selectivity from this region. A comparison of the crystal structures of <b>25</b> bound to JAK1 and JAK2 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>) suggested that the P-loop in JAK2 is clamped down slightly more onto the active site than the one observed in the relatively more open JAK1 P-loop. It is possible that although the side chains of residues within the P-loop region are oriented away from the ligand binding site, the residue differences between the JAK1 and JAK2 (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) along the P-loop may still affect the rigidity of the P-loop and allow different conformations to be accessed by JAK1 compared to JAK2. A shift in the P-loop position observed between the JAK1 and JAK2 X-ray structures has been previously invoked to explain the selectivity of a series of imidazopyrrolopyridines.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Orientations of the P-loops in JAK1 (cyan) and JAK2 (green) in the ligand <b>25</b> bound X-ray structures. The JAK1 bound ligand is shown in yellow, while the JAK2 bound ligand is shown in magenta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As a consequence of the disparate P-loop orientations, the ligand is forced to adopt different conformations in the bound states for the two torsion angles, i.e., S(O<sub>2</sub>)âCâCâC and NâS(O<sub>2</sub>)âCâC, in order to maximize its shape and electrostatic complimentarity with the P-loop. To get a better understanding of the energetics associated with these dihedrals, we calculated the torsion profile using the simple fragment <i>N</i>-methylpropane-1-sulfonamide in a quantum mechanical calculation at the B3LYP/6-31++G level<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a,b). For both dihedrals, two minima are observed, i.e., anti and gauche, with the anti being lower in energy. In the JAK1 structure, the ligand adopts a low-energy anti conformation for the propyl chain, i.e., S(O<sub>2</sub>)âCâCâC dihedral â¼175Â°, while in JAK2 a higher-energy (Î<i>E</i> = 1.2 kcal/mol) conformation exists having a dihedral of â¼95Â°. In contrast, the observed torsional angle NâS(O<sub>2</sub>)âCâC is in a high-energy (Î<i>E</i> = 3.2 kcal/mol) conformation in JAK1 (dihedral of 126Â°), while a lower-energy dihedral (171Â°) is seen in JAK2. These calculations suggest that, in both ligand bound states, an internal energy penalty is paid by the ligand to adopt a conformation that makes efficient van der Waals and electrostatic interactions with the P-loop. While the overall energy penalty is calculated to be higher in JAK1, the ligand seems able to overcome the conformational penalty from the NâS(O<sub>2</sub>)âCâC torsion by forming more favorable van der Waals contacts with the P-loop, thus improving JAK1 selectivity. This is consistent with the observed trend of an increase in selectivity with larger alky groups as these are able to make better P-loop interactions in JAK1 than JAK2, i.e., <b>5</b> (14-fold), <b>6</b> (>19-fold), <b>25</b> (28-fold), and <b>27</b> (66-fold).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Torsional profile of the dihedral (a) S(O<sub>2</sub>)âCâCâC and (b) NâS(O<sub>2</sub>)âCâC calculated from B3LYP/6-31++G basis set. Green and blue arrows indicate observed dihedrals in the X-ray bound state of <b>25</b> in JAK1 and JAK2, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Structure-Enlightened âSecond Generationâ Analog Design</h3><div class="NLM_p">Based on insights provided from the X-ray crystallography studies and analysis, a number of new analogs were prepared in the sulfamide, sulfonamide, and reverse sulfonamide series (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Biological and Physical Properties of âSecond Generationâ Pyrrolopyrimidine Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0016.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">All compounds were assayed at 1 mM ATP least twice, and the IC<sub>50</sub> values were averaged.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">All compounds were assayed at least twice, and the IC<sub>50</sub> values were averaged.</p></div><div class="footnote" id="t5fn3"><sup>Table c</sup><p class="last">In vitro stability in cyropreserved human liver microsomes.</p></div><div class="footnote" id="t5fn4"><sup>Table d</sup><p class="last">Logâ¯<i>D</i> measured between octanol/water phosphate buffered to pH 7.4.</p></div></div><div></div></div><div id="sec2-5-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Sulfamides</h4><div class="NLM_p">As noted previously, the observed conformation of sulfonamide <b>25</b> has an HâNâSâO dihedral<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> of â¼10Â°, which allows for the stabilization of this rotamer by the nitrogen lone pair interaction with the sulfur d orbitals. We reasoned that, in the case of sulfamides, the distal NH (i.e., NH furthest from the pyrrolopyrimidine ring) would form a similar interaction with the other S=O group, giving rise to an s-<i>cis</i>, s<i>-trans</i> conformation (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>a). Indeed, a search of the Cambridge Crystallographic Database for acyclic sulfamides revealed a strong preference for this conformation. All 21 CSD entries from the search displayed a preference for the s<i>-cis</i>, s<i>-trans</i> conformation (for example, see <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>b). Interestingly, this conformational preference implies that, in the bound state, the ligand would favor the proximal NH in an s<i>-cis</i> configuration so as to make hydrogen bond interactions with both the backbone carbonyl of Arg1007(JAK1)/Arg980(JAK2) and the side chain of Asn1008(JAK1)/Asn981(JAK2), while the distal NH would be favored in an <i>s-trans</i> conformation. This would have the undesirable effect of orienting the R-group away from the P-loop and thus have a detrimental effect on JAK1 potency. We reasoned that this was a possible explanation for the lower potency and selectivity observed with the sulfamides <b>11</b>â<b>15</b>. We hypothesized that <i>N</i>-alkylation of the distal sulfamide nitrogen would disrupt the conformational preference of the distal NâHâSâO group and thereby allow the R-group to make an interaction with the P-loop and potentially improve potency. Indeed, <i>N-</i>methyl analogs <b>37</b> and <b>38</b> exhibited a 4â7-fold increase in potency for JAK1 over the nonmethylated analogs <b>11</b> and <b>13</b>, respectively, and >2-fold increase in JAK1/JAK2 selectivity (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). This was attributed to the asymmetric nature of the substituents on the distal nitrogen that allows the alkyl group, i.e., ethyl in <b>37</b> and cyclopropyl in <b>38</b>, to be directed toward the P-loop. We also prepared symmetrical piperidine <b>39</b>, which retained JAK1 potency and demonstrated improved JAK2/JAK1 selectivity. Unfortunately, <b>37</b> and <b>38</b> still lacked the desired selectivity, while <b>39</b> had poor HWB potency and HLM stability. Thus, in spite of the improvements in potency and selectivity, the overall profiles were not improved.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Conformational preference for sulfamides. N<sup>1</sup> showing the s-<i>cis</i> relationship with the oxygen of the sulfone (shown in bold), while N<sup>2</sup> has a s-<i>trans</i> relationship with that same oxygen. (b) Example from a CSD entry (HIXNUX) showing the s-<i>cis</i> and s-<i>trans</i> relationship in sulfamides. Both nitrogens have pyramidal character.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On the basis of the mixed results seen with these second-generation sulfamides, no further advancement of the compounds was undertaken, and we focused our efforts on the sulfonamide and reverse sulfonamide analogs.</div></div><div id="sec2-5-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Sulfonamides</h4><div class="NLM_p last">Applying insight from our structural studies indicating that the sulfonamide NH group is an important determinant of JAK1 selectivity and that interaction of the alkyl group with the P-loop contributes to potency and selectivity, sulfonamides containing polar functionality were prepared (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). The choice of polar groups was based on the reported interaction of the nitrile in <b>1</b> with the P-loop of JAK3 to confer high potency. Compound <b>35</b> containing the nitrile functionality was potent and metabolically stable and had excellent selectivity. Its potency in the HWB IFNÎ± assay (IC<sub>50</sub> = 216 nM) was in a desirable range and was well-separated from HWB EPO (IC<sub>50</sub> > 6934 nM). The oxetane <b>36</b> had a similar profile, demonstrating excellent potency and selectivity in the HWB assays and high metabolic stability. Although only slightly more potent than the acyclic ether <b>34</b> in the JAK1 biochemical assay, the logâ¯<i>D</i> was reduced by 0.5, which may account in part for the 4-fold improvement in HWB IFNÎ± potency.</div></div><div id="sec2-5-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Reverse Sulfonamides</h4><div class="NLM_p last">On the basis of the success with distal <i>N</i>-methylation in the sulfamide series, we prepared additional <i>N</i>-methyl reverse sulfonamides having the potential for improvements in potency and selectivity through interactions with the P-loop. Analogs <b>41</b> and <b>42</b> (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>) showed the expected improvements in JAK1 potency and selectivity versus JAK2 when compared to the corresponding NH analogs <b>23</b> and <b>24</b>. These results are comparable in magnitude to those observed with the sulfamides. Cyclopropylmethyl analog <b>42</b> demonstrated good HWB IFNÎ± potency but suffered from poor metabolic stability. Once again we introduced symmetry to improve selectivity and prepared the pyrrolidine sulfonamide <b>43</b> as a cyclized version of <i>n</i>-butyl sulfonamide <b>23</b>. The potency was modestly improved, but selectivity was reduced, likely due to the smaller size of the unsubstituted 5-membered ring and resulting weaker interaction with the P-loop. In this cohort, high selectivity was associated with poor metabolic stability, although HWB activity was acceptable for several analogs.</div></div></div><div id="sec2-6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pharmacokinetics</h3><div class="NLM_p">On the basis of JAK1 potency (biochemical and HWB), JAK1/JAK2 selectivity, and acceptable in vitro metabolic stability, second generation sulfonamides <b>35</b> and <b>36</b> (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>) were selected for pharmacokinetic profiling along with sulfone <b>19</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) and sulfonamide <b>25</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Pharmacokinetic parameters were determined in rats at 1 mg/kg iv or 3 mg/kg po (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Clearances of <b>19</b> and <b>25</b> were low relative to total liver blood flow, whereas <b>35</b> and <b>36</b> showed higher clearance values. Oral bioavailability was better for compounds <b>19</b> and <b>25</b>, consistent with lower clearance as well as good in vitro permeability and solubility. In addition, volumes of distribution were moderate (0.74â1.99 L/kg) for this cohort of analogs. Accordingly, single species allometric scaling predicted more favorable human clearance values for compounds <b>19</b> and <b>25</b> compared with <b>35</b> and <b>36</b>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Physicochemical Properties and Pharmacokinetic Parameters of JAK1 Inhibitors <b>19</b>, <b>25</b>, <b>35</b>, and <b>36</b> in Rats (<i>n</i> = 2) Following Doses of 1 mg/kg iv or 3 mg/kg po</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Vdss (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (hours)</th><th class="colsep0 rowsep0" align="center" char=".">oral bioavailibility (%)</th><th class="colsep0 rowsep0" align="center" char=".">LE<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">LipE<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">TPSA (Ã<sup>2</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">HBD</th><th class="colsep0 rowsep0" align="center" char=".">HBA</th><th class="colsep0 rowsep0" align="center" char=".">aqueous solubility_pH7.4 (Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">HLM CLint, app (Î¼L/min/mg)</th><th class="colsep0 rowsep0" align="center" char=".">RRCK<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> Papp AB (Ã10<sup>â6</sup>Â cm/sec)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>19</b></td><td class="colsep0 rowsep0" align="char" char=".">14.6</td><td class="colsep0 rowsep0" align="char" char=".">0.74</td><td class="colsep0 rowsep0" align="char" char=".">0.92</td><td class="colsep0 rowsep0" align="char" char=".">119</td><td class="colsep0 rowsep0" align="char" char=".">0.49</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="char" char=".">87</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">213</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>25</b></td><td class="colsep0 rowsep0" align="char" char=".">26.6</td><td class="colsep0 rowsep0" align="char" char=".">1.04</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">95.6</td><td class="colsep0 rowsep0" align="char" char=".">0.48</td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">503</td><td class="colsep0 rowsep0" align="char" char="."><9</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>35</b></td><td class="colsep0 rowsep0" align="char" char=".">56.4</td><td class="colsep0 rowsep0" align="char" char=".">1.42</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">61.1</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="char" char=".">123</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">259</td><td class="colsep0 rowsep0" align="char" char="."><8</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>36</b></td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">1.99</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">48.3</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">108</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">437</td><td class="colsep0 rowsep0" align="char" char="."><8</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Ligand efficiency = (â1.4â¯logâ¯IC<sub>50</sub>(JAK1(biochemical)))/(number of heavy atoms).</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Ligand-lipophilicity efficiency = (âlogâ¯IC<sub>50</sub>(JAK1(biochemical)))/(measured logâ¯<i>D</i>).</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Apparent permeability as measured in an RRCK assay.</p></div></div></div><div class="NLM_p">Although compounds <b>19</b> and <b>25</b> showed similar pharmacokinetic profiles and similar potencies in JAK biochemical and cellular assays, a broad functional CEREP screen at 10 Î¼M consisting of a diverse set of GPCR, ion channel, transporter, and enzymes (64 targets in total) for off-target effects indicated that <b>19</b> showed activity against the CB-1 receptor in a binding assay (IC<sub>50</sub> = 120 nM). This translated into observed motor effects consistent with CB-1 inhibition in a rat toxicokinetic study. Compound <b>25</b> showed no measurable activity (>50%) at any targets profiled with the exception of KDR kinase (VEGFR2, IC<sub>50</sub> = 1.2 Î¼M) and weak activity on monoamine oxidase A (MAO-A, IC<sub>50</sub> = 6 Î¼M). A follow-up study in a functional Caliper whole cell KDR kinase assay showed no effects on KDR kinase activity at concentrations up to 30 Î¼M.</div><div class="NLM_p last">Sulfonamide <b>25</b> was also evaluated in a broad kinase panel (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_001.pdf" class="ext-link">Table S3</a>), which indicated that it is a highly selective compound, crossing over most potently onto JAK3 with 61% inhibition at 1 uM. The lack of off-target kinase inhibition is particularly notable, given that the broad kinase panel was run at the <i>K</i><sub>m</sub> of ATP to maximize assay sensitivity for the detection of potential off-target activity. Although JAK3 showed up as an off target in the broad kinase panel, <b>25</b> had an IC<sub>50</sub> of 605 nM when measured at the <i>K</i><sub>m</sub> of ATP and >10 Î¼M when measured at 1 mM ATP. In summary, compound <b>25</b> is a potent JAK1 inhibitor with 28-fold selectivity over JAK2, >340-fold over JAK3, and 43-fold over TYK2 (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_001.pdf" class="ext-link">Table S1</a>) at 1 mM ATP and has an excellent selectivity profile over the broader kinome. Based on its favorable overall properties and pharmacokinetic profile across multiple species (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_001.pdf" class="ext-link">Tables S4 and S5</a>), <b>25</b> progressed into pharmacodynamic and efficacy studies in vivo.</div></div><div id="sec2-7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Rat Target Modulation</h3><div class="NLM_p">The in vivo pharmacokineticâpharmacodynamic relationship of <b>25</b> was characterized following single oral doses of 5, 15, and 50 mg/kg to naÃ¯ve Lewis rats. Serial blood samples were taken at 0.25, 0.5, 2, 4, 8, and 24 h and analyzed for drug concentrations and STAT phosphorylation (pSTAT) activities. pSTAT1 was measured following ex vivo stimulation of blood with IL-6 or IFNÎ³ to assess JAK1/JAK2 signal inhibition, while pSTAT3 was measured following stimulation with IL-21 to assess JAK1/JAK3 signal inhibition (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). The inhibition of pSTAT formation induced by IFNÎ³, IL-21, and IL-6 was directly linked to the plasma concentration of <b>25</b> and was independent of time. The respective calculated unbound plasma IC<sub>50</sub> values were 191, 938, and 176 nM.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibition of cytokine-induced STAT phosphorylation (pSTAT) in whole blood of rats dosed orally with <b>25.</b> NaÃ¯ve Lewis rats were given a single dose of <b>25</b> at 50, 15, or 5 mg/kg, and peripheral blood was taken at 0.25, 0.5, 2, 4, 8, and 24 h post dose. STAT phosphorylation was assayed at each time point by stimulation with relevant cytokines (A) IFNÎ³, (B) IL-21, and (C) IL-6, then subsequent measurement of appropriate pSTATs was performed. Intracellular STAT3 and STAT1 phosphorylation was determined within a CD3+ gate representing the T cell population. Data are presented as compared to maximal response in vehicle-dosed animals.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2-8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Rat Adjuvant-Induced Arthritis Model</h3><div class="NLM_p">The effect of JAK1 inhibition by <b>25</b> in vivo was evaluated using a therapeutic dosing paradigm in a rat adjuvant-induced arthritis (AIA) disease model.<a onclick="showRef(event, 'cit31a'); return false;" href="javascript:void(0);" class="ref cit31a">(31a)</a> Female Lewis rats immunized with complete Freundâs adjuvant were dosed orally with <b>25</b> or vehicle for seven consecutive days after disease onset as measured by hind paw volume using plethysmography. Paw volumes and weights were followed throughout the study. At the end of 7 days of dosing, plasma concentrations of <b>25</b> were assessed. Two studies were completed. In the initial study, immunized rats were dosed QD with either 5, 15, or 50 mg/kg of <b>25</b> or vehicle (PO) (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_001.pdf" class="ext-link">Figure S3</a>). Because a significant reduction in paw swelling was observed for all doses, a second study was conducted focused on lower doses (0.5, 1, 5, or 15 mg/kg <b>25</b> or vehicle control). A significant reduction of hind paw swelling was observed down to 1 mg/kg (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>, days 6 and 7). Collective pharmacodynamics modeling of both studies using an <i>E</i><sub>max</sub> model fit indicated an unbound <i>C</i><sub>ave50</sub> of approximately 1.3 Î¼M (<i>r</i><sup>2</sup> â¼ 0.91) (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Rats with AIA were treated with 15, 5, 1, or 0.5 mg/kg of <b>25</b> or vehicle control. A significant reduction of hind paw swelling was seen on days 3â7 (15 mg/kg), days 4â7 (5 mg/kg), and days 6 and 7 (1 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. PK/PD modeling of exposure (<i>C</i><sub>ave</sub>) and its AUC of effect of <b>25</b> after 7 days of dosing in the rat AIA model. The unbound EC<sub>ave</sub>50 concentration was determined to be 1.3 Î¼M.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To determine the effect of <b>25</b> on JAK2/JAK2-dependent GM-CSF signaling, blood samples were taken at peak plasma concentration (0.25 h post dose) in the rats treated with <b>25</b> on day 7. GM-CSF induced pSTAT5 in monocytes was reduced by approximately 30% at the top dose of 15 mg/kg and less than 5% at lower doses. In contrast, IL-21, IFNÎ±, and IFNÎ³ induced stat phosphorylation were reduced >60% at 1 mg/kg.</div></div><div id="sec2-9" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Human Prediction of Pharmacokinetics and Pharmacodynamics</h3><div class="NLM_p">The primary clearance mechanisms of compound <b>25</b> were determined to be mediated by CYP450 metabolism, with limited renal and biliary clearance expected. Human clearance predictions were made using human liver microsomes and hepatocyte data as well as standard single-species allometric scaling techniques, all of which suggested low to moderate human clearance would be observed (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Summary of Predicted Human Pharmacokinetics of <b>25</b> from in Vivo and in Vitro Systems<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">human prediction</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">method</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>b</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human liver microsomes</td><td class="colsep0 rowsep0" align="char" char="."><2.4</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human hepatocytes</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat single species scaling</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog single species scaling</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">CL<sub>b</sub>, blood clearance; <i>V</i><sub>ss</sub>, volume of distribution at steady state. Unbound plasma protein binding is consistent across rat, dog, and human: â¼0.4.</p></div></div></div><div class="NLM_p">Preclinical and clinical studies with JAK inhibitors have shown the value in using average drug plasma concentration (<i>C</i><sub>ave</sub>) in predicting anti-inflammatory response.<a onclick="showRef(event, 'ref19 cit31b ref32'); return false;" href="javascript:void(0);" class="ref ref19 cit31b ref32">(19, 31b, 32)</a> The percent level of cytokine inhibition (IC<sub><i>xx</i></sub>) of compound <b>25</b> for each cytokine pathway can be calculated by combining the corresponding unbound whole cell IC<sub>50</sub> value (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>) with the predicted unbound human <i>C</i><sub>ave</sub> value (i.e., IC<sub><i>xx</i></sub> = 100Â·<i>C</i><sub>ave</sub>/(IC<sub>50</sub> + <i>C</i><sub>ave</sub>)). The overall selectivity profile of cytokine inhibition can be visualized at an expected efficacious human dose of 200 mg QD (based on human hepatocyte scaling), which is expected to achieve a <i>C</i><sub>ave80</sub> for IFNÎ± using this method of analysis (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). Selectivity of inhibition of compound <b>25</b> for cytokines signaling through JAK1 heterodimer pairs (IFNÎ±, IFNÎ³, IL-6, IL-10, IL-15, IL-21, and IL-27) (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>) was evident compared to the sparing of JAK2/JAK2 (EPO) and JAK2/TYK2 (IL-12 and IL-23) signaling. Additional data showing the cytokine inhibition profile for compounds <b>19</b>, <b>35</b>, and <b>36</b> in the HWB assays is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_001.pdf" class="ext-link">Table S6</a>.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Extent of cytokine inhibition resulting from an expected efficacious dose of <b>25</b> (200 mg QD) in human (p-STAT abbreviated as ST).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Cytokine Inhibition Profile of <b>25</b> in HWB: IC<sub>50</sub> Values and Number of Repeats (<i>n</i>)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">IFNÎ±<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> pSTAT3 IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">IFNÎ³<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a> pSTAT1 IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">CD14+ IL-6<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a> pSTAT1 IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">IL-10<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> pSTAT3 IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">CD8+IL-15<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a> pSTAT5 IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">IL-21<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a> pSTAT3 IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">IL-27<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a> pSTAT3 IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">IL-12<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a> pSTAT4 IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">IL-23<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a> pSTAT3 IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">CD34<sup>+</sup> EPO<a class="ref internalNav" href="#t8fn6" aria-label="f">f</a> pSTAT5 IC<sub>50</sub> (Î¼M)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">(<i>n</i>Â =Â 4)</th><th class="colsep0 rowsep0" align="center">(<i>n</i>Â =Â 2)</th><th class="colsep0 rowsep0" align="center">(<i>n</i>Â =Â 4)</th><th class="colsep0 rowsep0" align="center">(<i>n</i>Â =Â 2)</th><th class="colsep0 rowsep0" align="center">(<i>n</i>Â =Â 5)</th><th class="colsep0 rowsep0" align="center">(<i>n</i>Â =Â 2)</th><th class="colsep0 rowsep0" align="center">(<i>n</i>Â =Â 2)</th><th class="colsep0 rowsep0" align="center">(<i>n</i>Â =Â 2)</th><th class="colsep0 rowsep0" align="center">(<i>n</i>Â =Â 1)</th><th class="colsep0 rowsep0" align="center">(<i>n</i>Â =Â 5)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">0.189</td><td class="colsep0 rowsep0" align="left">0.163</td><td class="colsep0 rowsep0" align="left">0.163</td><td class="colsep0 rowsep0" align="left">2.511</td><td class="colsep0 rowsep0" align="left">1.298</td><td class="colsep0 rowsep0" align="left">0.511</td><td class="colsep0 rowsep0" align="left">0.271</td><td class="colsep0 rowsep0" align="left">13.673</td><td class="colsep0 rowsep0" align="left">>16.452</td><td class="colsep0 rowsep0" align="left">7.178</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Signals through JAK1/TYK2.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Signals through JAK1/JAK2Â·</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Signals through JAK1/JAK2 or TYK2.</p></div><div class="footnote" id="t8fn4"><sup>d</sup><p class="last">Signals through JAK1/JAK3.</p></div><div class="footnote" id="t8fn5"><sup>e</sup><p class="last">Signals through JAK2/TYK2.</p></div><div class="footnote" id="t8fn6"><sup>f</sup><p class="last">Signals through JAK2/JAK2.</p></div></div></div></div><div id="sec2-10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemistry</h3><div class="NLM_p">Preparative routes to the sulfonamide and sulfamide analogs are shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Sulfonamide and Sulfamide Analogs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span><b>44</b>, MeNH<sub>2</sub>, THF, AcOH, rt then NaBH<sub>4</sub>, 0 Â°C to rt.</p><p><span class="fn-label">Scheme b</span><b><i>cis</i>-45</b>, <b>46a</b>, DIPEA, <i>i</i>-PrOH, 75 Â°C.</p><p><span class="fn-label">Scheme c</span><b>46b</b>, <b><i>cis</i>-45</b>, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, 95 Â°C.</p><p><span class="fn-label">Scheme d</span><b>47a</b>, HBr, AcOH, EtOAc, rt.</p><p><span class="fn-label">Scheme e</span><b>47b</b>, Pd(OH)<sub>2</sub>, cyclohexene, EtOH, 78 Â°C.</p><p><span class="fn-label">Scheme f</span>RSO<sub>2</sub>Cl, TEA or DIPEA.</p><p><span class="fn-label">Scheme g</span>aq OH<sup>â</sup> or CO<sub>3</sub><sup>2â</sup>/ROH.</p><p><span class="fn-label">Scheme h</span><b>48b</b>Â·HCl, LiHDMS, TMSCl, rt then RSO<sub>2</sub>Cl, rt.</p><p><span class="fn-label">Scheme i</span>ClSO<sub>2</sub>NCO, 2-bromoethanol, DCM, 0 Â°C then <b>48a</b>Â·2HBr, TEA, rt.</p><p class="last"><span class="fn-label">Scheme j</span>R<sup>1</sup>R<sup>2</sup>NH, TEA or DIPEA, MeCN, 100 Â°C (sealed tube).</p></p></figure><div class="NLM_p">Benzyl (3-oxocyclobutyl)carbamate (<b>44</b>) was condensed with methylamine (AcOH/THF/rt) and then treated with NaBH<sub>4</sub> (0 Â°C to rt) to afford cyclobutylamine <b>45</b> as a mixture of <i>cis</i> and <i>trans</i> isomers. Hydrochloride salt formation followed by recrystallization allowed the isolation of the major isomer, <i>cis</i>-<b>45</b>Â·HCl, in moderate yield (63%). In addition, the minor isomer <i>trans</i>-<b>45</b> (used for the preparation of <b>26</b>), could be isolated by supercritical fluid chromatography. Subsequent reaction of <i>cis</i>-<b>45</b>Â·HCl with 4-chloro-7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>46a</b>)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> in the presence of DIPEA (<i>i</i>-PrOH/75 Â°C) provided the protected intermediate <b>47a</b>. Here, the electron-withdrawing tosyl protecting group allowed the nucleophilic aromatic substitution reaction to occur readily in high yield (95%).</div><div class="NLM_p">Treatment of <b>47a</b> with HBr (EtOAc/AcOH/rt) served to remove the pendant carbobenzyloxy protecting group and provided <b>48a</b>, isolated as the stable, free-flowing dihydrobromide salt. Conversion of <b>48a</b>Â·2HBr to target sulfonamides was then achieved in two steps: sulfonylation (RSO<sub>2</sub>Cl/base) followed by removal of the tosyl group. Typically aqueous hydroxide was used for the deprotection step, but occasionally, because of the potential for side reactions involving the sulfonamide side-chain, other conditions were used, such as in the preparation of <b>35</b>, where the presence of the nitrile function necessitated use of Cs<sub>2</sub>CO<sub>3</sub> as base.</div><div class="NLM_p">Several sulfonamide analogs were prepared starting with 2,4-dichloro-7<i>H</i>-pyrrolo(2,3-<i>d</i>)pyrimidine (<b>46b</b>). Though less robust, this route was generally useful in compound preparation, not requiring the sometimes problematic tosyl deprotection step. Taking advantage of the activation effect of the additional chlorine atom on the pyrrolopyrimidine ring, <b>46b</b> was combined with <i>cis</i>-<b>45</b>Â·HCl (K<sub>2</sub>CO<sub>3</sub>/H<sub>2</sub>O/95 Â°C) to afford adduct <b>47b</b> in high yield (98%). Exposure of <b>47b</b> to catalytic hydrogenation conditions (Pd(OH)<sub>2</sub>) then gave amine <b>48b</b>, which was taken on either as the hydrochloride salt or as the free base.</div><div class="NLM_p">Sulfonamide formation using <b>48b</b> could be carried out directly under standard conditions (RSO<sub>2</sub>Cl/base), but often mixtures arose and yields were low because of competing sulfonylation of the pyrrolopyrimidine NH. This problem could be avoided by in situ protection of the pyrrolopyrimidine NH function. Thus, <b>48b</b> (hydrochloride) was first treated with LiHDMS (2.2 equiv) and TMSCl (2.2 equiv) in THF to provide what was assumed to be a bis-TMS derivative (pyrrolidine NH and primary amine capped by TMS). Addition of RSO<sub>2</sub>Cl then afforded the desired sulfonamide target after workup, presumably via preferential sulfonylation of âNHTMS.</div><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, sulfamide analogs were accessed via reaction of <i>N</i>-sulfamoyloxazolidinone <b>50</b>, prepared from <b>48a</b>Â·2HBr by the method of Montero<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> with primary and secondary amines (R<sup>1</sup>R<sup>2</sup>NH) at elevated temperature in the presence of base (TEA or DIPEA).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> As with the preparation of sulfonamides, removal of the <i>N</i>-tosyl group was typically carried out using aqueous LiOH or NaOH, often in the presence of a cosolvent such as EtOH.</div><div class="NLM_p">Compounds in the reverse sulfonamide and sulfone series were prepared starting with the two-step conversion of ethyl 3-aminocyclobutanecarboxylate hydrochloride (<i>cis</i>:<i>trans</i> = 10:1) (<b>52</b>Â·HCl)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> to 3-(methylamino)cyclobutyl]methanol (<b>53</b>), also a 10:1 mixture of <i>cis</i>- and <i>tran</i>s- isomers (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Reaction of <b>53</b> with 4-chloro-7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>46a</b>) (TEA/KI/acetone/56 Â°C) gave alcohol <b>54</b> as a mixture of isomers (85%) which were separated by supercritical fluid chromatography. The major isomer, <i>cis</i>-<b>54</b>, was then advanced in good overall yields to common intermediates <b>55a</b> and <b>55b</b> via <i>O</i>-tosylation and <i>O</i>-mesylation, respectively (<i>p</i>-TsCl or MsCl/DMAP/DCM). Tosylate displacement on <b>55a</b> with potassium thioacetate (DMF/55 Â°C) provided <i>S</i>-acetate <b>56</b>.</div><figure id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Sulfone and Reverse Sulfonamide Analogs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span><b>52</b>Â·HCl, Boc<sub>2</sub>O, TEA, DCM, 0 Â°C to rt.</p><p><span class="fn-label">Scheme b</span>LiAlH<sub>4</sub>, THF, 0 to 66 Â°C.</p><p><span class="fn-label">Scheme c</span><b>46a</b>, <b>53</b>, TEA, cat. KI.</p><p><span class="fn-label">Scheme d</span><i>p</i>-TsCl, DMAP, DCM, 0 Â°C to rt.</p><p><span class="fn-label">Scheme e</span>KSAc, DMF, 55 Â°C.</p><p><span class="fn-label">Scheme f</span>30% aq H<sub>2</sub>O<sub>2</sub>, HCO<sub>2</sub>H.</p><p><span class="fn-label">Scheme g</span>SOCl<sub>2</sub>, cat. DMF, DCM, 0 to 75 Â°C.</p><p><span class="fn-label">Scheme h</span>R<sup>3</sup>R<sup>4</sup>NH, TEA or DIPEA.</p><p><span class="fn-label">Scheme i</span>aq OH<sup>â</sup> or CO<sub>3</sub><sup>2â</sup>/ROH.</p><p><span class="fn-label">Scheme j</span>K<sub>2</sub>CO<sub>3</sub>, MeOH, 0 Â°C then R<sup>2</sup>-X, rt.</p><p><span class="fn-label">Scheme k</span>Oxone, THF, EtOH, H<sub>2</sub>O.</p><p class="last"><span class="fn-label">Scheme l</span>R<sup>2</sup>SH, DBU, NMP, rt.</p></p></figure><div class="NLM_p">Compounds in the reverse sulfonamide series (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) were obtained in four steps from <b>56</b>. Oxidation to sulfonic acid <b>57a</b> (aq H<sub>2</sub>O<sub>2</sub>/HCO<sub>2</sub>H) followed by reaction with thionyl chloride (cat. DMF/DCM/0 Â°C) provided sulfonyl chloride <b>57b</b> which, after sulfonamide formation (R<sup>3</sup>R<sup>4</sup>NH/base) and deprotection, gave the target analogs.</div><div class="NLM_p last">Sulfone analogs could be accessed in two or three steps from either tosylate <b>55a</b> or mesylate <b>55b</b>. Sulfonate displacement with in situ generated thiolate (R<sup>2</sup>SH/DBU/NMP/rt) provided thioethers of general structure <b>58a</b>, which usually underwent cleavage of the <i>N</i>-tosyl group under the reaction conditions to afford deprotected thioethers <b>58b</b>. In some cases, tosyl cleavage was incomplete, necessitating a subsequent tosyl group removal step (e.g., aq LiOH/EtOH). Oxidation of <b>58b</b> with Oxone then provided the target sulfones. These could also be prepared via <i>S</i>-acetate <b>56</b> starting with cleavage of the acetyl group (K<sub>2</sub>CO<sub>3</sub>/NaBH<sub>4</sub>/MeOH/0 Â°C)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and in situ alkylation of the resulting thiolates with alkyl halides, alkyl tosylates, and alkyl mesylates (R<sup>2</sup>-X). The product thioethers <b>58a</b> then afforded the target sulfone analogs after tosyl group cleavage and oxidation. Sulfone synthesis via <b>56</b> became a preferred method as it obviated the need to use thiols as starting materials.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47833" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47833" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">By replacement of the 3-aminopiperidine in tofacitinib (<b>1</b>) with a <i>cis</i>-1,3-cyclobutyldiamine capped with a sulfonamide, we were able to identify highly potent and selective JAK1 inhibitors in good physicochemical space. We found that various permutations around the sulfonyl moeity (i.e., sulfamides, sulfones and reverse sulfonamides) also afforded potent and selective molecules. Clearance was recognized as a key factor in identifying compounds suitable for development. Therefore, the observation that compounds with logâ¯<i>D</i> < 2 demonstrated very low HLM clearance enabled us to design molecules with the right balance of lipophilicity and polarity required for good potency and metabolic stability. Profiling in HWB assays demonstrated that the excellent potency for JAK1 translated to a cellular system and that JAK2 selectivity, as assessed by the inhibition of EPO in CD34<sup>+</sup> cells, was confirmed relative to the biochemical assays. Insights obtained through X-ray crystallography as to how analogs bind to JAK1 allowed us to improve potency, especially within the sulfamide and reverse sulfonamide series. Assessment of rat pharmacokinetics for the four analogs that met advancement criteria demonstrated that two (<b>19</b> and <b>25</b>) had low in vivo clearance values. Compound <b>25</b> exhibited a superior pharmacology profile compared to <b>19</b> and therefore was further advanced. Compound <b>25</b> was 28-fold selective over JAK2, >340-fold over JAK3, and 43-fold over TYK2 at 1 mM ATP and demonstrated broad kinase selectivity. In a rat target modulation study, compound <b>25</b> inhibited pSTAT formation induced by IL-6, IL-2, and IFNÎ³ in a manner directly linked to the drug plasma concentration. Similarly, compound <b>25</b> demonstrated efficacy in a dose-responsive manner in a therapeutic rat AIA model. By using allometric scaling and human hepatocyte clearance, a human dose of approximately 200 mg QD was projected to achieve <i>C</i><sub>ave80</sub> inhibition of IFNÎ±. Following appropriate in vivo toxicological testing, compound <b>25</b> (PF-04965842)<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> progressed into a phase 1 clinical study, the results of which will be reported elsewhere.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70641" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70641" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Chemistry: General Information</h3><div class="NLM_p">Chemicals were typically obtained from Sigma-Aldrich or Alfa Aesar and used as received, unless noted otherwise. Solvents were commercial anhydrous grade, used as received. Unless otherwise stated, reactions were run under a positive pressure of nitrogen at ambient temperature. Except where otherwise noted, âchromatographedâ and âflash chromatographyâ refer to normal phase chromatography using a medium pressure Biotage or ISCO system employing commercial prepacked silica gel columns. Supercritical fluid chromatography (SFC) was performed on an Agilent SFC system in APCI negative mode. Analytical thin-layer chromatography (TLC) was performed on 60 Ã F254 glass plates precoated with a 0.25 mm thickness of silica gel purchased from EMD Chemicals Inc. TLC plates were visualized with ultraviolet (UV) light. Except where otherwise noted, purities of compounds used in biological studies were >95%, determined by HPLC, UPLC, or LC/MS. Ultraviolet (typically 215â220 nm) and evaporative light scattering detection (ELSD) were typically employed for detection.</div><div class="NLM_p">Nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on a Bruker or Varian spectrometer operating at 400 MHz or a Bruker spectrometer operating at 500 MHz. Chemical shifts are reported in parts per million (Î´) relative to CDCl<sub>3</sub> (7.26 ppm), DMSO-<i>d</i><sub>6</sub> (2.50 ppm), MeOH-<i>d</i><sub>4</sub> (3.31 ppm), or D<sub>2</sub>O (4.79 ppm). The following abbreviations are used for peak multiplicites: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broadened, dd = doublet of doublets, and dt = doublet of triplets.</div><div class="NLM_p">Low-resolution mass spectroscopy was carried out using liquid chromatographyâmass spectrometry (LC/MS) on a Waters Acquity UPLC instrument using atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI).</div><div id="sec4-1-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(<i>cis</i>-3-(Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)benzenesulfonamide (<b>4</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>25</b> starting from <b>48a</b>Â·HBr. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 12.42 (br s, 1H), 8.27 (s, 1H), 8.08 (d, <i>J</i> = 9.0 Hz, 1H), 7.85 (d, <i>J</i> = 7.0 Hz, 2H), 7.55â7.74 (m, 3H), 7.30â7.42 (m, 1H), 6.75â6.92 (m, 1H), 4.58â4.82 (m, 1H), 3.46â3.73 (m, 1H), 3.26 (s, 3H), 2.28â2.46 (m, 2H), 1.95â2.18 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>17</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>S: 358. Found: 358.</div></div><div id="sec4-1-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide (<b>5</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>25</b> starting from <b>48a</b>Â·HBr. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz): 11.64 (br s, 1H), 8.10 (s, 1H), 7.40 (d, <i>J</i> = 8.8 Hz, 1H), 7.14â7.16 (m, 1H), 6.63â6.64 (m, 1H), 4.90â4.98 (m, 1H), 3.54â3.64 (m, 1H), 3.25 (s, 3H), 2.89 (s, 3H), 2.58â2.65 (m, 2H), 2.20â2.28 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>12</sub>H<sub>18</sub>N<sub>5</sub>O<sub>2</sub>S: 296. Found: 296.</div></div><div id="sec4-1-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}ethanesulfonamide (<b>6</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>25</b> starting from <b>48a</b>Â·HBr. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz): 11.64 (br s, 1H), 8.10 (s, 1H), 7.50 (d, <i>J</i> = 8.5 Hz, 1H), 7.15â7.16 (m, 1H), 6.63â6.65 (m, 1H), 4.87â4.94 (m, 1H), 3.53â3.61 (m, 1H), 3.26 (s, 3H), 2.97 (q, <i>J</i> = 7.7 Hz, 2H), 2.57â2.62 (m, 2H), 2.21â2.27 (m, 2H), 1.21 (t, <i>J</i> = 7.7 Hz, 3H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>13</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>S: 310. Found: 310. Purity (HPLC) = 98.5% (UV), 85.7% (ELSD).</div></div><div id="sec4-1-4" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-Methyl-<i>N</i>-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (<b>7</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>36</b> starting from <b>48b</b>Â·HCl. White solid, 52% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.62 (br s, 1H), 8.10 (s, 1H), 7.49 (d, <i>J</i> = 9.4 Hz, 1H), 7.13â7.15 (m, 1H), 6.65 (dd, <i>J</i> = 2.0, 3.5 Hz, 1H), 4.85â4.94 (m, 1H), 3.52â3.63 (m, 1H), 3.24 (s, 3H), 2.85 (d, <i>J</i> = 6.6 Hz, 2H), 2.56â2.62 (m, 2H), 2.18â2.26 (m, 2H), 2.04â2.14 (m, 1H), 1.02 (d, <i>J</i> = 7.0 Hz, 6H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>S: 338. Found: 338. Anal. Calcd for C<sub>15</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>S: C, 53.39; H, 6.87; N, 20.75; S, 9.50. Found: C, 53.27; H, 7.13; N, 20.58; S, 9.12.</div></div><div id="sec4-1-5" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2,2,2-Trifluoro-<i>N</i>-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}ethanesulfonamide (<b>8</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>36</b> starting from <b>48b</b>Â·HCl. White solid, 65% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.63 (br s, 1H), 8.22 (d, <i>J</i> = 8.8 Hz, 1H), 8.10 (s, 1H), 7.15 (d, <i>J</i> = 2.5, 3.5 Hz, 1H), 6.62 (dd, <i>J</i> = 2.0, 3.5 Hz, 1H), 4.85â4.94 (m, 1H), 4.36 (q, <i>J</i> = 10.0 Hz, 2H), 3.62â3.72 (m, 1H), 3.25 (s, 3H), 2.59â2.66 (m, 2H), 2.22â2.30 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>13</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S: 364. Found: 364. Anal. Calcd for C<sub>13</sub>H<sub>16</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S: C, 42.97; H, 4.44; F, 15.69; N, 19.27; S, 8.82. Found: C, 42.64; H, 4.23; F, 15.89; N, 19.08; S, 9.75.</div></div><div id="sec4-1-6" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-Fluoro-<i>N</i>-(<i>cis</i>-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)benzenesulfonamide (<b>9</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>25</b> starting from <b>48a</b>Â·HBr. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 12.44 (br s, 1H), 8.27 (s, 1H), 8.11 (d, <i>J</i> = 9.0 Hz, 1H), 7.82â7.93 (m, 2H), 7.39â7.50 (m, 2H), 7.32â7.39 (m, 1H), 6.85 (d, <i>J</i> = 2.0 Hz, 1H), 4.69 (m, 1H), 3.57 (m, 1H), 3.25 (s, 3H), 2.30â2.44 (m, 2H), 2.00â2.16 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>17</sub>H<sub>19</sub>FN<sub>5</sub>O<sub>2</sub>S: 376. Found: 376.</div></div><div id="sec4-1-7" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-(<i>cis</i>-3-(Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)-1-phenylmethanesulfonamide (<b>10</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>25</b> starting from <b>48a</b>Â·HBr. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 12.46 (br s, 1H), 8.31 (s, 1H), 7.59 (d, <i>J</i> = 8.6 Hz, 1H), 7.27â7.48 (m, 6H), 6.78â6.97 (m, 1H), 4.72 (m, 1H), 4.31 (s, 2H), 3.47â3.71 (m, 1H), 3.32 (s, 3H), 2.57â2.75 (m, 2H), 2.13â2.41 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>18</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>S: 372. Found: 372.</div></div><div id="sec4-1-8" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-Ethyl-<i>N</i>â²-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}sulfamide (<b>11</b>)</h4><div class="NLM_p last">This sulfamide analog was prepared using a procedure similar to that used to prepare compound <b>14</b>, starting with intermediate <b>50</b>. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): 8.11 (s, 1H), 7.13 (d, <i>J</i> = 3.6 Hz, 1H), 6.69 (d, <i>J</i> = 3.6 Hz, 1H), 3.56â3.60 (m, 1H), 3.36 (s, 3H), 3.02 (q, <i>J</i> = 7.2 Hz, 2H), 2.70â2.77 (m, 2H), 2.25â2.33 (m, 2H), 1.18 (t, <i>J</i> = 7.2 Hz, 3H). (The H<sub>2</sub>O peak at Î´ 4.90 obscures a methine proton signal.) LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>13</sub>H<sub>21</sub>N<sub>6</sub>O<sub>2</sub>S: 325. Found: 325.</div></div><div id="sec4-1-9" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-Prop-1-yl-<i>N</i>â²-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}sulfamide (<b>12</b>)</h4><div class="NLM_p last">This sulfamide analog was prepared using a procedure similar to that used to prepare compound <b>14</b>, starting with intermediate <b>50</b>. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): 8.12 (s, 1H), 7.12 (d, <i>J</i> = 3.6 Hz, 1H), 6.69 (d, <i>J</i> = 3.6 Hz, 1H), 3.53â3.62 (m, 1H), 3.36 (s, 3H), 2.93 (t, <i>J</i> = 7.2 Hz, 2H), 2.70â2.77 (m, 2H), 2.25â2.33 (m, 2H), 1.54â1.63 (m, 2H), 1.18 (t, <i>J</i> = 7.2 Hz, 3H). (The H<sub>2</sub>O peak at 4.90 obscures a methine proton signal.) LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>14</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub>S: 339. Found: 339.</div></div><div id="sec4-1-10" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-Cyclopropyl-<i>N</i>â²-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}sulfamide (<b>13</b>)</h4><div class="NLM_p last">This sulfamide analog was prepared using a procedure similar to that used to prepare compound <b>14</b>, starting with intermediate <b>50</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.66 (br s, 1H), 8.09 (s, 1H), 7.39 (d, <i>J</i> = 8.8 Hz, 1H), 7.24 (br s, 1H), 7.14â7.15 (m, 1H), 6.61â6.62 (m, 1H), 4.86â4.95 (m, 1H), 3.40â3.46 (m, 1H, overlapped), 3.25 (s, 3H), 2.50â2.57 (m, 2H, overlapped), 2.22â2.29 (m, 3H), 0.50â0.54 (m, 4H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>14</sub>H<sub>21</sub>N<sub>6</sub>O<sub>2</sub>S: 337. Found: 337.</div></div><div id="sec4-1-11" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(Cyclopropylmethyl)-<i>N</i>â²-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}sulfamide (<b>14</b>)</h4><div id="sec4-1-11-1" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Step 1</h5><div class="NLM_p last">A solution of <b>50</b> (150 mg, 0.29 mmol), cyclopropanemethylamine (51 mg, 0.72 mmol), and TEA (116 mg, 1.15 mmol) in MeCN (3 mL) was stirred for 15 min at 100 Â°C in a sealed tube under microwave heating. The reaction mixture was concentrated to afford the crude <i>N</i>-(cyclopropylmethyl)-<i>N</i>â²-[<i>cis</i>-3-(methyl{7-[(4-methylphenyl)-sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}amino)cyclobutyl]sulfamide (146 mg, 100% crude yield) as a yellow oil. LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>22</sub>H<sub>29</sub>N<sub>6</sub>O<sub>4</sub>S<sub>2</sub>: 505. Found: 505.</div></div><div id="sec4-1-11-2" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Step 2</h5><div class="NLM_p last">A solution of <i>N</i>-(cyclopropylmethyl)-<i>N</i>â²-[<i>cis</i>-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}amino)cyclobutyl]sulfamide (146 mg, 0.29 mmol), LiOHÂ·H<sub>2</sub>O (48 mg, 1.14 mmol) in EtOH (5 mL), and H<sub>2</sub>O (2.5 mL) was stirred at 100 Â°C for 1 h. The reaction mixture was concentrated under vacuum, and the crude product was purified by preparative HPLC to afford the title compound (14 mg, 14%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): 8.12 (s, 1H), 7.12 (d, <i>J</i> = 3.6 Hz, 1H), 6.69 (d, <i>J</i> = 3.6 Hz, 1H), 3.59â3.63 (m, 1H), 3.37 (s, 3H), 2.84 (d, <i>J</i> = 7.2 Hz, 2H), 2.71â2.78 (m, 2H), 2.26â2.33 (m, 2H), 1.03â1.05 (m, 1H), 0.52â0.57 (m, 2H), 0.25â0.30 (m, 2H). (The H<sub>2</sub>O peak at 4.90 obscures a methine proton signal.) LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub>S: 351. Found: 351.</div></div></div><div id="sec4-1-12" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-(3-Cyanoprop-1-yl)-<i>N</i>â²-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}sulfamide (<b>15</b>)</h4><div class="NLM_p last">This sulfamide analog was prepared using a procedure similar to that used to prepare compound <b>14</b>, starting with intermediate <b>50</b>. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): 8.11 (s, 1H), 7.12 (d, <i>J</i> = 3.6 Hz, 1H), 6.68 (d, <i>J</i> = 3.6 Hz, 1H), 4.88â4.92 (m, 1H, overlapped), 3.57â3.63 (m, 1H), 3.36 (s, 3H), 3.10 (t, <i>J</i> = 6.6 Hz, 2H), 2.72â2.78 (m, 2H), 2.59 (t, <i>J</i> = 7.2 Hz, 2H), 2.27â2.34 (m, 2H), 1.87â1.94 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>S: 364. Found: 364.</div></div><div id="sec4-1-13" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-Methyl-<i>N</i>-{<i>ci</i>s-3-[(ethylsulfonyl)methyl]cyclobutyl}-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>16</b>)</h4><div id="sec4-1-13-1" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Step 1</h5><div class="NLM_p last">A solution of <b>56</b> (489 mg, 1.11 mmol) in MeOH (5.5 mL) was cooled in an ice bath and sparged with N<sub>2</sub> for 10 min. Subsequently, K<sub>2</sub>CO<sub>3</sub> (608 mg, 4.39 mmol) and NaBH<sub>4</sub> (166 mg, 4.4 mmol) were added, and the resulting mixture was stirred at 0 Â°C for 3 h. Ethyl iodide (0.22 mL, 2.74 mmol) was added. The reaction mixture was stirred overnight and allowed to warm to rt; the reaction was then quenched by addition of 1 M aq HCl solution. The mixture was extracted three times with EtOAc, and the combined organic extracts were dried over MgSO<sub>4</sub> and concentrated under vacuum. The crude product mixture was chromatographed eluting with a gradient of 5â100% EtOAc/heptane to provide <i>N</i>-{<i>cis</i>-3-[(ethylthio)methyl]cyclobutyl}-<i>N</i>-methyl-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine as an oil (200 mg, 42%). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): 8.22 (s, 1H), 8.00 (d, <i>J</i> = 8.6 Hz, 2H), 7.57 (d, <i>J</i> = 4.3 Hz, 1H), 7.39 (d, <i>J</i> = 8.2 Hz, 2H), 6.89 (d, <i>J</i> = 3.9 Hz, 1H), 4.89â4.99 (m, 1H), 3.28 (s, 3H), 2.69 (d, <i>J</i> = 7.0 Hz, 2H), 2.57 (q, <i>J</i> = 7.4 Hz, 2H), 2.43â2.52 (m, 2H), 2.41 (s, 3H), 2.24â2.32 (m, 1H), 1.96â2.05 (m, 2H), 1.27 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4-1-13-2" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Step 2</h5><div class="NLM_p last"><i>N</i>-{<i>cis</i>-3-[(Ethylthio)methyl]cyclobutyl}-<i>N</i>-methyl-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (200 mg, 0.46 mmol) was dissolved in EtOH (4.6 mL) and H<sub>2</sub>O (2.3 mL). The mixture was treated with LiOHÂ·H<sub>2</sub>O (98 mg, 2.33 mmol) and heated at 70 Â°C overnight. The solvents were evaporated under vacuum, and the residue was taken up in 1 M aq NaOH solution. The mixture was extracted three times with EtOAc, and the combined organic layers were dried over MgSO<sub>4</sub> and concentrated. The desired product, <i>N</i>-(<i>cis</i>-3-{[ethylthio)methyl]cyclobutyl}-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (110 mg, 86%), was isolated by flash chromatography eluting with a gradient of 5â100% EtOAc/heptane. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.61 (br s, 1H), 8.11 (s, 1H), 7.15 (dd, <i>J</i> = 2.3, 3.5 Hz, 1H), 6.61 (dd, <i>J</i> = 1.6, 3.5 Hz, 1H), 5.04â5.13 (m, 1H), 3.25 (s, 3H), 2.68 (d, <i>J</i> = 7.0 Hz, 2H), 2.53 (q, <i>J</i> = 7.4 Hz, 2H, overlapped by solvent peak), 2.32â2.39 (m, 2H), 2.16â2.27 (m, 1H), 1.93â2.01 (m, 2H), 1.21 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4-1-13-3" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> Step 3</h5><div class="NLM_p last"><i>N</i>-(<i>cis</i>-3-{[Ethylthio)methyl]cyclobutyl}-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (55 mg, 0.20 mmol) was dissolved in a mixture of THF (2 mL) and EtOH (2 mL). The mixture was cooled in an ice bath, and then a solution of Oxone (342 mg, 1.11 mmol) in water (2 mL) was added dropwise over 30 min. The cooling bath was removed, and the reaction mixture was stirred for another 2.5 h, warming to rt during this period. The reaction was quenched with 10% aq NaHSO<sub>3</sub> solution (20 mL). Saturated aq NaHCO<sub>3</sub> (30 mL) was added to adjust the pH to â¼7, and the resulting reaction mixture was quenched three times with EtOAc. The combined organic extracts were dried over MgSO<sub>4</sub> and concentrated under vacuum to provide the title compound (48 mg, 80%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 11.73, (br s, 1H), 8.23 (s, 1H), 7.17 (dd, <i>J</i> = 1.8, 3.5 Hz, 1H), 6.64 (dd, <i>J</i> = 1.6, 3.5 Hz, 1H), 5.15â5.23 (m, 1H), 3.46 (s, 3H), 3.16 (d, <i>J</i> = 7.0 Hz, 2H), 3.01 (q, <i>J</i> = 7.4 Hz, 2H), 2.66â2.81 (overlapping m, 3H), 2.18â2.25 (m, 2H), 1.44 (t, <i>J</i> = 7.4 Hz, 3H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>14</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub>S: 309. Found: 309. Purity (LC/MS) = 90% (UV), 100% (ELSD).</div></div></div><div id="sec4-1-14" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-Methyl-<i>N</i>-{<i>ci</i>s-3-[(cyclopropylsulfonyl)methyl]cyclobutyl}-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>17</b>)</h4><div class="NLM_p last">This sulfone analog was made in a manner similar to that used to prepare compound <b>19</b> starting with intermediate <b>55b</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 11.59, (br s, 1H), 8.26 (s, 1H), 7.20â7.21 (m, 1H), 6.66â6.67 (m, 1H), 5.21 (br s, 1H), 3.46 (s, 3H), 3.26 (d, <i>J</i> = 6.8 Hz, 2H), 2.70â2.80 (m, 3H), 2.35â2.41 (m, 1H), 2.20 (br s, 2H), 1.25â1.30 (m, 2H), 1.05â1.11 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub>S: 321. Found: 321.</div></div><div id="sec4-1-15" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>-Methyl-<i>N</i>-{<i>ci</i>s-3-[(propylsulfonyl)methyl]cyclobutyl}-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>18</b>)</h4><div class="NLM_p last">This sulfone analog was made in a manner similar to that used to prepare compound <b>16</b> starting with intermediate <b>56</b>. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): 8.11 (s, 1H), 7.11 (d, <i>J</i> = 3.6 Hz, 1H), 6.68 (d, <i>J</i> = 3.6 Hz, 1H), 5.07â5.16 (m, 1H), 3.36 (s, 3H), 3.03â3.07 (m, 2H), 2.57â2.65 (m, 3H), 2.17â2.26 (m, 2H), 1.80â1.89 (m, 2H), 1.10 (t, <i>J</i> = 7.2 Hz, 3H). (The solvent peak at Î´ 3.31 obscures a methylene proton signal.) LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>S: 323. Found: 323.</div></div><div id="sec4-1-16" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i>-{<i>cis</i>-3-[(Butylsulfonyl)methyl]cyclobutyl}-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>19</b>)</h4><div id="sec4-1-16-1" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> Step 1</h5><div class="NLM_p last">A solution of <b>55a</b> (23 g, 42.6 mmol) was stirred in NMP (100 mL). DBU (12.8 g, 85.2 mmol), and 1-butanethiol (7.8 g, 85.2 mmol) was added to the reaction mixture. The reaction was stirred at rt for 16 h. H<sub>2</sub>O (200 mL) and EtOAc (500 mL) were added. The aqueous layer was extracted with EtOAc (2 Ã 500 mL), and the combined organic layers were dried and concentrated. The residue was chromatographed eluting with a gradient of DCM and MeOH (100:0 to 90:10) to afford <i>N</i>-{<i>ci</i>s-3-[(butylthio)methyl]cyclobutyl}-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (11.8 g, 91%). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>16</sub>H<sub>25</sub>N<sub>4</sub>S: 305. Found: 305.</div></div><div id="sec4-1-16-2" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> Step 2</h5><div class="NLM_p last"><i>N</i>-{<i>cis</i>-3-[(Butylthio)methyl]cyclobutyl}-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (12 g, 39.5 mmol) was dissolved in a mixture of THF (200 mL), EtOH (200 mL), and H<sub>2</sub>O (200 mL). Oxone (48.6 g, 158 mmol) was added, and the reaction was stirred at rt for 1 h. The mixture was then filtered, washing the solids with a mixture of THF (40 mL), EtOH (40 mL), and H<sub>2</sub>O (20 mL). The filtrate was treated with 10% aq NaHSO<sub>3</sub> solution (200 mL) and stirred at rt for 20 min. Saturated aq NaHCO<sub>3</sub> was added to adjust the pH to â¼7. The mixture was extracted with DCM (3 Ã 800 mL), and the combined organic layers were dried and concentrated under vacuum. The crude residue was chromatographed eluting with a gradient of DCM and MeOH (100:0 to 95:5) to obtain the title compound (11.4 g, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.63, (br s, 1H), 8.12 (s, 1H), 7.15â7.17 (m, 1H), 6.63â6.65 (m, 1H), 5.10â5.19 (m, 1H), 3.35 (d, <i>J</i> = 7.0 Hz, 2H), 3.27 (s, 3H), 3.03â3.07 (m, 2H), 2.41â2.50 (m, 3H), 2.11â2.21 (m, 2H), 1.64â1.72 (m, 2H), 1.48â1.57 (m, 2H), 0.92 (t, <i>J</i> = 7.4 Hz, 3H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>16</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub>S: 337. Found: 337.</div></div></div><div id="sec4-1-17" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-{<i>cis</i>-3-[(Phenylsulfonyl)methyl]cyclobutyl}-<i>N</i>-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>20</b>)</h4><div class="NLM_p last">This sulfone analog was prepared in a manner similar to that used to prepare compound <b>19</b>, starting with intermediate <b>55b</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 11.01, (br s, 1H), 8.30 (s, 1H), 7.94 (d, <i>J</i> = 6.8 Hz, 2H), 7.65â7.68 (m, 1H), 7.57â7.61 (m, 2H), 7.07 (d, <i>J</i> = 3.6 Hz, 1H), 6.54 (d, <i>J</i> = 3.6 Hz, 1H), 5.09â5.14 (m, 1H), 3.30 (d, <i>J</i> = 6.8 Hz, 2H, overlapped), 3.29 (s, 3H), 2.45â2.54 (m, 2H), 2.36â2.43 (m, 1H), 1.99â2.02 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>18</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub>S: 357. Found: 357.</div></div><div id="sec4-1-18" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-Ethyl-1-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide (<b>21</b>)</h4><div class="NLM_p last">This reverse sulfonamide analog was prepared in parallel chemistry format in a manner similar to that used to prepare compound <b>43</b>. LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>14</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>S: 324. Found: 324. Purity (HPLC) = 87% (UV), 98.1% (ELSD).</div></div><div id="sec4-1-19" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}-<i>N</i>-propylmethanesulfonamide (<b>22</b>)</h4><div class="NLM_p last">This reverse sulfonamide analog was prepared in parallel chemistry format in a manner similar to that used to prepare compound <b>43</b>. LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>S: 338. Found: 338.</div></div><div id="sec4-1-20" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-Butyl-1-{<i>cis-</i>3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide (<b>23</b>)</h4><div class="NLM_p last">This reverse sulfonamide analog was prepared in parallel chemistry format in a manner similar to that used to prepare compound <b>43</b>. LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>16</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub>S: 352. Found: 352. Purity (HPLC) = 94% (UV), 100% (ELSD).</div></div><div id="sec4-1-21" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-(Cyclopropylmethyl)-1-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide (<b>24</b>)</h4><div class="NLM_p last">This reverse sulfonamide analog was prepared in parallel chemistry format in a manner similar to that used to prepare compound <b>43</b>. LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>16</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>S: 350. Found: 350. Purity (HPLC) = 90% (UV), 98.9% (ELSD).</div></div><div id="sec4-1-22" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (<b>25</b>)<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></h4><div class="NLM_p">Compound <b>48a</b>Â·2HBr (125 g, 0.234 mol) was added in portions to a mixture of 2-MeTHF (1.25 L) and TEA (442 mL, 3.17 mol). The resulting mixture was stirred at rt for 1 h, and then 1-propanesulfonyl chloride (45 mL, 0.40 mol) was added over 10 min. The reaction mixture was stirred for 1 h at rt and then washed with 10% aq citric acid solution (2 Ã 1.25 L). Aqueous 3 M NaOH solution (1.25 L, 3.75 mol) was combined with the organic layer in a reaction vessel, and the resulting mixture was heated to reflux with stirring for 1 h.</div><div class="NLM_p last">The reaction mixture was allowed to cool to rt at which point the layers were separated. The organic layer was extracted with 3 M aq NaOH (2 Ã 60 mL). All aqueous phases were combined and cooled to 15 Â°C in an ice bath. Acidification to pH â¼6 was carried out by slow addition of aq 6 M HCl solution (â¼1.3 L). During the addition, precipitation of the desired product took place. The resulting slurry was cooled to 5 Â°C and stirred for 1 h at this temperature. The title compound, a tan granular solid (66.2 g, 87%), was collected by filtration, washed with H<sub>2</sub>O (500 mL), and dried overnight in a vacuum oven at 40 Â°C. The material was recrystallized from a mixture of EtOH (442 mL) and H<sub>2</sub>O (221 mL), heating to reflux until all solids dissolved and allowing the solution to cool slowly to rt. The title compound (56.2 g, 74%) was collected by filtration, washed with 2:1 EtOH/H<sub>2</sub>O (100 mL), and again dried overnight in a vacuum oven at 40 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.64 (br s, 1H), 8.12 (s, 1 H), 7.50 (d, <i>J</i> = 9.4 Hz, 1H), 7.10â7.22 (m, 1H), 6.65 (dd, <i>J</i> = 1.8, 3.3 Hz, 1H), 4.87â4.96 (m, 1H), 3.53â3.64 (m, 1H), 3.27 (s, 3H), 2.93â2.97 (m, 2H), 2.57â2.64 (m, 2H), 2.20â2.28 (m, 2H), 1.65â1.74 (m, 2H), 0.99 (t, <i>J</i> = 7.4 Hz, 3H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>14</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>S: 324. Found: 324. Anal. Calcd for C<sub>14</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S: C, 51.99; H, 6.54; N, 21.65; O, 9.89; S, 9.91. Found: C, 52.06; H, 6.60; N, 21.48; O, 10.08; S, 9.97.</div></div><div id="sec4-1-23" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-{<i>trans</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (<b>26</b>)</h4><div class="NLM_p last">This compound was made starting with <i>trans</i>-<b>45</b>, which was combined with compound <b>46a</b> and advanced as described for the preparation of <b>25</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.64 (br s, 1H), 8.11 (s, 1H), 7.66 (d, <i>J</i> = 7.2 Hz, 1H), 7.15â7.17 (m, 1H), 6.60â6.62 (m, 1H), 5.42â5.46 (m, 1H), 3.85â3.87 (m, 1H), 3.26 (s, 3H), 2.93â2.96 (m, 2H), 2.60â2.67 (m, 2H), 2.27â2.33 (m, 2H), 1.63â1.71 (m, 2H), 0.98 (t, <i>J</i> = 7.6 Hz, 3H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>14</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>S: 324. Found: 324.</div></div><div id="sec4-1-24" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i>-(<i>cis</i>-3-(Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)butane-1-sulfonamide (<b>27</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>25</b> starting from <b>48a</b>Â·HBr. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.63 (br s, 1H), 8.10 (s, 1H), 7.49 (d, <i>J</i> = 9.1 Hz, 1H), 7.15 (dd, <i>J</i> = 2.5, 3.5 Hz, 1H), 6.64 (dd, <i>J</i> = 1.9, 3.5 Hz, 1H), 4.86â4.95 (m, 1H), 3.52â3.63 (m, 1H), 3.26 (s, 3H), 2.93â2.97 (m, 2H), 2.55â2.62 (m, 2H), 2.19â2.27 (m, 2H), 1.60â1.68 (m, 2H), 1.35â1.44 (m, 2H), 0.89 (t, <i>J</i> = 7.3 Hz, 3H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>S: 338. Found: 338. Purity (HPLC) = 100% (UV), 92.0% (ELSD).</div></div><div id="sec4-1-25" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i>-(<i>cis</i>-3-(Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)cyclopropanesulfonamide (<b>28</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>25</b> starting from <b>48a</b>Â·HBr. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.63 (br s, 1H), 8.10 (s, 1H), 7.48 (d, <i>J</i> = 9.6 Hz, 1H), 7.15 (dd, <i>J</i> = 2.5, 3.5 Hz, 1H), 6.64 (dd, <i>J</i> = 1.8, 3.5 Hz, 1H), 4.90â4.99 (m, 1H), 3.54â3.65 (m, 1H), 3.26 (s, 3H), 2.56â2.63 (m, 2H), 2.44â2.48 (m, 1H, overlapped), 2.22â2.30 (m, 2H), 0.91â0.97 (m, 4H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>14</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>S: 322. Found: 322.</div></div><div id="sec4-1-26" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 1-Cyclopropyl-<i>N</i>-(<i>cis</i>-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)methanesulfonamide (<b>29</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>25</b> starting from <b>48a</b>Â·HBr. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.63 (br s, 1H), 8.10 (s, 1H), 7.52 (d, <i>J</i> = 9.4 Hz, 1H), 7.14â7.15 (m, 1H), 6.63â6.64 (m, 1H), 4.85â4.94 (m, 1H), 3.55â3.65 (m, 1H), 3.26 (s, 3H), 2.91 (d, <i>J</i> = 7.0 Hz, 2H), 2.57â2.63 (m, 2H), 2.21â2.28 (m, 2H), 0.97â1.09 (m, 1H), 0.56â0.61 (m, 2H), 0.32â0.36 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>S: 336. Found: 336. Anal. Calcd for C<sub>15</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S: C, 53.71; H, 6.31; N, 20.88; S, 9.56. Found: C, 53.42; H, 6.46; N, 20.10; S, 9.33.</div></div><div id="sec4-1-27" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 1-Cyclobutyl-<i>N</i>-(<i>cis</i>-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)methanesulfonamide (<b>30</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>25</b> starting from <b>48a</b>Â·HBr. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 12.37 (br s, 1H), 8.28 (s, 1H), 7.47 (d, <i>J</i> = 9.0 Hz, 1H), 7.37 (br s, 1H), 6.88 (br s, 1H), 4.66â4.89 (m, 1H), 3.49â3.71 (m, 1H), 3.33 (s, 3H), 3.08 (d, <i>J</i> = 7.0 Hz, 2H), 2.58â2.76 (m, 3H), 2.20â2.37 (m, 2H), 2.01â2.15 (m, 2H), 1.71â1.95 (m, 4H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>16</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>S: 350. Found: 350. Purity (HPLC) = 100% (UV), 88% (ELSD).</div></div><div id="sec4-1-28" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 3,3,3-Trifluoro-<i>N</i>-(<i>cis</i>-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide (<b>31</b>)</h4><div class="NLM_p last">To a solution of <b>48b</b> (80 mg, 0.37 mmol) in THF (6 mL) and H<sub>2</sub>O (2 mL) was added K<sub>2</sub>CO<sub>3</sub> (150 mg, 1.1 mmol) and 3,3,3-trifluoropropane-1-sulfonyl chloride (95 mg, 0.48 mmol) at 0 Â°C. The reaction mixture was stirred at rt overnight and then concentrated to dryness. The residue was purified by prep-HPLC to afford the title compound (37 mg, 26%) as white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 8.13 (s, 1H), 7.12 (d, <i>J</i> = 3.6 Hz, 1H), 6.70 (d, <i>J</i> = 3.6 Hz, 1H), 4.96 (m, 1H), 3.76 (m, 1H), 3.33 (s, 3H), 3.26 (m, 2H), 2.80 (m, 2H), 2.65 (m, 2H), 2.25 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>14</sub>H<sub>19</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S: 378. Found: 378.</div></div><div id="sec4-1-29" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 4,4,4-Trifluoro-<i>N</i>-(<i>cis</i>-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)butane-1-sulfonamide (<b>32</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>31</b> starting from <b>48b</b>. White solid, 21% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): (all broadened unresolved peaks) 11.64 (1H), 8.10 (1H), 7.66 (1H), 7.15 (1H), 6.64 (1H), 4.90 (1H), 3.59 (1H), 3.25 (3H), 3.10 (2H), 2.35 (2H), 1.89 (2H) (other signals overlapped by DMSO signal at 2.50 or H<sub>2</sub>O peak at 3.35). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S: 392. Found: 392.</div></div><div id="sec4-1-30" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 2-Methoxy-<i>N</i>-(<i>cis</i>-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)ethanesulfonamide (<b>33</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>25</b> starting from <b>48a</b>Â·HBr. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.63 (br s, 1H), 8.10 (s, 1H), 7.55 (d, <i>J</i> = 9.1 Hz, 1H), 7.14â7.16 (m, 1H), 6.63â6.64 (m, 1H), 4.86â4.95 (m, 1H), 3.67 (t, <i>J</i> = 6.4 Hz, 2H), 3.54â3.63 (m, 1H), 3.27 (s, 3H), 3.25 (s, 3H), 3.25 (t, <i>J</i> = 6.4 Hz, 2H, overlapped), 2.55â2.63 (m, 2H), 2.21â2.28 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>14</sub>H<sub>22</sub>N<sub>5</sub>O<sub>3</sub>S: 340. Found: 340.</div></div><div id="sec4-1-31" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 3-Methoxy-<i>N</i>-(<i>cis</i>-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide (<b>34</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>31</b> starting from <b>48b</b>. White solid, 39% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.63 (br s, 1H), 8.10 (s, 1H), 7.55 (d, <i>J</i> = 9.2 Hz, 1H), 7.14 (br s, 1H), 6.64 (br s, 1H), 4.86â4.95 (m, 1H), 3.54â3.60 (m, 1H), 3.39â3.42 (m, 2H, overlapped), 3.25 (s, 3H), 3.22 (s, 3H), 2.97â3.00 (m, 2H), 2.57â2.59 (m, 2H), 2.19â2.26 (m, 2H), 1.85â1.91 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>24</sub>N<sub>5</sub>O<sub>3</sub>S: 354. Found: 354.</div></div><div id="sec4-1-32" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 3-Cyano-<i>N</i>-(<i>cis</i>-3-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide (<b>35</b>)</h4><div class="NLM_p last">This sulfonamide analog was prepared using a procedure similar to that used to prepare compound <b>25</b> starting from <b>48a</b>Â·HBr. In this case the <i>N</i>-tosyl group was removed by heating with Cs<sub>2</sub>CO<sub>3</sub> (3 equiv) in EtOH at â¼85 Â°C overnight (sealed vessel). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.64 (br s, 1H), 8.12 (s, 1H), 7.68 (d, <i>J</i> = 9.4 Hz, 1H), 7.15â7.17 (m, 1H), 6.49â6.74 (m, 1H), 4.88â4.97 (m, 1H), 3.55â3.65 (m, 1H), 3.33 (s, 3H), 3.06â3.10 (m, 2H), 2.69 (t, <i>J</i> = 7.2 Hz, 2H), 2.59â2.65 (m, 2H), 2.21â2.29 (m, 2H), 1.92â2.00 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>21</sub>N<sub>6</sub>O<sub>2</sub>S: 349. Found: 349.</div></div><div id="sec4-1-33" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}-1-oxetan-3-ylmethanesulfonamide (<b>36</b>)</h4><div class="NLM_p">To a solution of <b>48b</b>Â·HCl (1.38 g, 5.4 mmol) in THF (20 mL) was added a 1 M solution of LiHMDS in THF (13.8 mL, 13.8 mmol). After 10 min, TMSCl (1.08 g, 10 mmol) was added. The resulting mixture was stirred at rt for 1h at which point a solution of oxetan-3-ylmethanesulfonyl chloride (0.85 g, 5 mmol) in THF (5 mL) was added dropwise. The reaction mixture was stirred at rt for 8 h, and then the reaction was quenched by addition of aq NH<sub>4</sub>Cl solution. The mixture was extracted twice with 3:1 DCM/<i>i</i>-PrOH (2 Ã 150 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The crude product was purified by flash chromatography eluting with 7% MeOH/DCM to afford the title compound as white solid (700 mg, 39%). The compound was recrystallized from EtOH (612 mg, 34%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.64 (br s, 1H), 8.12 (s, 1H), 7.61 (d, <i>J</i> = 9.0 Hz, 1H), 7.15â7.17 (m, 1H), 6.64â6.66 (m, 1H), 4.87â4.95 (m,1H), 4.65â4.68 (m, 2H), 4.44â4.47 (m, 2H), 3.54â3.64 (m, 1H), 3.56â3.58 (m, 1H), 3.35â3.49 (m, 2H), 3.27 (s, 3H), 2.56â2.68 (m, 2H), 2.20â2.28 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>22</sub>N<sub>5</sub>O<sub>3</sub>S: 352. Found: 352.</div><div class="NLM_p last">[Oxetan-3-ylmethanesulfonyl chloride was prepared as follows. To a solution of oxetan-3-ylmethyl 4-methylbenzenesulfonate (4.8 g, 20 mmol) in EtOH (100 mL) was added KSCN (2.91 g, 30 mmol) at rt.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The mixture was heated to reflux for 12 h, giving a clear solution. The mixture was concentrated to afford a white solid containing oxetan-3-ylmethyl thiocyanate. This was taken up H<sub>2</sub>O (25 mL) and cooled to 0 Â°C. Chlorine gas was then bubbled through the mixture for about 30 min, giving a yellow solution. The mixture was extracted twice with MTBE (2 Ã 100 mL). The combined organic layers were washed with H<sub>2</sub>O (4 Ã 10 mL) and concentrated to afford crude oxetan-3-ylmethanesulfonyl chloride as yellow oil (1.7 g, 50%), which was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 4.60 (dd, <i>J</i> = 7.2, 9.6 Hz, 2H), 4.34 (dd, <i>J</i> = 6.4, 9.6 Hz, 2H), 3.74 (d, <i>J</i> = 6.4 Hz, 2H), 3.31â3.40 (m, 1H).]</div></div><div id="sec4-1-34" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>N</i>-Ethyl-<i>N</i>-methyl-<i>N</i>â²-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}sulfamide (<b>37</b>)</h4><div class="NLM_p last">This sulfamide analog was prepared using a procedure similar to that used to prepare compound <b>14</b>, starting with intermediate <b>50</b>. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): 8.11 (s, 1H), 7.11 (d, <i>J</i> = 3.6 Hz, 1H), 6.68 (d, <i>J</i> = 3.6 Hz, 1H), 3.54â3.61 (m, 1H), 3.34 (s, 3H), 3.20 (q, <i>J</i> = 7.2 Hz, 2H), 2.78 (s, 3H), 2.68â2.75 (m, 2H), 2.23â2.30 (m, 2H), 1.19 (t, <i>J</i> = 7.2 Hz, 3H). (The H<sub>2</sub>O peak at 4.90 obscures a methine proton signal.) LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>14</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub>S: 339. Found: 339.</div></div><div id="sec4-1-35" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>-Cyclopropyl-<i>N</i>-methyl-<i>N</i>â²-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}sulfamide (<b>38</b>)</h4><div class="NLM_p last">This sulfamide analog was prepared using a procedure similar to that used to prepare compound <b>14</b>, starting with intermediate <b>50</b>. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): 8.10 (s, 1H), 7.11 (d, <i>J</i> = 3.6 Hz, 1H), 6.68 (d, <i>J</i> = 3.6 Hz, 1H), 4.80â4.89 (m, 1H), 3.60â3.68 (m, 1H), 3.35 (s, 3H), 2.81 (s, 3H), 2.68â2.74 (m, 2H), 2.25â2.32 (m, 3H), 0.73â0.74 (m, 4H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub>S: 351. Found: 351.</div></div><div id="sec4-1-36" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>N</i>-(<i>cis</i>-3-(Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)cyclobutyl)piperidine-1-sulfonamide (<b>39</b>)</h4><div class="NLM_p last">This sulfamide analog was prepared using a procedure similar to that used to prepare compound <b>14</b>, starting with intermediate <b>50</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.62 (br s, 1H), 8.10 (s, 1H), 7.57 (d, <i>J</i> = 9.1 Hz, 1H), 7.13â7.15 (m, 1H), 6.63â6.64 (m, 1H), 4.85â4.94 (m, 1H), 3.57 (s, 3H), 3.45â3.54 (m, 1H), 2.99â3.02 (m, 4H), 2.50â2.57 (m, 2H, overlapped), 2.17â2.25 (m, 2H), 1.51â1.57 (br m, 4H), 1.43â1.50 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>16</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub>S: 365. Found: 365.</div></div><div id="sec4-1-37" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>N</i>-(2-Cyanoethyl)-<i>N</i>-methyl-<i>N</i>â²-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}sulfamide (<b>40</b>)</h4><div class="NLM_p last">This sulfamide analog was prepared using a procedure similar to that used to prepare compound <b>14</b>, starting with intermediate <b>50</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.63 (br s, 1H), 8.10 (s, 1H), 7.73 (d, <i>J</i> = 9.0 Hz, 1H), 7.14â7.16 (m, 1H), 6.63â6.64 (m, 1H), 4.87â4.96 (m, 1H), 3.49â3.59 (m, 1H), 3.33 (t, <i>J</i> = 6.6 Hz, 2H, overlapped by H<sub>2</sub>O peak), 3.26 (s, 3H), 2.80 (t, <i>J</i> = 6.6 Hz, 2H), 2.75 (s, 3H), 2.53â2.59 (m, 2H, overlapped by solvent peak), 2.18â2.28 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>15</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>S; 364. Found: 364.</div></div><div id="sec4-1-38" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> <i>N</i>-Butyl-<i>N</i>-methyl-1-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide (<b>41</b>)</h4><div class="NLM_p last">This reverse sulfonamide analog was prepared in parallel chemistry format in a manner similar to that used to prepare compound <b>43</b>. LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>17</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub>S: 366. Found: 366.</div></div><div id="sec4-1-39" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> <i>N</i>-(Cyclopropylmethyl)-<i>N</i>-methyl-1-{<i>cis</i>-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide (<b>42</b>)</h4><div class="NLM_p last">This reverse sulfonamide analog was prepared in parallel chemistry format in a manner similar to that used to prepare compound <b>43</b>. LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>17</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub>S: 364. Found: 364.</div></div><div id="sec4-1-40" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>N</i>-methyl-<i>N</i>-{<i>cis</i>-3-[(pyrrolidin-1-ylsulfonyl)methyl]cyclobutyl}-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>43</b>)</h4><div id="sec4-1-40-1" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Step 1</h5><div class="NLM_p last">Pyrrolidine (30 mg, 0.42 mmol) was added to a solution of <b>57b</b> (100 mg, 0.21 mmol) and DIPEA (0.18 mL, 1.0 mmol) in DCM (3 mL) at rt. The reaction mixture was stirred for 2 h at rt and then quenched with H<sub>2</sub>O. The mixture was extracted with EtOAc (20 mL). The organic layer was separated, washed with brine, and concentrated to afford crude <i>N</i>-methyl-<i>N</i>-{<i>cis</i>-3-[(pyrrolidin-1-ylsulfonyl)methyl]cyclobutyl}-7-[(4-methylphenyl)sulfonyl)]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine as a yellow oil, which was used in the following step without purification. LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>23</sub>H<sub>30</sub>N<sub>5</sub>O<sub>4</sub>S<sub>2</sub>: 504. Found: 504.</div></div><div id="sec4-1-40-2" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Step 2</h5><div class="NLM_p last">K<sub>2</sub>CO<sub>3</sub> (74 mg, 0.54 mmol) was added to a solution of crude <i>N</i>-methyl-<i>N</i>-{<i>cis</i>-3-[(pyrrolidin-1-ylsulfonyl)methyl]cyclobutyl}-7-[(4-methylphenyl)sulfonyl)]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (90 mg, 0.18 mmol) in MeOH (3 mL) and THF (3 mL). The mixture was stirred at 50 Â°C for 2 h, and then the reaction was quenched by addition of 1 M aq HCl solution (1 mL). The mixture was concentrated under vacuum and then purified by preparative HPLC (column, DuraShell 150 Ã 25 mm Ã 5um; mobile phase, 23% MeCN to 43% MeCN in H<sub>2</sub>O (0.05% NH<sub>4</sub>OH)) to afford the title compound as a white solid, 18.7 mg (30%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 9.49 (br s, 1H), 8.33 (s, 1H), 7.08 (d, <i>J</i> = 3.7 Hz, 1H), 6.63 (d, <i>J</i> = 3.7 Hz, 1H), 5.11â5.20 (m, 1H), 3.39â3.44 (m, 4H), 3.38 (s, 3H), 3.16 (d, <i>J</i> = 7.0 Hz, 2H), 2.65â2.92 (m, 2H), 2.56â2.64 (m, 1H), 2.12â2.19 (m, 2H), 1.96â2.00 (m, 4H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>16</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub>S: 350. Found: 350.</div></div></div><div id="sec4-1-41" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Benzyl [<i>cis</i>-3-(Methylamino)cyclobutyl]carbamate Hydrochloride and Benzyl [<i>trans</i>-3-(Methylamino)cyclobutyl]carbamate (<i>cis</i>-45Â·HCl and <i>tran</i>s-45)</h4><div class="NLM_p last">A 2 M solution of methylamine in THF (825 mL, 1.65 mol) was slowly added to a mechanically stirred slurry of benzyl (3-oxocyclobutyl)carbamate (88 g, 0.40 mol) and AcOH (48.5 mL) at rt. The reaction mixture was stirred at rt for 2.5 h and then cooled to 0 Â°C. NaBH<sub>4</sub> (49.5 g, 1.31 mol) was added in portions over 10 min. After addition was complete, the reaction mixture was allowed to warm to rt overnight. The reaction was quenched with saturated aq NH<sub>4</sub>Cl solution (250 mL, added slowly in portions of 25 mL), and then the mixture was diluted with 5 M aq NaOH solution until pH > 12. The mixture was extracted with MTBE (1500 mL). The organic layer was separated and washed with H<sub>2</sub>O (250 mL) and brine (250 mL). Aqueous layers were back-extracted with MTBE (500 mL), and the combined MTBE layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under vacuum to afford an oil. This was taken up in DCM (250 mL), concentrated again, and redissolved in DCM (1100 mL). Anhydrous HCl gas was passed into the resulting solution at rt. The resulting slurry was concentrated under vacuum to afford the crude hydrochloride salt, which was recrystallized by dissolving in <i>i</i>-PrOH (1040 mL) at 70 Â°C, adding heptane (260 mL), purging with additional HCl gas, and cooling to about 15 Â°C. The solid (68.0 g, 63%) was collected by filtration, washing with 1:1 <i>i</i>-PrOH/heptane (250 mL), and drying under vacuum; HPLC analysis indicated the material contained 98.4% benzyl [<i>cis</i>-3-(methylamino)cyclobutyl]carbamate hydrochloride and 1.6% benzyl [<i>trans</i>-3-(methylamino)cyclobutyl]carbamate hydrochloride. A second crop of material (18.9 g, 17%) containing 53% <i>cis</i> isomer and 47% <i>trans</i> isomer was subsequently obtained from the mother liquor. Small amounts of pure <i>trans</i> isomer were isolated by supercritical fluid chromatography on the free base mixture. <i>cis</i>-<b>45</b>Â·HCl: <sup>1</sup>H NMR: (400 MHz, D<sub>2</sub>O): 7.30â7.34 (m, 5H); 5.00 (s, 2H), 3.80â3.88 (m, 1H), 3.31â3.40 (m, 1H), 2.61â2.70 (m, 2H), 2.52 (s, 3H), 1.95â2.05 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>13</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub>: 235. Found: 235. <i>trans</i>-<b>45</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 7.61 (br. d, <i>J</i> = 6.6 Hz, 1H), 7.29â7.42 (m, 5H), 5.01 (s, 2H), 4.22 (br s, 1H), 4.06â4.15 (m, 1H), 3.13â3.27 (m, 1H), 2.23 (s, 3H), 2.06â2.08 (m, 4H).</div></div><div id="sec4-1-42" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Benzyl [<i>cis</i>-3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}amino)cyclobutyl]carbamate (<b>47a</b>)</h4><div class="NLM_p last">4-Chloro-7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>46a</b>) (15 g, 48.7 mmol) and <b><i>cis</i>-45Â·</b>HCl (17.2 g, 63.5 mmol) were mixed with <i>i</i>-PrOH (180 mL) and DIPEA (28 mL, 161 mmol). The resulting slurry was heated at 75 Â°C for 6 h. The reaction was cooled to rt, filtered, washed with <i>i</i>-PrOH (150 mL), and dried in an oven at 50 Â°C to give the title compound (23.5 g, 95%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 8.24 (s, 1H), 7.97 (d, <i>J</i> = 8.1 Hz, 2H), 7.62 (d, <i>J</i> = 4.0 Hz, 1H), 7.42 (d, <i>J</i> = 8.1 Hz, 2H), 7.29â7.40 (m, 6H), 6.98 (d, <i>J</i> = 4.0 Hz, 1H), 5.02 (s, 2H), 4.80â4.88 (m, 1H), 3.78â3.88 (m, 1H), 3.22 (s, 3H), 2.46â2.55 (m, 2H), 2.35 (s, 3H), 2.17â2.25 (m, 2H).</div></div><div id="sec4-1-43" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Benzyl{<i>ci</i>s-3-[(2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)(methyl)amino]-cyclobutyl}carbamate (<b>47b</b>)</h4><div class="NLM_p last">To a solution of K<sub>2</sub>CO<sub>3</sub> (459.3 g, 3.32 mol) in H<sub>2</sub>O (3 L) was added <i>cis</i>-<b>45</b>Â·HCl (225 g, 0.832 mol), followed by 2,4-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>46b</b>) (156.4 g, 0.832 mol) at rt. After addition was complete, the reaction mixture was stirred at 95 Â°C overnight. The mixture was filtered to collect the solid. The filter cake was washed with H<sub>2</sub>O and dried under vacuum to afford the title compound (315 g, 98%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.81 (br s, 1H), 7.63 (d, <i>J</i> = 8.2 Hz, 1H), 7.29â7.37 (m, 5H), 7.13 (d, <i>J</i> = 3.6 Hz, 1H), 6.64 (d, <i>J</i> = 3.6 Hz, 1H), 5.00 (s, 2H), 4.75â4.83 (m, 1H), 3.77â3.87 (m, 1H), 3.23 (s, 3H), 2.47â2.55 (m, 2H), 2.19â2.26 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>19</sub>H<sub>21</sub>ClN<sub>5</sub>O<sub>2</sub>: 386. Found: 386.</div></div><div id="sec4-1-44" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> <i>cis</i>-<i>N</i>-Methyl-N-{7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}cyclobutane-1,3-diamine dihydrobromide (<b>48a</b>Â·2HBr)</h4><div class="NLM_p last">Compound <b>47a</b> (15.2 g, 30.1 mmol) was suspended in EtOAc (45 mL) and AcOH (45 mL). To the slurry was slowly added a 4 M solution of HBr in AcOH (45 mL, 180 mmol), and the temperature was maintained below 25 Â°C. The resulting slurry was stirred at rt for 2 h. The solids were collected by filtration, washed with EtOAc (450 mL), and dried at 40 Â°C to afford the title compound (16 g, 100%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): 8.43 (s, 1 H), 8.10 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 (d, <i>J</i> = 4.1 Hz, 1H), 7.47 (d, <i>J</i> = 8.4 Hz, 2H), 7.21 (d, <i>J</i> = 4.1 Hz, 1H), 4.83â4.93 (m, 1H), 3.69â3.77 (m, 1H), 3.50 (s, 3 H), 2.86â2.93 (m, 2H), 2.58â2.67 (m, 2H), 2.45 (s, 3H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>18</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>S: 372. Found: 372. Anal. Calcd for C<sub>18</sub>H<sub>23</sub>Br<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S: C, 40.54; H, 4.35; Br, 29.97; N, 13.13. Found: C, 40.10; H, 4.11; Br, 29.56; N, 12.86.</div></div><div id="sec4-1-45" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> <i>cis</i>-<i>N</i>-Methyl-N-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-ylcyclobutane-1,3-diamine hydrochloride (<b>48b</b>Â·HCl)</h4><div class="NLM_p last">A mixture of <b>47b</b> (38.0 g, 98.4 mmol), Pd(OH)<sub>2</sub> (18.6 g, 119 mmol), and cyclohexene (212 mL, 2.08 mol) in EtOH (800 mL) was stirred at reflux for 3 h. The reaction mixture was filtered through a pad of diatomaceous earth washing with MeOH. The filtrate was concentrated under vacuum to afford the title compound (19 g, 76%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.66 (br, 1H), 8.48 (br s, 3H), 8.09 (s, 1H), 7.14 (dd, <i>J</i> = 2.3, 3.7 Hz, 1H), 6.62 (dd, <i>J</i> = 1.9, 3.7 Hz, 1H), 5.06â5.15 (m, 1H), 3.43â3.51 (m, 1H), 3.31 (s, 3H) (remaining signals obscured by solvent). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>11</sub>H<sub>16</sub>N<sub>5</sub>: 218. Found: 218.</div></div><div id="sec4-1-46" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> <i>N</i>-[<i>ci</i>s-3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}amino)cyclobutyl]-2-oxo-1,3-oxazolidine-3-sulfonamide (<b>50</b>)</h4><div class="NLM_p last">To a solution of chlorosulfonyl isocyanate (1.76 mL, 20.6 mmol) in DCM (150 mL) was added dropwise a solution of 2-bromoethanol (1.43 mL, 20.6 mmol) in DCM (80 mL) at 0 Â°C. After 30 min at 0 Â°C, a solution of <b>48a</b>Â·2HBr (11.0 g, 20.6 mmol) and TEA (10.42 g, 103.2 mmol) in dry DCM (80 mL) was added dropwise, and the reaction mixture was allowed to warm to rt overnight. The reaction solution was dissolved in DCM (1 L) and washed with aq 1 M HCl solution (2 Ã 800 mL) and brine (500 mL). The solution was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to afford the title compound as white solid (8.5 g, 79%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 8.83 (d, <i>J</i> = 9.4 Hz, 1H), 8.26 (s, 1H), 7.98 (d, <i>J</i> = 8.4 Hz, 2H), 7.66 (d, <i>J</i> = 4.1 Hz,1H), 7.44 (d, <i>J</i> = 8.4 Hz, 2H), 7.03 (d, <i>J</i> = 4.1 Hz, 1H), 4.80â4.88 (m, 1H), 4.38â4.41 (m, 2H), 3.95â3.99 (m, 2H), 3.63â3.73 (m,1H), 3.23 (s, 3H), 2.50â2.58 (m, 2H), 2.37 (s, 3H); 2.22â2.30 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>21</sub>H<sub>25</sub>N<sub>6</sub>O<sub>6</sub>S<sub>2</sub>: 521. Found: 521.</div></div><div id="sec4-1-47" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> <i>cis</i>- and <i>trans</i>-[3-(Methylamino)cyclobutyl]methanol (<b>53</b>)</h4><div id="sec4-1-47-1" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> Step 1</h5><div class="NLM_p last">di-<i>tert</i>-Butyl dicarbonate (15.8 g, 72.3 mmol) was added dropwise to a cold (0 Â°C) solution of <i>cis</i>- and <i>trans</i>-<b>52</b> (<i>cis</i>:<i>trans</i> â¼ 9:1)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (10 g, 55.7 mmol) and TEA (19.4 mL, 139.1 mmol) in DCM (370 mL). After addition was complete, the mixture was stirred at rt overnight. The solvent was evaporated under vacuum. The resulting residue was chromatographed, eluting with a gradient of petroleum ether and EtOAc (10:1 to 3:1) to afford a â¼ 9:1 mixture of <i>cis</i>- and <i>trans</i>-ethyl 3-[(tert-butoxycarbonyl)amino]cyclobutane carboxylate as a white solid (19 g, 92%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 4.80 (br s, 1H), 4.12â4.18 (m, 3H), 2.72â2.81 (m, 1H), 2.60â2.63 (m, 2H), 2.06â2.14 (m, 2H), 1.45 (s, 9 H), 1.27 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4-1-47-2" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> Step 2</h5><div class="NLM_p last">LiAlH<sub>4</sub> (9.14 g, 240.4 mmol) was suspended in dry THF (350 mL). The mixture was cooled to 0 Â°C, and a solution of ethyl 3-[(tert-butoxycarbonyl)amino]cyclobutane carboxylate (<i>cis</i>:<i>trans</i> â¼ 9:1) (11.7 g, 48.1 mmol) in dry THF (170 mL) was added dropwise. After addition was complete, the resulting mixture was heated to reflux overnight. After it was cooled to rt, the reaction was diluted with THF (1.5 L) and then cooled to 0 Â°C. Small portions of Na<sub>2</sub>SO<sub>4</sub>Â·10H<sub>2</sub>O were added until gas evolution ceased. The mixture was filtered to remove the solids, which were washed with more THF (500 mL). The filtrate was concentrated to dryness, affording the title mixture (<i>cis</i>:<i>trans</i> = 10:1) as an oil (10 g, >100%). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): 3.60 (d, <i>J</i> = 7.0 Hz, 0.2H), 3.52 (d, <i>J</i> = 5.8 Hz, 1.8H), 3.15 (quin, <i>J</i> = 7.9 Hz, 0.9H), 2.28â2.42 (m, 1.8H), 2.34 (s, 3 H), 2.26â2.08 (m, 1.3H), 1.92â2.01 (m, 0.1H), 1.55â1.62 (m, 1.8 H).</div></div></div><div id="sec4-1-48" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> <i>cis</i>-[3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}amino)cyclobutyl]methanol (<b>54</b>)</h4><div class="NLM_p last">Potassium iodide (173 mg) and TEA (13 mL, 93.8 mmol) were added to a solution of <i>cis</i>/<i>trans</i>-<b>53</b> (6.0 g, 52.1 mmol) in acetone (250 mL). 4-Chloro-7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>46a</b>) (14.4 g, 46.8 mmol) was added, and the resulting mixture was heated to reflux overnight. After evaporation of the solvent under reduced pressure, the residue was diluted with DCM (500 mL). The solution was washed sequentially with H<sub>2</sub>O (300 mL), 2% aq citric acid (300 mL), and brine (300 mL) and then dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration, the solution was filtered and concentrated to afford the title mixture as a light solid (15.3 g, 85%). A portion (5.0 g) of the mixture was separated by supercritical fluid chromatography using a Chiralpak-AD column: <i>cis</i>-<b>54</b>: 4.6 g: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 8.23 (s, 1H), 7.97 (d, <i>J</i> = 8.2 Hz, 2H), 7.61 (d, <i>J</i> = 3.9 Hz, 1H), 7.42 (d, <i>J</i> = 8.2 Hz, 2H), 6.94 (d, <i>J</i> = 3.9 Hz, 1H), 4.96â5.05 (m, 1H), 4.58 (t, <i>J</i> = 5.3 Hz, 1H) 3.39â3.41 (m, 2H), 3.19 (s, 3H), 2.35 (s, 3H), 2.08â2.19 (m, 3H), 1.99â2.07 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>19</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub>S: 387. Found: 387. In the <sup>1</sup>H NMR spectrum (400 MHz, DMSO-<i>d</i><sub>6</sub>) of the mixture of <i>cis</i>- and <i>tran</i>s-<b>54</b> (before SFC), the latter isomer displayed distinct signals at 6.90 (d, <i>J</i> = 3.8 Hz, 1H), 5.19â5.27 (m, 1H), 4.69â4.73 (m, 1H), 3.50â3.53 (m, 2H), and 3.23 (s, 3H).</div></div><div id="sec4-1-49" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> <i>cis</i>-[3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}amino)cyclobutyl]methyl 4-methylbenzenesulfonate (<b>55a</b>)</h4><div class="NLM_p last">To a solution of <b>54</b> (20 g, 51.8 mmol) and DMAP (12.6 g, 103.6 mmol) in DCM (500 mL) at 0 Â°C was added <i>p</i>-toluenesulfonyl chloride (14.8 g, 77.7 mmol). The reaction mixture was stirred at rt for 16 h and then washed with H<sub>2</sub>O (total 500 mL). The combined aqueous washes were extracted with DCM (2 Ã 800 mL). The combined organic layers were dried, filtered, and concentrated under vacuum. The residue was chromatographed, eluting with a gradient of 0% to 5% MeOH/DCM to afford the title compound (23 g, 82%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 8.23 (s, 1H), 7.97 (d, <i>J</i> = 8.0 Hz, 2H), 7.81 (d, <i>J</i> = 8.7 Hz, 2H), 7.62 (d, <i>J</i> = 3.9 Hz, 1H), 7.49 (d, <i>J</i> = 8.7 Hz, 2H), 7.44 (d, <i>J</i> = 8.0 Hz, 2H), 6.95 (d, <i>J</i> = 4.3 Hz, 1H), 4.95â5.03 (m, 1H), 4.10 (d, <i>J</i> = 6.2 Hz, 2H), 3.16 (s, 3H), 2.43 (s, 3H), 2.37 (s, 3H), 2.26â2.40 (m, 1H), 2.16â2.22 (m, 2H), 1.90â1.98 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>26</sub>H<sub>29</sub>N<sub>4</sub>O<sub>5</sub>S<sub>2</sub>: 541. Found: 541.</div></div><div id="sec4-1-50" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> <i>cis</i>-[3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}amino)cyclobutyl]methylmethanesulfonate (<b>55b</b>)</h4><div class="NLM_p last">To a solution of <b>54</b> (2.06 g, 5.3 mmol), TEA (2.25 mL, 16 mmol) and DMAP (33 mg, 0.23 mmol) in DCM (27 mL) at 0 Â°C was added methanesulfonyl chloride (14.8 g, 77.7 mmol). The reaction mixture was stirred at 0 Â°C for 2 h and then poured into saturated aq NaHCO<sub>3</sub> solution. The resulting mixture was extracted three times with DCM. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under vacuum. The residue was chromatographed, eluting with a gradient of 5% to 100% EtOAc/heptane to afford the title compound (2.23 g, 90%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 8.39 (s, 1H), 8.05 (d, <i>J</i> = 8.3 Hz, 2H), 7.47 (d, <i>J</i> = 4.0 Hz, 1H), 7.28 (d, <i>J</i> = 8.0 Hz, 2H), 6.64 (d, <i>J</i> = 4.0 Hz, 1H), 5.04â5.13 (m, 1H), 4.23 (d, <i>J</i> = 4.8 Hz, 2H), 3.24 (s, 3H), 3.03 (s, 3H), 2.39â2.46 (m, 3H), 2.38 (s, 3H), 2.05â2.13 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>20</sub>H<sub>24</sub>N<sub>4</sub>O<sub>5</sub>S<sub>2</sub>: 465. Found: 465.</div></div><div id="sec4-1-51" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>S</i>-{[<i>cis</i>-3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}amino)cyclobutyl]methyl} ethanethioate (<b>56</b>)</h4><div class="NLM_p last">A solution of <b>55a</b> (2.0 g, 3.70 mmol) in DMF (6 mL) was added dropwise over 5 min to a solution of potassium thioacetate (678 mg, 5.93 mmol) in DMF (5 mL) at rt. The mixture was heated at 50â55 Â°C overnight. The mixture was cooled to rt, and the reaction was quenched by pouring into saturated aq NaHCO<sub>3</sub> solution (60 mL). The mixture was extracted with EtOAc (3 Ã 30 mL), and the combined organic layers were washed with H<sub>2</sub>O (3 Ã 30 mL) and brine (30 mL). After drying over Na<sub>2</sub>SO<sub>4</sub>, the solution was concentrated. The residue was chromatographed, eluting with a gradient of DCM and MeOH (100:0 to 80:20) to afford the title compound (1.2 g, 73%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 8.24 (s, 1H), 7.97 (d, <i>J</i> = 7.7 Hz, 2H), 7.62 (d, <i>J</i> = 3.9 Hz, 1H), 7.44 (d, <i>J</i> = 8.2 Hz, 2H), 6.96 (d, <i>J</i> = 4.3 Hz, 1H), 4.88â4.96 (m, 1H), 3.20 (s, 3H), 3.02 (d, <i>J</i> = 7.0 Hz, 2H), 2.37 (s, 3H), 2.35 (s, 3H), 2.26â2.33 (m, 2H), 2.13â2.24 (m, 1H), 1.87â1.92 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub>: 445. Found: 445.</div></div><div id="sec4-1-52" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> [<i>cis</i>-3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}amino)cyclobutyl]methanesulfonic acid (<b>57a</b>)</h4><div class="NLM_p last">To a solution of <b>56</b> (580 mg, 1.30 mmol) in formic acid (10 mL) at rt was added 30% aq H<sub>2</sub>O<sub>2</sub> solution (0.7 mL, 6.9 mmol). The resulting mixture was stirred at rt overnight. The reaction was poured into 33% aq Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> solution (1.1 mL) and then stirred for 10 min. Aqueous 33% NaOH solution (1.8 mL) was then added to adjust the pH to 5. The resulting mixture was stirred at rt for 1 h. The solid was collected by filtration, washed with H<sub>2</sub>O (10 mL), and vacuum-dried at about 60 Â°C to afford the title compound (634 mg, crude) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 8.24 (s, 1H), 7.97 (d, <i>J</i> = 8.4 Hz, 2H), 7.62 (d, <i>J</i> = 4.2 Hz, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 6.96 (d, <i>J</i> = 4.2 Hz, 1H), 4.85â4.90 (m, 1H), 3.20 (s, 3H), 2.60â2.62 (m, 2H), 2.36 (s, 3H), 2.35â2.30 (m, 3H), 1.98â2.02 (m, 2H). LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>19</sub>H<sub>23</sub>N<sub>4</sub>O<sub>5</sub>S<sub>2</sub>: 451. Found: 451.</div></div><div id="sec4-1-53" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> <i>cis</i>-[3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}amino)cyclobutyl]methanesulfonyl chloride (<b>57b</b>)</h4><div class="NLM_p last">Thionyl chloride (0.3 mL, 3.33 mmol) was added dropwise over 5 min to a solution of <b>57a</b> (150 mg, 0.33 mmol) in DCM (20 mL) at 0 Â°C. Two drops of DMF were added to the solution, which was then heated at 75 Â°C for 2 h. The mixture was cooled, and the solvent was evaporated. The residue was washed with anhydrous DCM (3 Ã 10 mL) to afford the crude title compound (170 mg) as a yellow solid. LC/MS <i>m</i>/<i>z</i> (M + H<sup>+</sup>) calcd for C<sub>19</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>4</sub>S<sub>2</sub>: 469. Found: 469.</div></div></div><div id="sec4-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Caliper JAK Enzyme End Point IC<sub>50</sub> Assays at 1 mM ATP</h3><div id="sec4-2-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Sample Preparation</h4><div class="NLM_p">Test compounds were solubilized in DMSO to a stock concentration of 30 mM. Compounds were diluted in DMSO to create an 11-point half log dilution series with a top concentration of 600 Î¼M. The test compound plate also contained positive control wells with a known inhibitor to define 100% inhibition and negative control wells with DMSO to define no inhibition. The compound plates were diluted 1:60 in the assay, resulting in a final assay compound concentration range of 10 Î¼M to 100 pM and a 1.7% DMSO concentration.</div><div class="NLM_p last">The human JAK activity was determined by using a microfluidic assay to monitor phosphorylation of a synthetic peptide by the recombinant human kinase domain of each of the four members of the JAK family: JAK1, JAK2, JAK3, and TYK2. Each assay condition was optimized for enzyme concentration and room temperature incubation time to obtain a conversion rate of 20%â30% phosphorylated peptide product. The 250 nL samples of test compounds and controls solubilized in 100% DMSO were added to a 384-well polypropylene plate (MatricalMP101 or Corning Costar 3676) using a noncontact acoustic dispenser. Kinase assays were carried out at room temperature in a 15 Î¼L reaction buffer containing 20 mM HEPES, pH 7.4, 1 mM ATP, 10 mM magnesium chloride, 0.01% bovine serum albumin (BSA), 0.0005% Tween 20, and 1 mM DTT. Reaction mixtures contained 1 Î¼M of a fluorescently labeled synthetic peptide, a concentration less than the apparent <i>K</i><sub>m</sub>. The JAK1 and TYK2 assays contained 1 Î¼M of the peptide 5FAM-KKSRGDYMTMQID, and the JAK2 and JAK3 assays contained 1 Î¼M of the peptide FITC-KGGEEEEYFELVKK. The assays were initiated by the addition of enzyme. The assays were stopped with 15 Î¼L of a buffer containing 180 mM HEPES, pH 7.4, 20 mM EDTA, 0.2% Coating Reagent, resulting in a final concentration of 10 mM EDTA, 0.1% Coating Reagent, and 100 mM HEPES, pH 7.4. Utilizing the LabChip 3000 mobility shift technology (Caliper Life Science), each assay reaction was sampled to determine the level of phosphorylation. This technology is separation-based, allowing direct detection of fluorescently labeled substrates and products. Separations are controlled by a combination of vacuum pressure and electric field strength optimized for each peptide substrate.</div></div><div id="sec4-2-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> Human Whole Blood (HWB) Assays</h4><div class="NLM_p">Test articles were prepared as 30 mM stocks in 100% DMSO and then diluted to 5 mM. A 10-point 2.5 dilution series was created in DMSO with a top concentration of 5 mM. Further dilution was done by adding 4 Î¼L of the above test article solutions into 96 Î¼L of PBS with a top concentration of 200 Î¼M.</div><div class="NLM_p">Cytokines IL-6 (cat. no. 206-IL), IL-10 (cat. no. 217-IL), IL-12 (cat. no. 219-IL), IL-15 (cat. no. 247-IL), IL-23 (cat. no. 1290-IL), IL-27 (cat. no. 2526-IL), IFNÎ± (cat. no. 11200â2), IFNÎ³ (cat. no. 285-IF), and EPO (cat no. 287 TC) were obtained from R&D Systems (Minneapolis, MN). IL-21 (cat. no. AF-200-21) was purchased from PeproTech (Rocky Hill, NJ). Antibodies specific to pSTATs and CDs were supplied by BD Biosciences (San Jose, CA); Anti-pSTAT1-AlexaFluor647, cat. no. 612597; Anti-pSTAT3-AlexaFluor647, cat. no. 557815; Anti-pSTAT4-AlexaFluor647, cat. no. 558137; Anti-pSTAT5-AlexaFluor647, cat. no. 612599; anti-CD3-Pacific Blue, cat. no. 558117; anti-CD14-Pacific Blue, cat. no. 558121. Phosflow 5x Lyse/Fix Buffer (cat. no. 558049) was purchased from BD Biosciences. Bovine serum albumin (BSA, 30% sterile solution; cat. no. A8327) and sodium azide (cat. no. S8032) were received from Sigma-Aldrich. D-PBS (without Ca<sup>2+</sup> or Mg<sup>2+</sup>) was from Invitrogen (cat. no. 14190; Grand Island, NY).</div><div class="NLM_p">Cryopreserved human bone marrow CD34<sup>+</sup> cells (cat. no. ABM022F) were purchased from Allcells. Frozen bone marrow CD34<sup>+</sup> cells were thawed, washed once with IMEM, resuspended in Stem Span medium (cat. no. 09600; STEMCELL Technologies, Vancouver, Canada) supplemented with 20 ug/mL of LDL (cat. no. 02698; STEMCELL Technologies), 100 ng/mL Kit Ligand (cat. no. 255 SC; R&D Systems), and 2 U/mL EPO at 20â¯000 cells/mL and cultured for 7 days. CD34<sup>+</sup> cells were then harvested, washed once with D-PBS, and resuspended at 0.5 million cells/mL in HWB to be used in the EPO stimulation assay.</div><div class="NLM_p last">To a 96-well polypropylene plate (VWR cat. no. 82007-292), 90 Î¼L of HWB was added per well, followed by addition of 5 Î¼L of test article solutions prepared above to give a top concentration of 10 Î¼M. The plate was mixed and incubated for 45 min at 37 Â°C. To each well was added 5 Î¼L of cytokine (5 uL/well; final, 5000 U/mL IFNÎ±, 100 ng/mL IFNÎ³, 50 ng/mL IL-6, 30 ng/mL IL-10, 5 ng/mL IL-12, 30 ng/mL IL-15, 50 ng/mL IL-21, 100 ng/mL IL-23, 1200 ng/mL IL-27, or 2 U/mL EPO) for 15 min. Anti-CD3-Pacific Blue and anti-CD14-Pacific Blue antibodies (1:6 dilution in D-PBS, 3 uL/well) were added to samples 15 min before the stimulation of IL-6 and IFNÎ³, respectively. The reaction was quenched by adding Lyse/Fix Buffer to all wells at 1000 Î¼L/well and incubated for 20 min at 37 Â°C; after washing with FACS buffer [D-PBS containing 0.1% BSA and 0.1% sodium azide], 400 Î¼L ice cold 90% MeOH/H<sub>2</sub>O was added to each well, and the sampels were incubated on ice for 30 min. One more wash was done with cold FACS buffer, and all samples were finally resuspended in 250 Î¼L/well of the desired Alexa Fluor 647 conjugated antiphospho-STAT antibodies at 1:125 dilution in FACS buffer. Anti-pSTAT1-AlexaFluor647 was used in assays with stimulation from IFNÎ³ and IL-6. Anti-pSTAT3-AlexaFluor647 was used in assays with stimulation from IFNÎ±, IL-6, IL-10, IL-21, IL-23, and IL-27. Anti-pSTAT4-AlexaFluor647 was used in assays with stimulation from IL-12. Anti-pSTAT5-AlexaFluor647 was used for IL-15 and EPO stimulated cells. After overnight incubation at 4 Â°C, all the samples were transferred into a 96-well polypropylene U-bottom plate (Falcon cat. no. 353077) and flow cytometric analysis was performed on a FACSCalibur, FACSCanto or LSRFortessa equipped with a HTS plate loader (BD Biosciences). For IL-10, IL-12, IL-15, IL-21, IL-23, IL-27, and IFNÎ± stimulation, the lymphocyte population was gated for histogram analysis of pSTAT3, 4, or 5 staining. For EPO stimulation, all events (entire populations) were gated for histogram analysis of pSTAT5 staining. For IFNÎ³ stimulation, CD14<sup>+</sup> cells were gated for histogram analysis of pSTAT1 staining. For IL-6 stimulation, CD3<sup>+</sup> cells were gated for histogram analysis of pSTAT1 and 3 staining. Background fluorescence was defined using unstimulated cells, and a gate was placed at the foot of the peak to include â¼0.5% gated population. The histogram statistical analysis was performed using CellQuest Pro version 5.2.1 (BD Biosciences), FACSDiva version 6.2 (BD Biosciences), or FlowJo version 7.6.1 (Ashland, OR) software. Relative fluorescence unit (RFU), which measures the level of phospho STAT, was calculated by multiplying the percent positive population and its mean fluorescence. Data from 10 compound concentrations (singlicate at each concentration) was normalized as a percentage of control based on the formula<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/jm-2017-015983_m001.gif" alt="" /></img></span>where <i>A</i> is the RFU from wells containing compound and cytokine, <i>B</i> is the RFU from wells without cytokine (minimum fluorescence) and <i>C</i> is the RFU from wells containing only cytokine (maximum fluorescence). Inhibition curves and IC<sub>50</sub> values were determined using the Prism version 5 software (GraphPad, La Jolla, CA).</div></div></div><div id="sec4-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Rat Pharmacology Studies</h3><div id="sec99" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Rat WB Stimulation and Flow Cytometry</h4><div class="NLM_p last">A 70 Î¼L sample of rat WB was surface stained with Anti-CD3-PE (eBiosciences cat. no. 12-0030-82) and rat antimouse CD4-FITC (BD Biosciences cat. no. 554843) for 15 min at 37 Â°C. Rat whole blood was then stimulated with either 100 ng/mL rmIL-21 (R&D Systems cat. no. 594-ML), 100 ng/mL rhIL6 (R&D Systems cat. co. 206-IL), or 100 ng/mL of rrIFNÎ³ (R&D Systems cat. no. 585-IF) for 20 min at 37 Â°C. Following incubation, RBCs were lysed using BD Phosflow Lyse/Fix buffer (BD Biosciences cat. no. 558049) and cells were subsequently permeabilized at 4 Â°C using 90% MeOH. Cells were washed twice in FACS buffer and stained using Alexa Fluor 647 conjugated antiphospho-STAT1 (PY701, BD Biosciences, cat. no. 612597) or antiphospho STAT3 (PY705, BD Biosciences, cat. co. 557815). Flow cytometry was performed using a FACS LSR Fortessa (BD Biosciences). FlowJo software version 7.6.1 was used for data analysis (Tree Star Inc., Ashland, OR). Intracellular STAT3 and STAT1 phosphorylation was determined within a CD3+ gate representing the T cell population. The level of STAT phosphorylation observed in whole blood from vehicle-treated rats was referenced as the maximal response to cytokine stimulation. Data was normalized as a percent of vehicle-treated animals using the following formula:<span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/jm-2017-015983_m002.gif" alt="" /></img></span>where <i>A</i> is experimental mean fluorescence, <i>B</i> background fluorescence determined from unstimulated cells, and <i>C</i> maximum fluorescence determined by vehicle-treated animals. Graphs were generated using Prism Graph Pad version 6 (La Jolla, CA).</div></div><div id="sec100" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Rat Adjuvant Induced Arthritis Model</h4><div class="NLM_p">The effect of JAK1 inhibition by <b>25</b> was evaluated in vivo using a therapeutic dosing paradigm in a rat adjuvant-induced arthritis. The efficacy of this molecule was evaluated in two separate studies using successively lower doses. Arthritis was induced by immunization of female Lewis rats (8â10 weeks old; Charles River Laboratories, Portage, MI) via intradermal injection at the base of the tail with complete Freundâs adjuvant with three 50 Î¼L injections (15 mg/mL <i>Mycobacterium tuberculosis</i> (Difco) in incomplete Freundâs adjuvant (Sigma-Aldrich)). Seven days after the initial immunization, the baseline hind paw volume of the immunized rats was measured via plethysmograph (Buxco Inc.). The rats were monitored daily for signs of arthritis including change in body weight and hind paw volume measurement. When individual hind paw volume measurements indicated an increase of 0.2 mL (or greater) in a single hind paw, animals were randomly assigned to a treatment group. Daily treatment with <b>25</b> was administered via oral gavage. Treatment groups for experiment 1 were 50, 15, and 5 mg/kg or vehicle (2% Tween 80/0.5% methylcellulose/deionized H<sub>2</sub>O). Treatment groups for experiment 2 were 15, 5, 1, and 0.5 mg/kg or vehicle (2% Tween 80/0.5% methylcellulose/deionized H<sub>2</sub>O). Dosing began once individuals were enrolled into respective groups. Treatment continued for 7 days. Animals were euthanized after 7 days of dosing. At the conclusion of the study, whole blood was taken at 15 min postdose (peak concentration in plasma) for analysis of STAT phosphorylation, and plasma was taken at peak (0.25 h) and trough (24 h) time points for exposure PK.</div><div class="NLM_p last">All activities involving laboratory animals were carried out in accordance with federal, state, local, and institutional guidelines governing the use of laboratory animals in research and were reviewed and approved by Pfizer (or other) Institutional Animal Care and Use Committee. Pfizer animal care facilities that supported this work are fully accredited by AAALAC International.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i99"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01598">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17004" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17004" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01598" class="ext-link">10.1021/acs.jmedchem.7b01598</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Inhibition values for JAK3 and TYK2 and permeability measured using RRCK; fraction unbound compared to logâ¯<i>D</i>; kinase selectivity table for <b>25</b>; initial range finding rAIA study with <b>25</b> at doses of 5, 15, and 50 mpk; cytokine inhibition values in HWB for <b>19</b>, <b>25</b>, <b>35</b>, and <b>36</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_001.pdf">jm7b01598_si_001.pdf (1.41 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_002.csv">jm7b01598_si_002.csv (2.41 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structure of compound <b>25</b> in JAK1 and JAK2 can be accessed using PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BBU">6BBU</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BBV">6BBV</a>, respectively, in the RCSB Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">www.rcsb.org</a>). Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b01598" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73687" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73687" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ralph P. Robinson</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4066-5299" title="Orcid link">http://orcid.org/0000-0002-4066-5299</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bdcfdcd1cdd593cd93cfd2dfd4d3ced2d3fdcddbd4c7d8cf93ded2d0"><span class="__cf_email__" data-cfemail="f4869598849cda84da869b969d9a879b9ab484929d8e9186da979b99">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ray Unwalla</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5789-7336" title="Orcid link">http://orcid.org/0000-0002-5789-7336</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1260736b3c677c65737e7e735262747b6877603c717d7f"><span class="__cf_email__" data-cfemail="6210031b4c170c15030e0e032212040b1807104c010d0f">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael L. Vazquez</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6244-6540" title="Orcid link">http://orcid.org/0000-0001-6244-6540</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neelu Kaila</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph W. Strohbach</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John D. Trzupek</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew F. Brown</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark E. Flanagan</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark J. Mitton-Fry</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy A. Johnson</span> - <span class="hlFld-Affiliation affiliation">Veterinary
Medicine Research and Development, Pfizer
Inc, 333 Portage Street, Kalamazoo, Michigan 49007, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ruth E. TenBrink</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Pfizer Inc, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric P. Arnold</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arindrajit Basak</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven E. Heasley</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Soojin Kwon</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan Langille</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mihir D. Parikh</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah H. Griffin</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Development, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey M. Casavant</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian A. Duclos</span> - <span class="hlFld-Affiliation affiliation">Veterinary
Medicine Research and Development, Pfizer
Inc, 333 Portage Street, Kalamazoo, Michigan 49007, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ashley E. Fenwick</span> - <span class="hlFld-Affiliation affiliation">Veterinary
Medicine Research and Development, Pfizer
Inc, 333 Portage Street, Kalamazoo, Michigan 49007, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas M. Harris</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Seungil Han</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicole Caspers</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin E. Dowty</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Yang</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Ellen Banker</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Hegen</span> - <span class="hlFld-Affiliation affiliation">Inflammation
and Immunology, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter T. Symanowicz</span> - <span class="hlFld-Affiliation affiliation">Inflammation
and Immunology, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Li</span> - <span class="hlFld-Affiliation affiliation">Inflammation
and Immunology, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lu Wang</span> - <span class="hlFld-Affiliation affiliation">Inflammation
and Immunology, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsung H. Lin</span> - <span class="hlFld-Affiliation affiliation">Inflammation
and Immunology, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Jussif</span> - <span class="hlFld-Affiliation affiliation">Inflammation
and Immunology, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James D. Clark</span> - <span class="hlFld-Affiliation affiliation">Inflammation
and Immunology, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Baptiste Telliez</span> - <span class="hlFld-Affiliation affiliation">Inflammation
and Immunology, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i101">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63264" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63264" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">M.L.V. was the project leader during the discovery of PF-04965842. We thank Karen Coffman, Chris Dehnhardt, Shane Eisenbeis, Steve Kortum, Matthew Reese, Derek Sheehan, and Jamison Tuttle for their contributions to analog synthesis, resynthesis, and characterization. We thank Blossom Sneed for running the JAK caliper assays.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i102" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i102"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i103" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i103"> Abbreviations Used</h2><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">(Boc)<sub>2</sub>O</td><td class="NLM_def"><p class="first last">di-<i>tert</i>-butyl dicarbonate</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicycloundec-7-ene</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">1,2-dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DTT</td><td class="NLM_def"><p class="first last">dithiothreitol</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour</p></td></tr><tr><td class="NLM_term"><i>i</i>-PrOH</td><td class="NLM_def"><p class="first last">isopropyl alcohol</p></td></tr><tr><td class="NLM_term">LiHDMS</td><td class="NLM_def"><p class="first last">lithium hexamethyldisilazide</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MTBE</td><td class="NLM_def"><p class="first last">methyl <i>tert</i>-butyl ether</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minute</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methylpyrrolidinone</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">RRCK</td><td class="NLM_def"><p class="first last">Ralph Russ canine kidney</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran.</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i104">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leonard, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">JAKS and STATS: biological implications</span> <span class="citation_source-journal">Annu. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">â</span> <span class="NLM_lpage">322</span><span class="refDoi">Â DOI: 10.1146/annurev.immunol.16.1.293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1146%2Fannurev.immunol.16.1.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=9597132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADyaK1cXislygurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=293-322&author=W.+J.+Leonardauthor=J.+J.+O%E2%80%99Shea&title=JAKS+and+STATS%3A+biological+implications&doi=10.1146%2Fannurev.immunol.16.1.293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">JAKS and STATS: Biological implications</span></div><div class="casAuthors">Leonard, Warren J.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">293-322</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 185 refs.  Cytokines and interferons are mols. that play central roles in the regulation of a wide array of cellular functions in the lympho-hematopoietic system.  These factors stimulate proliferation, differentiation, and survival signals, as well as specialized functions in host resistance to pathogens.  Although cytokines are known to activate multiple signaling pathways that together mediate these important functions, one of these pathways, the Jak-STAT pathway, is the focus of this chapter.  This pathway is triggered by both cytokines and interferons, and it very rapidly allows the transduction of an extracellular signal into the nucleus.  The pathway uses a novel mechanism in which cytosolic latent transcription factors, known as signal transducers and activators of transcription (STATs), are tyrosine phosphorylated by Janus family tyrosine kinases (Jaks), allowing STAT protein dimerization and nuclear translocation.  STATs then can modulate the expression of target genes.  The basic biol. of this system, including the range of known Jaks and STATs, is discussed, as are the defects in animals and human lacking some of these signaling mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkrO-nJd5D_LVg90H21EOLACvtfcHk0liaH4wFztnn-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislygurs%253D&md5=ac5eeeb0159c2c8769e2cb28720cdf98</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.16.1.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.16.1.293%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAKS%2520and%2520STATS%253A%2520biological%2520implications%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1998%26volume%3D16%26spage%3D293%26epage%3D322%26doi%3D10.1146%2Fannurev.immunol.16.1.293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">â</span> <span class="NLM_lpage">287</span><span class="refDoi">Â DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lgUi9cad2XHOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1002%2Fjlb.60.4.441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=8864127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1996&pages=441-452&author=J.+A.+Johnstonauthor=C.+M.+Baconauthor=M.+C.+Riedyauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+IL-2+and+related+cytokines%3A+JAKs%2C+STATs%2C+and+relationship+to+immunodeficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span></div><div class="casAuthors">Johnston, James A.; Bacon, Chris M.; Riedy, M. C.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 153 refs.  Cytokines that bind to the interleukin-2 (IL-2) receptor common gamma chain (Î³c), including IL-2, IL-4, IL-7, IL-9, and IL-15, are important for the growth and differentiation of T and B lymphocytes, natural killer cells, macrophages, and monocytes.  These cytokines have overlapping biol. effects that in part result from the use of the shared receptor subunit Î³c.  Recently it has become clear that these cytokines activate a no. of important intracellular signaling mols., including the Janus kinases JAK1 and JAK3 and members of the transcription factor family of signal transducers and activators of transcription (STATs).  The discovery of these signaling pathways has led to important new insights into their role of lymphocyte maturation, as it has emerged that mutations in the genes encoding both Î³c and JAK3 result in similar forms of severe combined immunodeficiency (SCID).  In this review we examine the structure and function of cytokine receptors and the signaling pathways involved in their regulation of gene expression.  Furthermore, we discuss recent advances that have led to a better understanding of how cytokines elicit intracellular responses, as well as their role in normal lymphoid development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBS-4Fw4Io7Vg90H21EOLACvtfcHk0lgUi9cad2XHOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D&md5=6ccea65ed0126878728f639506a565ac</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1002%2Fjlb.60.4.441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlb.60.4.441%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DBacon%26aufirst%3DC.%2BM.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520IL-2%2520and%2520related%2520cytokines%253A%2520JAKs%252C%2520STATs%252C%2520and%2520relationship%2520to%2520immunodeficiency%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D1996%26volume%3D60%26spage%3D441%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plenge, R.</span><span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">â</span> <span class="NLM_lpage">550</span><span class="refDoi">Â DOI: 10.1016/j.immuni.2012.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.immuni.2012.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=22520847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease&doi=10.1016%2Fj.immuni.2012.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease</span></div><div class="casAuthors">O'Shea, John J.; Plenge, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">542-550</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, a landmark in cell biol., provided a simple mechanism for gene regulation that dramatically advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleukins.  As we learn more about the complexities of immune responses, new insights into the functions of this pathway continue to be revealed, aided by technol. that permits genome-wide views.  As we celebrate the 20th anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this knowledge has rapidly been translated to human immune disease.  Not only have genome-wide assocn. studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc6dj5Zf9fdLVg90H21EOLACvtfcHk0lhxrACoH52LOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D&md5=de187a0555549f9f00f5a41052c05352</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2012.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2012.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550%26doi%3D10.1016%2Fj.immuni.2012.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Shuai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span> </span><span class="NLM_article-title">Regulation of JAK-STAT signaling in the immune system</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">â</span> <span class="NLM_lpage">911</span><span class="refDoi">Â DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signaling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1eR"><div class="casContent"><span class="casTitleNuber">1e</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lhxrACoH52LOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit1e&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signaling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Mavers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruderman, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, H.</span><span> </span><span class="NLM_article-title">Intracellular signal pathways: potential for therapies</span> <span class="citation_source-journal">Curr. Rheumatol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">â</span> <span class="NLM_lpage">385</span><span class="refDoi">Â DOI: 10.1007/s11926-009-0054-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1007%2Fs11926-009-0054-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=19772834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFeku7jE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=378-385&author=M.+Maversauthor=E.+M.+Rudermanauthor=H.+Perlman&title=Intracellular+signal+pathways%3A+potential+for+therapies&doi=10.1007%2Fs11926-009-0054-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular signal pathways: potential for therapies</span></div><div class="casAuthors">Mavers, Melissa; Ruderman, Eric M.; Perlman, Harris</div><div class="citationInfo"><span class="NLM_cas:title">Current Rheumatology Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">378-385</span>CODEN:
                <span class="NLM_cas:coden">CRRUCI</span>;
        ISSN:<span class="NLM_cas:issn">1523-3774</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Drawbacks to current therapies for rheumatoid arthritis and the high cost of many of these drugs have lead to the investigation of novel approaches for treatment of this disease.  One such tactic is the targeting of proteins involved in intracellular signal transduction.  Inhibitors of p38 kinase have largely failed in clin. trials, due to both lack of efficacy and adverse events.  The degree of adverse events may reflect off-target effects or, conversely, may be a mechanism-related event subsequent to successful inhibition of p38.  Drugs targeting Janus kinases or spleen tyrosine kinase have shown greater success in clin. trials.  A thorough anal. of specificity, as well as publication of both pos. and neg. results, must be the goal of continuing trials of these and other inhibitors of signal transduction mols.  The success of many clin. trials in this novel class of drugs provides optimism that more cost-effective and improved therapies will soon be available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBrleay_ctfrVg90H21EOLACvtfcHk0lh4kXK80JH3hA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFeku7jE&md5=f3a18d64ac9620db5e43ca55df40c83b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs11926-009-0054-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11926-009-0054-9%26sid%3Dliteratum%253Aachs%26aulast%3DMavers%26aufirst%3DM.%26aulast%3DRuderman%26aufirst%3DE.%2BM.%26aulast%3DPerlman%26aufirst%3DH.%26atitle%3DIntracellular%2520signal%2520pathways%253A%2520potential%2520for%2520therapies%26jtitle%3DCurr.%2520Rheumatol.%2520Rep.%26date%3D2009%26volume%3D11%26spage%3D378%26epage%3D385%26doi%3D10.1007%2Fs11926-009-0054-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Schindler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, T.</span><span> </span><span class="NLM_article-title">JAK-STAT Signaling: from interferons to cytokines</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">20059</span><span class="NLM_x">â</span> <span class="NLM_lpage">20063</span><span class="refDoi">Â DOI: 10.1074/jbc.R700016200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1074%2Fjbc.R700016200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=17502367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsFWntr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=20059-20063&author=C.+Schindlerauthor=D.+E.+Levyauthor=T.+Decker&title=JAK-STAT+Signaling%3A+from+interferons+to+cytokines&doi=10.1074%2Fjbc.R700016200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">JAK-STAT Signaling: From Interferons to Cytokines</span></div><div class="casAuthors">Schindler, Christian; Levy, David E.; Decker, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">20059-20063</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  The early availability of recombinant interferons (IFNs) afforded an opportunity to study how cytokines induce gene expression, culminating in the identification of JAK-STAT signaling paradigm.  Subsequent studies identified 7 STATs and 4 JAKs, providing an insight how IFNs and other members of the four-helix bundle cytokine family transduce their biol. responses.  Here, the authors briefly summarize this signaling paradigm and then focus on STAT-dependent transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3j1nH6yBhbVg90H21EOLACvtfcHk0lh4kXK80JH3hA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsFWntr8%253D&md5=9bbfc21b9afc22cd65dbd9a8605f7a03</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R700016200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R700016200%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DC.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDecker%26aufirst%3DT.%26atitle%3DJAK-STAT%2520Signaling%253A%2520from%2520interferons%2520to%2520cytokines%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D20059%26epage%3D20063%26doi%3D10.1074%2Fjbc.R700016200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Cytokines and their role in lymphoid development, differentiation and homeostasis</span> <span class="citation_source-journal">Curr. Opin. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">â</span> <span class="NLM_lpage">506</span><span class="refDoi">Â DOI: 10.1097/00130832-200212000-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1097%2F00130832-200212000-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=14752332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=495-506&author=S.+R.+Hofmannauthor=R.+Ettingerauthor=Y.-J.+Zhouauthor=M.+Gadinaauthor=P.+Lipskyauthor=R.+Siegelauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Shea&title=Cytokines+and+their+role+in+lymphoid+development%2C+differentiation+and+homeostasis&doi=10.1097%2F00130832-200212000-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines and their role in lymphoid development, differentiation and homeostasis</span></div><div class="casAuthors">Hofmann Sigrun R; Ettinger Rachel; Zhou Yong-Jie; Gadina Massimo; Lipsky Peter; Siegel Richard; Candotti Fabio; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-506</span>
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The development of lymphoid tissues as well as the ultimate differentiation of naive and memory T cells are dependent on cytokines.  In this review, we will focus on recent advances in the understanding of molecular mechanisms that regulate lymphoid development, homeostasis and tolerance.  RECENT FINDINGS:  Cytokines play a critical role in the development and differentiation of lymphoid cells.  In addition, newer data indicate important roles of interleukin-7 and interleukin-15 in lymphoid homeostasis and memory.  Furthermore, a new family of heterodimeric cytokines comprising interleukin-12, interleukin-23 and -27 is important for differentiation of helper T cells and cell-mediated immunity.  Finally the importance of tumor necrosis factor superfamily members in the development of lymphoid organs has recently been elucidated and will be discussed in detail.  SUMMARY:  New cytokines and receptors continue to be identified.  The discovery and characterization of cytokines, their receptors and signaling molecules will provide a more complete understanding of normal lymphoid development, differentiation and function.  In addition, this knowledge should improve our understanding of the pathogenesis of immunological diseases and hopefully will provide new treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTci7HKMzLxgUNHe_gFldTbfW6udTcc2eb3vU_u5FfRBrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D&md5=9480ae8620e9053745c038149a08a607</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1097%2F00130832-200212000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200212000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DEttinger%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.-J.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DCytokines%2520and%2520their%2520role%2520in%2520lymphoid%2520development%252C%2520differentiation%2520and%2520homeostasis%26jtitle%3DCurr.%2520Opin.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2002%26volume%3D2%26spage%3D495%26epage%3D506%26doi%3D10.1097%2F00130832-200212000-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Levy, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darnell, J. E.,  Jr</span><span> </span><span class="NLM_article-title">STATS: Transcriptional control and biological impact</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">â</span> <span class="NLM_lpage">662</span><span class="refDoi">Â DOI: 10.1038/nrm909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1038%2Fnrm909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=12209125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslansrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=651-662&author=D.+E.+Levyauthor=J.+E.+Darnell&title=STATS%3A+Transcriptional+control+and+biological+impact&doi=10.1038%2Fnrm909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Stats: transcriptional control and biological impact</span></div><div class="casAuthors">Levy, David E.; Darnell, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">651-662</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Extracellular proteins bound to cell-surface receptors can change nuclear gene expression patterns in minutes, with far-reaching consequences for development, cell growth, and homeostasis.  The signal transducer and activator of transcription (STAT) proteins are among the most well studied of the latent cytoplasmic signal-dependent transcription factor pathways.  In addn. to several roles in normal cell decisions, dysregulation of STAT function contributes to human disease, making the study of these proteins an important topic of current research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGqYF32j262LVg90H21EOLACvtfcHk0liLj0eEaqwUfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslansrw%253D&md5=4a04359c59e54b12d8a67efb6ef42e4c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrm909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm909%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26atitle%3DSTATS%253A%2520Transcriptional%2520control%2520and%2520biological%2520impact%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D651%26epage%3D662%26doi%3D10.1038%2Fnrm909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meraz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, K. C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennica, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, R. D.</span><span> </span><span class="NLM_article-title">Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the JAKs in cytokine-induced biologic responses</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">383</span><span class="refDoi">Â DOI: 10.1016/S0092-8674(00)81166-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2FS0092-8674%2800%2981166-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=9590172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFCjtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=373-383&author=S.+J.+Rodigauthor=M.+A.+Merazauthor=J.+M.+Whiteauthor=P.+A.+Lampeauthor=J.+K.+Rileyauthor=C.+D.+Arthurauthor=K.+L.+Kingauthor=K.+C.+F.+Sheehanauthor=L.+Yinauthor=D.+Pennicaauthor=E.+M.+Johnsonauthor=R.+D.+Schreiber&title=Disruption+of+the+Jak1+gene+demonstrates+obligatory+and+nonredundant+roles+of+the+JAKs+in+cytokine-induced+biologic+responses&doi=10.1016%2FS0092-8674%2800%2981166-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses</span></div><div class="casAuthors">Rodig, Scott J.; Meraz, Marco A.; White, J. Michael; Lampe, Pat A.; Riley, Joan K.; Arthur, Cora D.; King, Kathleen L.; Sheehan, Kathleen C. F.; Yin, Li; Pennica, Diane; Johnson, Eugene M., Jr.; Schreiber, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">373-383</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Herein we report the generation of mice lacking the ubiquitously expressed Janus kinase, Jak1.  Jak1-/- mice are runted at birth, fail to nurse, and die perinatally.  Although Jak1-/- cells are responsive to many cytokines, they fail to manifest biol. responses to cytokines that bind to three distinct families of cytokine receptors.  These include all class II cytokine receptors, cytokine receptors that utilize the Î³c subunit for signaling, and the family of cytokine receptors that depend on the gp130 subunit for signaling.  Our results thus demonstrate that Jak1 plays an essential and nonredundant role in promoting biol. responses induced by a select subset of cytokine receptors, including those in which Jak utilization was thought to be nonspecific.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxGavQ7H-weLVg90H21EOLACvtfcHk0liLj0eEaqwUfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFCjtLs%253D&md5=c96007f46457346d3446a6ed2c2e0e07</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981166-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981166-6%26sid%3Dliteratum%253Aachs%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DMeraz%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DLampe%26aufirst%3DP.%2BA.%26aulast%3DRiley%26aufirst%3DJ.%2BK.%26aulast%3DArthur%26aufirst%3DC.%2BD.%26aulast%3DKing%26aufirst%3DK.%2BL.%26aulast%3DSheehan%26aufirst%3DK.%2BC.%2BF.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DPennica%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DDisruption%2520of%2520the%2520Jak1%2520gene%2520demonstrates%2520obligatory%2520and%2520nonredundant%2520roles%2520of%2520the%2520JAKs%2520in%2520cytokine-induced%2520biologic%2520responses%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D373%26epage%3D383%26doi%3D10.1016%2FS0092-8674%2800%2981166-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kaur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaushal, S.</span><span> </span><span class="NLM_article-title">Systematic review of tofacitinib: A new drug for the management of rheumatoid arthritis</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1074</span><span class="NLM_x">â</span> <span class="NLM_lpage">1086</span><span class="refDoi">Â DOI: 10.1016/j.clinthera.2014.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.clinthera.2014.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=25047498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2014&pages=1074-1086&author=K.+Kaurauthor=S.+Kalraauthor=S.+Kaushal&title=Systematic+review+of+tofacitinib%3A+A+new+drug+for+the+management+of+rheumatoid+arthritis&doi=10.1016%2Fj.clinthera.2014.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis</span></div><div class="casAuthors">Kaur, Kirandeep; Kalra, Sonesh; Kaushal, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1074-1086</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The goal of this study was to review and summarize the efficacy and safety of use of tofacitinib for treating rheumatoid arthritis (RA).  A systematic literature review was conducted to identify English-language articles published through May 2013 within PubMed, ClinicalTrials.gov, and Cochrane Library reporting results from Phase II and Phase III tofacitinib randomized clin. trials.  Tofacitinib must have been used as monotherapy or in combination therapy with disease-modifying antirheumatic drugs (DMARDs) in the treatment of RA.  Study outcomes had to include at least 1 of the following: American College of Rheumatol. (ACR) 20%, 50%, or 70% response rates; tender/swollen joint count; health assessment questionnaire of disability; radiog. outcomes; and drug persistence.  Eight studies (4 Phase II and 4 Phase III trials) were included in the review.  Patients with active RA and who were nonresponders to a biol. agent or the nonbiol. DMARD methotrexate were included in these studies.  The results of the Phase II trials show that tofacitinib at doses â¥3 mg BID was efficacious among the nonresponders.  The results of the Phase III trials, comparing tofacitinib 5 and 10 mg with placebo, show that tofacitinib led to a significant improvement in ACR20 response (P < 0.0001), Health Assessment Questionnaire-Disability Index (P < 0.0001) scores, and ACR50 response (P < 0.0001) after 3 mo.  The efficacy of tofacitinib was numerically similar to adalimumab.  The most common adverse events were infections, infestations, increases in LDL-C and HDL-C levels, and a decrease in neutrophil counts.  Tofacitinib is an efficacious drug for the management of moderate to severe RA among patients with an inadequate response to methotrexate and tumor necrosis factor inhibitors.  Long-term studies can help in understanding the risk/benefit profile of tofacitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNhogMT16YO7Vg90H21EOLACvtfcHk0lh5MfqwIBnYbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI&md5=8ffd0a6e85f9b9880cc80462337ddc7f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2014.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2014.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DK.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DKaushal%26aufirst%3DS.%26atitle%3DSystematic%2520review%2520of%2520tofacitinib%253A%2520A%2520new%2520drug%2520for%2520the%2520management%2520of%2520rheumatoid%2520arthritis%26jtitle%3DClin.%2520Ther.%26date%3D2014%26volume%3D36%26spage%3D1074%26epage%3D1086%26doi%3D10.1016%2Fj.clinthera.2014.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">â</span> <span class="NLM_lpage">5307</span><span class="refDoi">Â DOI: 10.4049/jimmunol.0902819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-5307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050&doi=10.4049%2Fjimmunol.0902819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0lh5MfqwIBnYbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D5307%26doi%3D10.4049%2Fjimmunol.0902819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Ruxolitinib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">â</span> <span class="NLM_lpage">104</span><span class="refDoi">Â DOI: 10.1038/nrd3652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1038%2Fnrd3652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=22293561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=103-104&author=R.+A.+Mesaauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Ruxolitinib&doi=10.1038%2Fnrd3652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib</span></div><div class="casAuthors">Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-104</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Nov. 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-mol. inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf2yAGCsbIA7Vg90H21EOLACvtfcHk0ljOVybvq0H7EA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D&md5=5bcfbd15f4478268330ffc4c8855762d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd3652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3652%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DRuxolitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D103%26epage%3D104%26doi%3D10.1038%2Fnrd3652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schwartz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J.</span><span> </span><span class="NLM_article-title">Type 1/11 cytokines, JAKs, and new design strategies for treating autoimmune diseases</span> <span class="citation_source-journal">Nat. Rev. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">â</span> <span class="NLM_lpage">36</span><span class="refDoi">Â DOI: 10.1038/nrrheum.2015.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1038%2Fnrrheum.2015.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=26633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=25-36&author=D.+Schwartzauthor=M.+Bonelliauthor=M.+Gadinaauthor=J.+O%E2%80%99Shea&title=Type+1%2F11+cytokines%2C+JAKs%2C+and+new+design+strategies+for+treating+autoimmune+diseases&doi=10.1038%2Fnrrheum.2015.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Bonelli, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cytokines are major drivers of autoimmunity, and biol. agents targeting cytokines have revolutionized the treatment of immune-mediated diseases.  Despite the effectiveness of these drugs, they do not induce complete remission in all patients, prompting the development of alternative strategies - including targeting of intracellular signal transduction pathways downstream of cytokines.  Many cytokines that bind type I and type II cytokine receptors are crit. regulators of immune-mediated diseases and employ the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway to exert their effect.  Pharmacol. inhibition of JAKs blocks the actions of type I/II cytokines, and within the past 3 years therapeutic JAK inhibitors, or Jakinibs, have become available to rheumatologists.  Jakinibs have proven effective for the treatment of rheumatoid arthritis and other inflammatory diseases.  Adverse effects of these agents are largely related to their mode of action and include infections and hyperlipidemia.  Jakinibs are currently being investigated for a no. of new indications, and second-generation selective Jakinibs are being developed and tested.  Targeting STATs could be a future avenue for the treatment of rheumatol. diseases, although substantial challenges remain.  Nonetheless, the ability to therapeutically target intracellular signalling pathways has already created a new paradigm for the treatment of rheumatol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdr1Dh92dnLVg90H21EOLACvtfcHk0ljOVybvq0H7EA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ&md5=e06f7ab6424f1fbdbf481c75fa9ebd23</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.167%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DType%25201%252F11%2520cytokines%252C%2520JAKs%252C%2520and%2520new%2520design%2520strategies%2520for%2520treating%2520autoimmune%2520diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D25%26epage%3D36%26doi%3D10.1038%2Fnrrheum.2015.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Keystone, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beattie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berclaz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus-Gort, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macias, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M.</span><span> </span><span class="NLM_article-title">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have an inadequate response to methotrexate</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">â</span> <span class="NLM_lpage">340</span><span class="refDoi">Â DOI: 10.1136/annrheumdis-2014-206478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1136%2Fannrheumdis-2014-206478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=25431052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2015&pages=333-340&author=E.+C.+Keystoneauthor=P.+Taylorauthor=E.+Drescherauthor=D.+Schlichtingauthor=D.+Beattieauthor=P.+Berclazauthor=C.+Leeauthor=R.+Fidelus-Gortauthor=M.+Luchiauthor=T.+Rooneyauthor=W.+Maciasauthor=M.+Genovese&title=Safety+and+efficacy+of+baricitinib+at+24+weeks+in+patients+with+rheumatoid+arthritis+who+have+an+inadequate+response+to+methotrexate&doi=10.1136%2Fannrheumdis-2014-206478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate</span></div><div class="casAuthors">Keystone, Edward C.; Taylor, Peter C.; Drescher, Edit; Schlichting, Douglas E.; Beattie, Scott D.; Berclaz, Pierre-Yves; Lee, Chin H.; Fidelus-Gort, Rosanne K.; Luchi, Monica E.; Rooney, Terence P.; Macias, William L.; Genovese, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">333-340</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate.  Methods In this phase IIb study, 301 patients were randomized 2:1:1:1:1 to receive once daily doses of placebo or 1, 2, 4 or 8 mg baricitinib for 12 wk.  Patients assigned to 2, 4 and 8 mg baricitinib continued blinded treatment for an addnl. 12 wk.  Patients assigned to placebo or 1 mg baricitinib were reassigned to 2 mg twice daily or 4 mg once daily baricitinib between weeks 12-24.  The primary endpoint was the proportion of patients in the combined 4 and 8 mg groups achieving an American College of Rheumatol. 20% (ACR20) response vs. placebo at week 12.  Results Significantly more patients in the combined baricitinib 4 and 8 mg groups compared with placebo achieved an ACR20 response at week 12 (76% vs 41%, p<0.001).  At week 12, significant differences vs. placebo were also obsd. in patients achieving ACR50, ACR70 and remission as measured by Disease Activity Score for 28-joint counts, Clin. Disease Activity Index and Simplified Disease Activity Index.  Patients receiving 2, 4, or 8 mg baricitinib maintained or improved in all measures through 24 wk.  Similar proportions of patients experienced at least one adverse event in the placebo and baricitinib groups.  Serious infections developed in three patients receiving baricitinib.  No cases of tuberculosis, herpes zoster, opportunistic infections or deaths were reported.  Dose-dependent decreases in Hb were obsd. with baricitinib.  Conclusions Baricitinib improved the signs and symptoms of RA in methotrexate inadequate responders with active disease.  Baricitinib was well tolerated with no unexpected safety findings through week 24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz3lYB7HU_KbVg90H21EOLACvtfcHk0lgwI2fM7EACuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D&md5=2f13c96c1c1dc5f68e69cd3e6da457b7</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-206478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-206478%26sid%3Dliteratum%253Aachs%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DTaylor%26aufirst%3DP.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DSchlichting%26aufirst%3DD.%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBerclaz%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFidelus-Gort%26aufirst%3DR.%26aulast%3DLuchi%26aufirst%3DM.%26aulast%3DRooney%26aufirst%3DT.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DGenovese%26aufirst%3DM.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520baricitinib%2520at%252024%2520weeks%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520who%2520have%2520an%2520inadequate%2520response%2520to%2520methotrexate%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2015%26volume%3D74%26spage%3D333%26epage%3D340%26doi%3D10.1136%2Fannrheumdis-2014-206478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Strober, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonanno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harness, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, K.</span><span> </span><span class="NLM_article-title">Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">992</span><span class="NLM_x">â</span> <span class="NLM_lpage">999</span><span class="refDoi">Â DOI: 10.1111/bjd.12517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1111%2Fbjd.12517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=23855761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslakurzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=992-999&author=B.+Stroberauthor=M.+Buonannoauthor=J.+D.+Clarkauthor=T.+Kawabataauthor=H.+Tanauthor=R.+Wolkauthor=H.+Valdezauthor=R.+G.+Langleyauthor=J.+Harnessauthor=A.+Menterauthor=K.+Papp&title=Effect+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+on+haematological+parameters+during+12+weeks+of+psoriasis+treatment&doi=10.1111%2Fbjd.12517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment</span></div><div class="casAuthors">Strober, B.; Buonanno, M.; Clark, J. D.; Kawabata, T.; Tan, H.; Wolk, R.; Valdez, H.; Langley, R. G.; Harness, J.; Menter, A.; Papp, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">992-999</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : The Janus kinase (JAK) inhibitor, tofacitinib, has shown efficacy for the treatment of psoriasis in a phase IIb trial (A3921047; NCT00678210).  Objectives : To report haematol. data from the phase IIb trial, given the importance of JAK-dependent signalling in haematopoiesis.  Methods : Patients with moderate-to-severe chronic plaque psoriasis were randomized to receive tofacitinib 2, 5 or 15 mg, or placebo, twice daily over 12 wk.  Blood samples were collected at screening, baseline, weeks 2, 4, 8 and 12 during treatment, and weeks 14 and 16 during off-treatment follow-up.  Results : Baseline haematol. was similar across patients receiving tofacitinib 2 mg (n = 49), 5 mg (n = 49) or 15 mg (n = 49), or placebo (n = 50).  Tofacitinib conferred dose-dependent decreases in Hb, haematocrit and red blood cell counts, while reticulocyte counts initially declined, before recovering by week 8, and exceeding baseline levels after treatment cessation.  With regard to white blood cells, tofacitinib had no clear dose-dependent effects on basophils or monocytes, but appeared to be assocd. with transient or reversible dose-dependent decreases in neutrophil and eosinophil counts and transient increases in lymphocyte counts, which were primarily attributable to increases in B-cell counts.  Natural killer cell counts declined with tofacitinib.  Conclusions : Tofacitinib conferred tolerable, dose-dependent changes in haematol. parameters during short-term administration in patients with psoriasis.  The effects did not appear to be progressive, and were often transient or reversible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXc7wLFiJmW7Vg90H21EOLACvtfcHk0lgwI2fM7EACuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslakurzP&md5=c8427f4813dc663ef97a2fce48f6fd08</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fbjd.12517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.12517%26sid%3Dliteratum%253Aachs%26aulast%3DStrober%26aufirst%3DB.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DKawabata%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DHarness%26aufirst%3DJ.%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DPapp%26aufirst%3DK.%26atitle%3DEffect%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520on%2520haematological%2520parameters%2520during%252012%2520weeks%2520of%2520psoriasis%2520treatment%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2013%26volume%3D169%26spage%3D992%26epage%3D999%26doi%3D10.1111%2Fbjd.12517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovich, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">â</span> <span class="NLM_lpage">157</span><span class="refDoi">Â DOI: 10.1016/0092-8674(93)90167-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2F0092-8674%2893%2990167-O" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=147-157&author=M.+Noguchiauthor=H.+Yiauthor=H.+M.+Rosenblattauthor=A.+H.+Filipovichauthor=S.+Adelsteinauthor=W.+S.+Modiauthor=O.+W.+McBrideauthor=W.+J.+Leonard&title=Interleukin-2+receptor+gamma+chain+mutation+results+in+X-linked+severe+combined+immunodeficiency+in+humans&doi=10.1016%2F0092-8674%2893%2990167-O"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2893%2990167-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252893%252990167-O%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DRosenblatt%26aufirst%3DH.%2BM.%26aulast%3DFilipovich%26aufirst%3DA.%2BH.%26aulast%3DAdelstein%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DW.%2BS.%26aulast%3DMcBride%26aufirst%3DO.%2BW.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DInterleukin-2%2520receptor%2520gamma%2520chain%2520mutation%2520results%2520in%2520X-linked%2520severe%2520combined%2520immunodeficiency%2520in%2520humans%26jtitle%3DCell%26date%3D1993%26volume%3D73%26spage%3D147%26epage%3D157%26doi%3D10.1016%2F0092-8674%2893%2990167-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzuti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koslov, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckius, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beals, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagouras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magna, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltarelli, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelms, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Des Etages, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finco-Kent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paniagua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">â</span> <span class="NLM_lpage">878</span><span class="refDoi">Â DOI: 10.1126/science.1087061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=C.+Shang-Poaauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=S.+G.+Des+Etagesauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.+S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.+J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor&doi=10.1126%2Fscience.1087061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0lhk_phKcPZ0lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%2BEtages%26aufirst%3DS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878%26doi%3D10.1126%2Fscience.1087061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5023</span><span class="NLM_x">â</span> <span class="NLM_lpage">5038</span><span class="refDoi">Â DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0ljBzqTUs9UzAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">â</span> <span class="NLM_lpage">8484</span><span class="refDoi">Â DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=S.-P.+Changauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0ljBzqTUs9UzAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DS.-P.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrick, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saabye, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span> </span><span class="NLM_article-title">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span> <span class="citation_source-journal">J. Inflammation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="refDoi">Â DOI: 10.1186/1476-9255-7-41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41&author=D.+M.+Meyerauthor=M.+I.+Jessonauthor=X.+Liauthor=M.+M.+Elrickauthor=C.+L.+Funckes-Shippyauthor=J.+D.+Warnerauthor=C.+J.+Grossauthor=M.+E.+Dowtyauthor=S.+K.+Ramaiahauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+L.+Barksauthor=N.+Kishoreauthor=D.+L.+Morris&title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+the+JAK1%2FJAK3+inhibitor%2C+CP-690%2C550%2C+in+rat+adjuvant-induced+arthritis&doi=10.1186%2F1476-9255-7-41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Meyer Debra M; Jesson Michael I; Li Xiong; Elrick Mollisa M; Funckes-Shippy Christie L; Warner James D; Gross Cindy J; Dowty Martin E; Ramaiah Shashi K; Hirsch Jeffrey L; Saabye Matthew J; Barks Jennifer L; Kishore Nandini; Morris Dale L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of inflammation (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors.  CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.  In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment.  These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment.  METHODS:  Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays.  The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays.  In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model.  RESULTS:  CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays.  Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment.  Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease.  At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels.  The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2.  CONCLUSION:  Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2.  In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550.  Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17.  Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2.  Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-l9vqy6452oNpW7w2tapOfW6udTcc2eYf6SA6lXSQwrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D&md5=1190d7c5509fde79a7b56024a3aec9d9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DElrick%26aufirst%3DM.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DGross%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DBarks%26aufirst%3DJ.%2BL.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DAnti-inflammatory%2520activity%2520and%2520neutrophil%2520reductions%2520mediated%2520by%2520the%2520JAK1%252FJAK3%2520inhibitor%252C%2520CP-690%252C550%252C%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DJ.%2520Inflammation%26date%3D2010%26volume%3D7%26spage%3D41%26doi%3D10.1186%2F1476-9255-7-41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Menet, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Rompaey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geney, R.</span><span> </span><span class="NLM_article-title">Advances in the discovery of selective JAK inhibitors</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">â</span> <span class="NLM_lpage">223</span><span class="refDoi">Â DOI: 10.1016/B978-0-444-62652-3.00004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2FB978-0-444-62652-3.00004-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=23384668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=153-223&author=C.+J.+Menetauthor=L.+Van+Rompaeyauthor=R.+Geney&title=Advances+in+the+discovery+of+selective+JAK+inhibitors&doi=10.1016%2FB978-0-444-62652-3.00004-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery of selective JAK inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Van Rompaey, Luc; Geney, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-223</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses the advances in the discovery of selective JAK inhibitors.  JAK inhibitor includes JAK1, JAK2 and JAK3 and tyrosine kinase2.  Medicinal chem. and structural biol. fronts in designing and synthesizing selective or mixed JAK small-mol. inhibitors were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTg_zxiK5GGLVg90H21EOLACvtfcHk0ljBD3JS8kx3-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D&md5=3d7e6f0481e3a891c84c49ece6421d74</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-62652-3.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-62652-3.00004-1%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGeney%26aufirst%3DR.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520selective%2520JAK%2520inhibitors%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D153%26epage%3D223%26doi%3D10.1016%2FB978-0-444-62652-3.00004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Menet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mammoliti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Ramos, M.</span><span> </span><span class="NLM_article-title">Progress toward JAK1-selective inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">â</span> <span class="NLM_lpage">235</span><span class="refDoi">Â DOI: 10.4155/fmc.14.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.4155%2Ffmc.14.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=25686006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=203-235&author=C.+Menetauthor=O.+Mammolitiauthor=M.+Lopez-Ramos&title=Progress+toward+JAK1-selective+inhibitors&doi=10.4155%2Ffmc.14.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Progress toward JAK1-selective inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Mammoliti, Oscar; Lopez-Ramos, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-235</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the JAK-STAT pathway was a landmark in cell biol.  The identification of these pathways has changed the landscape of treatment of rheumatoid arthritis and other autoimmune diseases.  The two first (unselective) JAK inhibitors have recently been approved by the US FDA for the treatment of myelofibrosis and rheumatoid arthritis and many other JAK inhibitors are currently in clin. development or at the discovery stage.  Research groups have demonstrated the different roles of JAK member and the therapeutic potential of targeting them selectively.  JAK1 plays a crit. and potentially dominant role in the transduction of Î³c cytokine (Î³c = common Î³ chain) and in IL-6 signaling.  In this review, we will discuss the state-of-the-art research that evokes JAK1 selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFBuFU-x0dWrVg90H21EOLACvtfcHk0ljBD3JS8kx3-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D&md5=ef6cf011f0078aaa4f83560c98524d1c</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.149%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DLopez-Ramos%26aufirst%3DM.%26atitle%3DProgress%2520toward%2520JAK1-selective%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D203%26epage%3D235%26doi%3D10.4155%2Ffmc.14.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Thorarensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fensome, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juba, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casimiro-Garcia, A.</span><span> </span><span class="NLM_article-title">ATP mediated kinome selectivity â The missing link in understanding the contribution of individual JAK kinases isoforms to cellular signaling</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1552</span><span class="NLM_x">â</span> <span class="NLM_lpage">1558</span><span class="refDoi">Â DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.-B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP+mediated+kinome+selectivity+%E2%80%93+The+missing+link+in+understanding+the+contribution+of+individual+JAK+kinases+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP%2520mediated%2520kinome%2520selectivity%2520%25E2%2580%2593%2520The%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520kinases%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">â</span> <span class="NLM_lpage">3108</span><span class="refDoi">Â DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28KI%29+and+the+concentration+of+inhibitor+which+causes+50%25+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lh1yCkYwwba5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528KI%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Reino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Ramos, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">970</span><span class="NLM_x">â</span> <span class="NLM_lpage">981</span><span class="refDoi">Â DOI: 10.1002/art.33419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1002%2Fart.33419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=22006202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVygt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=970-981&author=J.+M.+Kremerauthor=S.+Cohenauthor=B.+E.+Wilkinsonauthor=C.+A.+Connellauthor=J.+L.+Frenchauthor=J.+Gomez-Reinoauthor=D.+Grubenauthor=K.+S.+Kanikauthor=S.+Krishnaswamiauthor=V.+Pascual-Ramosauthor=G.+Wallensteinauthor=S.+H.+Zwillich&title=A+phase+2B+dose-ranging+study+of+the+oral+JAK+inhibitor+tofacitinib+%28CP-690%2C550%29+versus+placebo+in+combination+with+background+methotrexate+in+patients+with+active+rheumatoid+arthritis+and+inadequate+response+to+methotrexate+alone&doi=10.1002%2Fart.33419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone</span></div><div class="casAuthors">Kremer, Joel M.; Cohen, Stanley; Wilkinson, Bethanie E.; Connell, Carol A.; French, Jonathan L.; Gomez-Reino, Juan; Gruben, David; Kanik, Keith S.; Krishnaswami, Sriram; Pascual-Ramos, Virginia; Wallenstein, Gene; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">970-981</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP-690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy.  Methods. In this 24-wk, double-blind, phase IIb study, patients with active RA (n = 507) were randomized to receive placebo or tofacitinib (20 mg/day, 1 mg twice daily, 3 mg twice daily, 5 mg twice daily, 10 mg twice daily, or 15 mg twice daily).  All patients continued to receive a stable dosage of MTX.  The primary end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at week 12.  Results. At week 12, ACR20 response rates for patients receiving all tofacitinib dosages â¥3 mg twice daily (52.9% for 3 mg twice daily, 50.7% for 5 mg twice daily, 58.1% for 10 mg twice daily, 56.0% for 15 mg twice daily, and 53.8% for 20 mg/day) were significantly (P â¤ 0.05) greater than those for placebo (33.3%).  Improvements were sustained at week 24 for the ACR20, ACR50, and ACR70 responses, scores for the Health Assessment Questionnaire disability index, the 3-variable Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP), and a 3-variable DAS28-CRP of <2.6.  The most common treatment-emergent adverse events occurring in >10% of patients in any tofacitinib group were diarrhea, upper respiratory tract infection, and headache; 21 patients (4.1%) experienced serious adverse events.  Sporadic increases in transaminase levels, increases in cholesterol and serum creatinine levels, and decreases in neutrophil and Hb levels were obsd.  Conclusion. In patients with active RA in whom the response to MTX has been inadequate, the addn. of tofacitinib at a dosage â¥3 mg twice daily showed sustained efficacy and a manageable safety profile over 24 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGQK92I8twr7Vg90H21EOLACvtfcHk0lh1yCkYwwba5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVygt78%253D&md5=69d74dbdde12d7d1b45fa3d3a413645a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fart.33419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33419%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DFrench%26aufirst%3DJ.%2BL.%26aulast%3DGomez-Reino%26aufirst%3DJ.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DPascual-Ramos%26aufirst%3DV.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DA%2520phase%25202B%2520dose-ranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520tofacitinib%2520%2528CP-690%252C550%2529%2520versus%2520placebo%2520in%2520combination%2520with%2520background%2520methotrexate%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520and%2520inadequate%2520response%2520to%2520methotrexate%2520alone%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D970%26epage%3D981%26doi%3D10.1002%2Fart.33419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Di, Li.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, Yi-An.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duckworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, S.</span><span> </span><span class="NLM_article-title">Mechanistics insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">448</span><span class="refDoi">Â DOI: 10.1016/j.ejmech.2012.06.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.ejmech.2012.06.043" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2012&pages=441-448&author=Li.+Diauthor=C.+Keeferauthor=D.+O.+Scottauthor=T.+Strelevitzauthor=G.+Changauthor=Yi-An.+Biauthor=Y.+Laiauthor=J.+Duckworthauthor=K.+Fennerauthor=M.+Troutmanauthor=S.+Obach&title=Mechanistics+insights+from+comparing+intrinsic+clearance+values+between+human+liver+microsomes+and+hepatocytes+to+guide+drug+design&doi=10.1016%2Fj.ejmech.2012.06.043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.06.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.06.043%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DLi.%26aulast%3DKeefer%26aufirst%3DC.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DStrelevitz%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DG.%26aulast%3DBi%26aufirst%3DYi-An.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DDuckworth%26aufirst%3DJ.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DTroutman%26aufirst%3DM.%26aulast%3DObach%26aufirst%3DS.%26atitle%3DMechanistics%2520insights%2520from%2520comparing%2520intrinsic%2520clearance%2520values%2520between%2520human%2520liver%2520microsomes%2520and%2520hepatocytes%2520to%2520guide%2520drug%2520design%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D57%26spage%3D441%26epage%3D448%26doi%3D10.1016%2Fj.ejmech.2012.06.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chrencik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gormley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommers, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenbrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, T. E.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">â</span> <span class="NLM_lpage">433</span><span class="refDoi">Â DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.-C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0liDWl4_G0vRnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Andrews, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craik, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. L.</span><span> </span><span class="NLM_article-title">Functional group contributions to drug-receptor interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1648</span><span class="NLM_x">â</span> <span class="NLM_lpage">1657</span><span class="refDoi">Â DOI: 10.1021/jm00378a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00378a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADyaL2cXmt1aju7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1984&pages=1648-1657&author=P.+R.+Andrewsauthor=D.+J.+Craikauthor=J.+L.+Martin&title=Functional+group+contributions+to+drug-receptor+interactions&doi=10.1021%2Fjm00378a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Functional group contributions to drug-receptor interactions</span></div><div class="casAuthors">Andrews, P. R.; Craik, D. J.; Martin, J. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1648-57</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">To overcome the difficulties in estg. the potential bond strengths involved in the interaction between a drug and a reasonable matched receptor, 200 drugs and enzyme inhibitors chosen on the basis of their apparent tight binding to their corresponding receptor sites, were used to provide a statistical est. of the strength of noncovalent bonds assocd. with each functional groups in an av. drug-receptor environment.  Values are presented to det. the goodness of fit of a drug to its receptor by comparing the obsd. binding const. to the av. binding energy calcd. by summing the intrinsic binding energies of the component groups and then subtracting 2 entropy related terms.  Drugs such as diazepam  [439-14-5] that match their receptors well have a measured binding energy exceeding the calcd. av. value, whereas others such as buprenorphine  [52485-79-7] who match their receptor less than the av. have binding energies less the calcd. av. value.  In addn. the binding energies of 3 central nervous system active drugs and representative amino acids within a polypeptide mol. are also given.  General principles for the application of intrinsic binding energies in drug design and structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9jA81gwVWgbVg90H21EOLACvtfcHk0lij5OYM6ndvWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmt1aju7g%253D&md5=9b499aee3899f6ffc3ac7e558f28f93f</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm00378a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00378a021%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DP.%2BR.%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26aulast%3DMartin%26aufirst%3DJ.%2BL.%26atitle%3DFunctional%2520group%2520contributions%2520to%2520drug-receptor%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1984%26volume%3D27%26spage%3D1648%26epage%3D1657%26doi%3D10.1021%2Fjm00378a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schonherr, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cernak, T.</span><span> </span><span class="NLM_article-title">Profound methyl effects in drug discovery and a call for new methylation reactions</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">12256</span><span class="NLM_x">â</span> <span class="NLM_lpage">12267</span><span class="refDoi">Â DOI: 10.1002/anie.201303207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1002%2Fanie.201303207" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=12256-12267&author=H.+Schonherrauthor=T.+Cernak&title=Profound+methyl+effects+in+drug+discovery+and+a+call+for+new+methylation+reactions&doi=10.1002%2Fanie.201303207"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201303207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201303207%26sid%3Dliteratum%253Aachs%26aulast%3DSchonherr%26aufirst%3DH.%26aulast%3DCernak%26aufirst%3DT.%26atitle%3DProfound%2520methyl%2520effects%2520in%2520drug%2520discovery%2520and%2520a%2520call%2520for%2520new%2520methylation%2520reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D12256%26epage%3D12267%26doi%3D10.1002%2Fanie.201303207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamohan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geoghegan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knafels, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaila, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span> </span><span class="NLM_article-title">Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system</span> <span class="citation_source-journal">Acta Crystallogr., Sect. F: Struct. Biol. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">840</span><span class="NLM_x">â</span> <span class="NLM_lpage">845</span><span class="refDoi">Â DOI: 10.1107/S2053230X16016356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1107%2FS2053230X16016356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=27827355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWmt7zI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=840-845&author=N.+Caspersauthor=S.+Hanauthor=F.+Rajamohanauthor=L.+Hothauthor=K.+Geogheganauthor=T.+Subashiauthor=J.+Knafelsauthor=M.+Vazquezauthor=N.+Kailaauthor=C.+Croninauthor=E.+Johnsonauthor=R.+Kurumbail&title=Development+of+a+high-throughput+crystal+structure-determination+platform+for+JAK1+using+a+novel+metal-chelator+soaking+system&doi=10.1107%2FS2053230X16016356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system</span></div><div class="casAuthors">Caspers, Nicole L.; Han, Seungil; Rajamohan, Francis; Hoth, Lise R.; Geoghegan, Kieran F.; Subashi, Timothy A.; Vazquez, Michael L.; Kaila, Neelu; Cronin, Ciaran N.; Johnson, Eric; Kurumbail, Ravi G.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">840-845</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Crystals of phosphorylated JAK1 kinase domain were initially generated in complex with nucleotide (ADP) and magnesium.  The tightly bound Mg2+-ADP at the ATP-binding site proved recalcitrant to ligand displacement.  Addn. of a molar excess of EDTA helped to dislodge the divalent metal ion, promoting the release of ADP and allowing facile exchange with ATP-competitive small-mol. ligands.  Many kinases require the presence of a stabilizing ligand in the ATP site for crystn.  This procedure could be useful for developing co-crystn. systems with an exchangeable ligand to enable structure-based drug design of other protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1j6dvXhIlZbVg90H21EOLACvtfcHk0lij5OYM6ndvWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWmt7zI&md5=b4c15c4bc3deb1e54710882a70607ec8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1107%2FS2053230X16016356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X16016356%26sid%3Dliteratum%253Aachs%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DRajamohan%26aufirst%3DF.%26aulast%3DHoth%26aufirst%3DL.%26aulast%3DGeoghegan%26aufirst%3DK.%26aulast%3DSubashi%26aufirst%3DT.%26aulast%3DKnafels%26aufirst%3DJ.%26aulast%3DVazquez%26aufirst%3DM.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DCronin%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DKurumbail%26aufirst%3DR.%26atitle%3DDevelopment%2520of%2520a%2520high-throughput%2520crystal%2520structure-determination%2520platform%2520for%2520JAK1%2520using%2520a%2520novel%2520metal-chelator%2520soaking%2520system%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2016%26volume%3D72%26spage%3D840%26epage%3D845%26doi%3D10.1107%2FS2053230X16016356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">232</span><span class="refDoi">Â DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+The+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0liDkkEi2Y73Dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520The%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaines, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile-Woo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span> </span><span class="NLM_article-title">Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">â</span> <span class="NLM_lpage">4785</span><span class="refDoi">Â DOI: 10.1021/jm4004895</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=P.+Bir+Kohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroxyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2&doi=10.1021%2Fjm4004895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Hurley, Christopher A.; Ward, Stuart I.; Bergeron, Philippe; Barrett, Kathy; Balazs, Mercedesz; Blair, Wade S.; Bull, Richard; Chakravarty, Paroma; Chang, Christine; Crackett, Peter; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ellwood, Charles; Gaines, Simon; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Gribling, Peter; Hamman, Chris; Harstad, Eric; Hewitt, Peter; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Labadie, Sharada; Lee, Wyne P.; Liao, Jiangpeng; Liimatta, Marya; Mendonca, Rohan; Narukulla, Raman; Pulk, Rebecca; Reeve, Austin; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; van Abbema, Anne; Aliagas, Ignacio; Avitabile-Woo, Barbara; Xiao, Yisong; Yang, Jing; Kulagowski, Janusz J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4764-4785</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors.  X-ray structures of a C-2 hydroxyethyl analog in complex with both JAK1 and JAK2 revealed differential ligand/protein interactions between the two isoforms and offered an explanation for the obsd. selectivity.  Anal. of historical data from related mols. was used to develop a set of physicochem. compd. design parameters to impart desirable properties such as acceptable membrane permeability, potent whole blood activity, and a high degree of metabolic stability.  This work culminated in the identification of a highly JAK1 selective compd. (31) exhibiting favorable oral bioavailability across a range of preclin. species and robust efficacy in a rat CIA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP0DlLtJCYq7Vg90H21EOLACvtfcHk0liDkkEi2Y73Dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D&md5=0b0d1950adebf325cc434344f57ca139</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroxyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785%26doi%3D10.1021%2Fjm4004895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupardus, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span> </span><span class="NLM_article-title">Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7627</span><span class="NLM_x">â</span> <span class="NLM_lpage">7633</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.bmcl.2012.10.008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7627-7633&author=S.+Labadieauthor=P.+S.+Dragovichauthor=K.+Barrettauthor=W.+S.+Blairauthor=P.+Bergeronauthor=C.+Changauthor=G.+Deshmukhauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=C.+A.+Hurleyauthor=A.+Johnsonauthor=J.+R.+Kennyauthor=P.+Bir+Kohliauthor=J.+J.+Kulagowskiauthor=M.+Liimattaauthor=P.+L.+Lupardusauthor=R.+Mendoncaauthor=J.+M.+Murrayauthor=R.+Pulkauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+Wardauthor=M.+Zak&title=Structure-based+discovery+of+C-2+substituted+imidazo-pyrrolopyridine+JAK1+inhibitors+with+improved+selectivity+over+JAK2&doi=10.1016%2Fj.bmcl.2012.10.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLupardus%26aufirst%3DP.%2BL.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%26aulast%3DZak%26aufirst%3DM.%26atitle%3DStructure-based%2520discovery%2520of%2520C-2%2520substituted%2520imidazo-pyrrolopyridine%2520JAK1%2520inhibitors%2520with%2520improved%2520selectivity%2520over%2520JAK2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7627%26epage%3D7633%26doi%3D10.1016%2Fj.bmcl.2012.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vasbinder, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alimzhanov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebernitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deegan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huszar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawatkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawatkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbacher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steuber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinda, M.</span><span> </span><span class="NLM_article-title">Identification of azabenzimidazoles as potent JAK1 selective inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">â</span> <span class="NLM_lpage">67</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.bmcl.2015.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=26614408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFagsLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=60-67&author=M.+M.+Vasbinderauthor=M.+Alimzhanovauthor=M.+Augustinauthor=G.+Bebernitzauthor=K.+Bellauthor=C.+Chuaquiauthor=T.+Deeganauthor=A.+D.+Fergusonauthor=K.+Goodwinauthor=D.+Huszarauthor=A.+Kawatkarauthor=S.+Kawatkarauthor=J.+Readauthor=J.+Shiauthor=S.+Steinbacherauthor=H.+Steuberauthor=Q.+Suauthor=D.+Toaderauthor=H.+Wangauthor=R.+Woessnerauthor=A.+Wuauthor=M.+Yeauthor=M.+Zinda&title=Identification+of+azabenzimidazoles+as+potent+JAK1+selective+inhibitors&doi=10.1016%2Fj.bmcl.2015.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of azabenzimidazoles as potent JAK1 selective inhibitors</span></div><div class="casAuthors">Vasbinder, Melissa M.; Alimzhanov, Marat; Augustin, Martin; Bebernitz, Geraldine; Bell, Kirsten; Chuaqui, Claudio; Deegan, Tracy; Ferguson, Andrew D.; Goodwin, Kelly; Huszar, Dennis; Kawatkar, Aarti; Kawatkar, Sameer; Read, Jon; Shi, Jie; Steinbacher, Stefan; Steuber, Holger; Su, Qibin; Toader, Dorin; Wang, Haixia; Woessner, Richard; Wu, Allan; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-67</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have identified a class of azabenzimidazoles as potent and selective JAK1 inhibitors.  Investigations into the SAR are presented along with the structural features required to achieve selectivity for JAK1 vs. other JAK family members.  An example from the series demonstrated highly selective inhibition of JAK1 vs. JAK2 and JAK3, along with inhibition of pSTAT3 in vivo, enabling it to serve as a JAK1 selective tool compd. to further probe the biol. of JAK1 selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQjKE058gZrVg90H21EOLACvtfcHk0lhHbN-SVpmJaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFagsLrL&md5=49f2cc63e15dcdf539fb7195a9c6224a</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DVasbinder%26aufirst%3DM.%2BM.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DDeegan%26aufirst%3DT.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGoodwin%26aufirst%3DK.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DKawatkar%26aufirst%3DA.%26aulast%3DKawatkar%26aufirst%3DS.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSteuber%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520azabenzimidazoles%2520as%2520potent%2520JAK1%2520selective%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D60%26epage%3D67%26doi%3D10.1016%2Fj.bmcl.2015.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Simov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elwood, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibeau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunaydin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraybill, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span> </span><span class="NLM_article-title">Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1803</span><span class="NLM_x">â</span> <span class="NLM_lpage">1808</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.bmcl.2016.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=26927423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt12mtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1803-1808&author=V.+Simovauthor=S.+V.+Deshmukhauthor=C.+J.+Dinsmoreauthor=F.+Elwoodauthor=R.+B.+Fernandezauthor=Y.+Garciaauthor=C.+Gibeauauthor=H.+Gunaydinauthor=J.+Jungauthor=J.+D.+Katzauthor=B.+Kraybillauthor=B.+Lapointeauthor=S.+B.+Patelauthor=T.+Siuauthor=H.+Suauthor=J.+R.+Young&title=Structure-based+design+and+development+of+%28benz%29imidazole+pyridones+as+JAK1-selective+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2016.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors</span></div><div class="casAuthors">Simov, Vladimir; Deshmukh, Sujal V.; Dinsmore, Christopher J.; Elwood, Fiona; Fernandez, Rafael B.; Garcia, Yudith; Gibeau, Craig; Gunaydin, Hakan; Jung, Joon; Katz, Jason D.; Kraybill, Brian; Lapointe, Blair; Patel, Sangita B.; Siu, Tony; Su, Hua; Young, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1803-1808</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mammalian Janus Kinases (JAK1, JAK2, JAK3 and TYK2) are intracellular, nonreceptor tyrosine kinases whose activities have been assocd. in the literature and the clinic with a variety of hyperproliferative diseases and immunol. disorders.  At the onset of the program, it was hypothesized that a JAK1 selective compd. over JAK2 could lead to an improved therapeutic index relative to marketed nonselective JAK inhibitors by avoiding the clin. AEs, such as anemia, presumably assocd. with JAK2 inhibition.  During the course of the JAK1 program, a no. of diverse chem. scaffolds were identified from both uHTS campaigns and de novo scaffold design.  As part of this effort, a (benz)imidazole scaffold evolved via a scaffold-hopping exercise from a mature chem. series.  Concurrent crystallog.-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeRwubYziKxrVg90H21EOLACvtfcHk0lhHbN-SVpmJaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt12mtLo%253D&md5=f863ad973f0f86993bb7f796821b5059</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DSimov%26aufirst%3DV.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DElwood%26aufirst%3DF.%26aulast%3DFernandez%26aufirst%3DR.%2BB.%26aulast%3DGarcia%26aufirst%3DY.%26aulast%3DGibeau%26aufirst%3DC.%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DKraybill%26aufirst%3DB.%26aulast%3DLapointe%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DSiu%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26atitle%3DStructure-based%2520design%2520and%2520development%2520of%2520%2528benz%2529imidazole%2520pyridones%2520as%2520JAK1-selective%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1803%26epage%3D1808%26doi%3D10.1016%2Fj.bmcl.2016.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Allen, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span> </span><span class="NLM_article-title">Research applications of the Cambridge Structural Database (CSD)</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">â</span> <span class="NLM_lpage">475</span><span class="refDoi">Â DOI: 10.1039/b309040j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1039%2Fb309040j" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=463-475&author=F.+H.+Allenauthor=R.+Taylor&title=Research+applications+of+the+Cambridge+Structural+Database+%28CSD%29&doi=10.1039%2Fb309040j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1039%2Fb309040j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb309040j%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DF.%2BH.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DResearch%2520applications%2520of%2520the%2520Cambridge%2520Structural%2520Database%2520%2528CSD%2529%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2004%26volume%3D33%26spage%3D463%26epage%3D475%26doi%3D10.1039%2Fb309040j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26"><span><span> </span><span class="NLM_article-title">CCDC Website database</span>: <a href="http://www.ccdc.cam.ac.uk/free_services/website/" class="extLink">http://www.ccdc.cam.ac.uk/free_services/website/</a> (acccessed December 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CCDC+Website+database%3A+http%3A%2F%2Fwww.ccdc.cam.ac.uk%2Ffree_services%2Fwebsite%2F+%28acccessed+December+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DCCDC%2520Website%2520database" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">24</span><span class="refDoi">Â DOI: 10.1021/ci7002494</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci7002494" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksV2isA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=1-24&author=K.+A.+Brameldauthor=B.+Kuhnauthor=D.+C.+Reuterauthor=M.+Stahl&title=Small+molecule+conformational+preferences+derived+from+crystal+structure+data.+A+medicinal+chemistry+focused+analysis&doi=10.1021%2Fci7002494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule conformational preferences derived from crystal structure data. a medicinal chemistry focused analysis</span></div><div class="casAuthors">Brameld, Ken A.; Kuhn, Bernd; Reuter, Deborah C.; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Based on torsion angle distributions of frequently occurring substructures, conformation preferences of druglike mols. are presented, accompanied by a review of the relevant literature.  First, the relevance of the Cambridge Structural Database (CSD) for drug design is demonstrated by comparing substructures present in compds. entering clin. trials with those found in the CSD and protein-bound ligands in the Protein Data Bank (PDB).  Next, we briefly highlight preferred conformations of elementary acyclic systems, followed by a discussion of sulfonamide conformations.  Due to their central role in medicinal chem., we discuss properties of aryl ring substituents in depth, including biaryl systems and systems of two aryl rings connected by two acyclic bonds.  For a subset of torsion motifs, we also compare torsion angle histograms derived from CSD structures with those derived from ligands in the PDB.  Furthermore, selected properties of some six- and seven-membered ring systems are discussed.  The article closes with a section on attractive sulfur-oxygen contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBrdvMrRvKirVg90H21EOLACvtfcHk0liPC_sEdOjdxA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksV2isA%253D%253D&md5=289969338dcb94a145ce736d19d05cf4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fci7002494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci7002494%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DReuter%26aufirst%3DD.%2BC.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DSmall%2520molecule%2520conformational%2520preferences%2520derived%2520from%2520crystal%2520structure%2520data.%2520A%2520medicinal%2520chemistry%2520focused%2520analysis%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26spage%3D1%26epage%3D24%26doi%3D10.1021%2Fci7002494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">vanAbbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkowycz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span> </span><span class="NLM_article-title">Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5901</span><span class="NLM_x">â</span> <span class="NLM_lpage">5921</span><span class="refDoi">Â DOI: 10.1021/jm300438j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300438j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5901-5921&author=J.+J.+Kulagowskiauthor=W.+Blairauthor=R.+J.+Bullauthor=C.+Changauthor=G.+Deshmukhauthor=H.+J.+Dykeauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=T.+K.+Harrisonauthor=P.+R.+Hewittauthor=M.+Liimattaauthor=C.+A.+Hurleyauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=K.+P.+Birauthor=R.+J.+Maxeyauthor=R.+Mendoncaauthor=K.+Mortaraauthor=J.+Murrayauthor=R.+Narukullaauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+vanAbbemaauthor=S.+I.+Wardauthor=B.+Waszkowyczauthor=M.+Zak&title=Identification+of+imidazo-pyrrolopyridines+as+novel+and+potent+JAK1+inhibitors&doi=10.1021%2Fjm300438j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors</span></div><div class="casAuthors">Kulagowski, Janusz J.; Blair, Wade; Bull, Richard J.; Chang, Christine; Deshmukh, Gauri; Dyke, Hazel J.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Harrison, Trevor K.; Hewitt, Peter R.; Liimatta, Marya; Hurley, Christopher A.; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Bir Kohli, Pawan; Maxey, Robert J.; Mendonca, Rohan; Mortara, Kyle; Murray, Jeremy; Narukulla, Raman; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Waszkowycz, Bohdan; Zak, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5901-5921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), by specific targeting of the JAK1 pathway.  Examn. of the preferred binding conformation of clin. effective, pan-JAK inhibitor 1 led to identification of a novel, tricyclic hinge binding scaffold 3.  Exploration of SAR through a series of cycloamino and cycloalkylamino analogs demonstrated this template to be highly tolerant of substitution, with a predisposition to moderate selectivity for the JAK1 isoform over JAK2.  This study culminated in the identification of subnanomolar JAK1 inhibitors such as 22 and 49, having excellent cell potency, good rat pharmacokinetic characteristics, and excellent kinase selectivity.  Detn. of the binding modes of the series in JAK1 and JAK2 by X-ray crystallog. supported the design of analogs to enhance affinity and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpamrk0bG1MK7Vg90H21EOLACvtfcHk0liPC_sEdOjdxA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D&md5=d91bc0e24abf14adcf44caf61e3e879f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300438j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300438j%26sid%3Dliteratum%253Aachs%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDyke%26aufirst%3DH.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHarrison%26aufirst%3DT.%2BK.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DBir%26aufirst%3DK.%2BP.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DvanAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DZak%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520imidazo-pyrrolopyridines%2520as%2520novel%2520and%2520potent%2520JAK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5901%26epage%3D5921%26doi%3D10.1021%2Fjm300438j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="note"><p class="first last">PetaChem, LLC, 26040 Elena Road, Los Altos Hills, CA 94022. Conformational Analysis: All quantum mechanical calculations were performed with the PetaChem software utilizing the B3LYP density functional with the 6-31G++ basis set in the gas phase. Dihedral scans were performed using a series of constrained optimizations, whereby the specified dihedral angle was kept frozen at a given value, with full optimization of the remaining geometric parameters subject to the given dihedral constraint. Total energies for a given system were then converted into relative energies (kilocalories per mole) for graphical depiction.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="note"><p class="first last">This dihedral value is dependent on the pyramidalization of the nitrogen in small-molecule X-ray structures. Sulfonamide nitrogen atoms are generally depicted as slightly less pyramidal with an N-plane distance between 0.25 and 0.4 Ã but often lower.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, J.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C.</span><span> </span><span class="NLM_article-title">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1505</span><span class="NLM_x">â</span> <span class="NLM_lpage">1515</span><span class="refDoi">Â DOI: 10.1136/ard.2007.076430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1136%2Fard.2007.076430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=18055474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=1505-1515&author=M.+Hegenauthor=J.+Keithauthor=M.+Collinsauthor=C.+Nickerson-Nutter&title=Utility+of+animal+models+for+identification+of+potential+therapeutics+for+rheumatoid+arthritis&doi=10.1136%2Fard.2007.076430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span></div><div class="casAuthors">Hegen, M.; Keith, J. C., Jr.; Collins, M.; Nickerson-Nutter, C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1505-1515</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Animal models of rheumatoid arthritis (RA) are widely used for testing potential new therapies for RA.  However, the question of which animal model is most predictive of therapeutic efficacy in human RA commonly arises in data evaluation.  A retrospective review of the animal models used to evaluate approved, pending RA therapies, and compds. that were discontinued during phase II or III clin. trials found that the three most commonly used models were adjuvant-induced arthritis (AIA) in rats and collagen-induced arthritis (CIA) in rats and mice.  Limited data were found for more recently developed genetically modified animal models.  Examn. of the efficacy of various compds. in these animal models revealed that a compd.'s therapeutic efficacy, rather than prophylactic efficacy, in AIA and CIA models was more predictive of clin. efficacy in human RA than data from either model alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruwo5lHLFB3bVg90H21EOLACvtfcHk0liPC_sEdOjdxA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP&md5=417b41682141901273229dacb8f63283</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1136%2Fard.2007.076430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2007.076430%26sid%3Dliteratum%253Aachs%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DKeith%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%26atitle%3DUtility%2520of%2520animal%2520models%2520for%2520identification%2520of%2520potential%2520therapeutics%2520for%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2008%26volume%3D67%26spage%3D1505%26epage%3D1515%26doi%3D10.1136%2Fard.2007.076430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span> </span><span class="NLM_article-title">Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">â</span> <span class="NLM_lpage">173</span><span class="refDoi">Â DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+clinical+translation+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+in+rheumatoid+arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of â¼100 nM.  Tofacitinib potency (ED50) in clin. studies was â¼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of â¼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within â¼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0lj5d_cCoMCT2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520clinical%2520translation%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Vanhoutte, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Aa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">vanât Klooster, G.</span><span> </span><span class="NLM_article-title">Selective JAK1 inhibition in the treatment of rheumatoid arthritis: Proof of concept with GLPG0634</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">2489</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=2489&author=F.+Vanhoutteauthor=M.+Mazurauthor=A.+Van+der+Aaauthor=P.+Wigerinckauthor=G.+van%E2%80%99t+Klooster&title=Selective+JAK1+inhibition+in+the+treatment+of+rheumatoid+arthritis%3A+Proof+of+concept+with+GLPG0634"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DMazur%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3Dvan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DSelective%2520JAK1%2520inhibition%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%253A%2520Proof%2520of%2520concept%2520with%2520GLPG0634%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D62%26spage%3D2489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Patil, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonde, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kekan, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathe, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, A.</span><span> </span><span class="NLM_article-title">An Improved and Efficient process for the preparation of tofacitinib citrate</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1714</span><span class="NLM_x">â</span> <span class="NLM_lpage">1720</span><span class="refDoi">Â DOI: 10.1021/op500274j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op500274j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=1714-1720&author=Y.+S.+Patilauthor=N.+L.+Bondeauthor=A.+S.+Kekanauthor=D.+G.+Satheauthor=A.+Das&title=An+Improved+and+Efficient+process+for+the+preparation+of+tofacitinib+citrate&doi=10.1021%2Fop500274j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fop500274j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop500274j%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DY.%2BS.%26aulast%3DBonde%26aufirst%3DN.%2BL.%26aulast%3DKekan%26aufirst%3DA.%2BS.%26aulast%3DSathe%26aufirst%3DD.%2BG.%26aulast%3DDas%26aufirst%3DA.%26atitle%3DAn%2520Improved%2520and%2520Efficient%2520process%2520for%2520the%2520preparation%2520of%2520tofacitinib%2520citrate%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D1714%26epage%3D1720%26doi%3D10.1021%2Fop500274j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Montero, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewynter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agoh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaunay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbach, J.-L.</span><span> </span><span class="NLM_article-title">Selective synthesis of sulfonylureas and carboxysulfamides. A novel route to oxazolidinones</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3091</span><span class="NLM_x">â</span> <span class="NLM_lpage">3094</span><span class="refDoi">Â DOI: 10.1016/S0040-4039(00)88103-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2FS0040-4039%2800%2988103-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1983&pages=3091-3094&author=J.-L.+Monteroauthor=G.+Dewynterauthor=B.+Agohauthor=B.+Delaunayauthor=J.-L.+Imbach&title=Selective+synthesis+of+sulfonylureas+and+carboxysulfamides.+A+novel+route+to+oxazolidinones&doi=10.1016%2FS0040-4039%2800%2988103-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2988103-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252988103-4%26sid%3Dliteratum%253Aachs%26aulast%3DMontero%26aufirst%3DJ.-L.%26aulast%3DDewynter%26aufirst%3DG.%26aulast%3DAgoh%26aufirst%3DB.%26aulast%3DDelaunay%26aufirst%3DB.%26aulast%3DImbach%26aufirst%3DJ.-L.%26atitle%3DSelective%2520synthesis%2520of%2520sulfonylureas%2520and%2520carboxysulfamides.%2520A%2520novel%2520route%2520to%2520oxazolidinones%26jtitle%3DTetrahedron%2520Lett.%26date%3D1983%26volume%3D24%26spage%3D3091%26epage%3D3094%26doi%3D10.1016%2FS0040-4039%2800%2988103-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Borghese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoine, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hoeck, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mockel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merschaert, A.</span><span> </span><span class="NLM_article-title">Mild and safer preparative method for nonsymmetrical sulfamides via N-sulfamoyloxazolidinone derivatives: Electronic effects affect the transsulfamoylation reactivity</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">770</span><span class="NLM_x">â</span> <span class="NLM_lpage">775</span><span class="refDoi">Â DOI: 10.1021/op0600106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op0600106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD28XkslyltLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=770-775&author=A.+Borgheseauthor=L.+Antoineauthor=J.+P.+Van+Hoeckauthor=A.+Mockelauthor=A.+Merschaert&title=Mild+and+safer+preparative+method+for+nonsymmetrical+sulfamides+via+N-sulfamoyloxazolidinone+derivatives%3A+Electronic+effects+affect+the+transsulfamoylation+reactivity&doi=10.1021%2Fop0600106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mild and Safer Preparative Method for Nonsymmetrical Sulfamides via N-Sulfamoyloxazolidinone Derivatives: Electronic Effects Affect the Transsulfamoylation Reactivity</span></div><div class="casAuthors">Borghese, A.; Antoine, L.; Van Hoeck, J. P.; Mockel, A.; Merschaert, A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">770-775</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sulfamides (R1R2N-SO2-NR3R4) are traditionally prepd. by using strong electrophilic and hazardous reagents such as N-sulfamoyl chloride, sulfonyl chloride, phosphorus oxychloride, or phosphorus pentachloride.  We report here a safer and more convenient synthetic methodol. for large-scale prepn. of sulfamides using the N-substituted oxazolidin-2-one derivs. 5 as synthetic equiv. of the corrosive and hazardous N-sulfamoyl chloride.  The scope of the use of N-sulfamoyloxazolidinones to prep. nonsym. sulfamides is explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgy3n1IzRZ57Vg90H21EOLACvtfcHk0lj5d_cCoMCT2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkslyltLw%253D&md5=d81a647f8a79a981be7ff53944a825fc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fop0600106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0600106%26sid%3Dliteratum%253Aachs%26aulast%3DBorghese%26aufirst%3DA.%26aulast%3DAntoine%26aufirst%3DL.%26aulast%3DVan%2BHoeck%26aufirst%3DJ.%2BP.%26aulast%3DMockel%26aufirst%3DA.%26aulast%3DMerschaert%26aufirst%3DA.%26atitle%3DMild%2520and%2520safer%2520preparative%2520method%2520for%2520nonsymmetrical%2520sulfamides%2520via%2520N-sulfamoyloxazolidinone%2520derivatives%253A%2520Electronic%2520effects%2520affect%2520the%2520transsulfamoylation%2520reactivity%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2006%26volume%3D10%26spage%3D770%26epage%3D775%26doi%3D10.1021%2Fop0600106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Mickelson, J. W.; Bhattacharya, S. K.; Brown, M. F.; Dorff, P. H.; LaGreca, S. D.; Maguire, R. J.; Cornicelli, J. A.; Brown, D. L.; Jennings, R.; Walker, J. K.; Huff, R. M.</span><span> </span><span class="NLM_article-title">Preparation of Oxadiazole Cyclobutyl Carboxylic Acid Derivatives as S1P Receptor Modulators for Treating Hyperproliferative and Autoimmune diseases</span>. Patent WO200960278 A1, May 14,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+W.+Mickelson&author=S.+K.+Bhattacharya&author=M.+F.+Brown&author=P.+H.+Dorff&author=S.+D.+LaGreca&author=R.+J.+Maguire&author=J.+A.+Cornicelli&author=D.+L.+Brown&author=R.+Jennings&author=J.+K.+Walker&author=R.+M.+Huff&title=Preparation+of+Oxadiazole+Cyclobutyl+Carboxylic+Acid+Derivatives+as+S1P+Receptor+Modulators+for+Treating+Hyperproliferative+and+Autoimmune+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMickelson%26aufirst%3DJ.%2BW.%26atitle%3DPreparation%2520of%2520Oxadiazole%2520Cyclobutyl%2520Carboxylic%2520Acid%2520Derivatives%2520as%2520S1P%2520Receptor%2520Modulators%2520for%2520Treating%2520Hyperproliferative%2520and%2520Autoimmune%2520diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Schmieder, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draelos, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pariser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfield, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieras, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons-Rich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salganik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeva, E.</span><span> </span><span class="NLM_article-title">Efficacy and safety of the Janus Kinase 1 inhibitor PF-04965842 in patients with moderate to severe psoriasis: phase 2, randomized, double-blind, placebo-controlled study</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi">Â DOI: 10.1111/bjd.16004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1111%2Fbjd.16004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=28949012" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Schmiederauthor=Z.+Draelosauthor=D.+Pariserauthor=C.+Banfieldauthor=L.+Coxauthor=M.+Hodgeauthor=E.+Kierasauthor=D.+Parsons-Richauthor=S.+Menonauthor=M.+Salganikauthor=K.+Pageauthor=E.+Peeva&title=Efficacy+and+safety+of+the+Janus+Kinase+1+inhibitor+PF-04965842+in+patients+with+moderate+to+severe+psoriasis%3A+phase+2%2C+randomized%2C+double-blind%2C+placebo-controlled+study&doi=10.1111%2Fbjd.16004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fbjd.16004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.16004%26sid%3Dliteratum%253Aachs%26aulast%3DSchmieder%26aufirst%3DG.%26aulast%3DDraelos%26aufirst%3DZ.%26aulast%3DPariser%26aufirst%3DD.%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DL.%26aulast%3DHodge%26aufirst%3DM.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DParsons-Rich%26aufirst%3DD.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DSalganik%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPeeva%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520the%2520Janus%2520Kinase%25201%2520inhibitor%2520PF-04965842%2520in%2520patients%2520with%2520moderate%2520to%2520severe%2520psoriasis%253A%2520phase%25202%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2017%26doi%3D10.1111%2Fbjd.16004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">Compound <b>25</b>, <i><b>N</b></i>-{<i><b>cis</b></i>-3-[Methyl(7<i><b>H</b></i>-pyrrolo[2,3-<i><b>d</b></i>]pyrimidin-4-yl)amino]cyclobutyl}-propane-1-sulfonamide is available through MilliporeSigma (cat. no. PZ0304).</p></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="note"><p class="first last">NaBH<sub>4</sub> is used to minimize oxidative disulfide formation.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c','cit1d','cit1e'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10','cit10b'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24a','cit24b'],'ref25':['cit25a','cit25b'],'ref26':['cit26a','cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':[],'ref30':[],'ref31':['cit31a','cit31b'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 35 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Christina G. Connor, Jacob C. DeForest, Phil Dietrich, Nga M. Do, Kevin M. Doyle, Shane Eisenbeis, Elizabeth Greenberg, Sarah H. Griffin, Brian P. Jones, Kris N. Jones, Michael Karmilowicz, Rajesh Kumar, Chad A. Lewis, Emma L. McInturff, J. Christopher McWilliams, Ruchi Mehta, Bao D. Nguyen, Anil M. Rane, Brian Samas, Barbara J. Sitter, Howard W. Ward, <span class="NLM_string-name hlFld-ContribAuthor">Mark E. Webster</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Nitrene-Type Rearrangement for the Commercial Route of the JAK1 Inhibitor Abrocitinib. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (3)
                                     , 608-615. <a href="https://doi.org/10.1021/acs.oprd.0c00366" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00366</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00366%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BNitrene-Type%252BRearrangement%252Bfor%252Bthe%252BCommercial%252BRoute%252Bof%252Bthe%252BJAK1%252BInhibitor%252BAbrocitinib%26aulast%3DConnor%26aufirst%3DChristina%2BG.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D12082020%26date%3D18092020%26volume%3D25%26issue%3D3%26spage%3D608%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ryan R. Davis, Baoli Li, Sang Y. Yun, Alice Chan, Pradeep Nareddy, Steven Gunawan, Muhammad Ayaz, Harshani R. Lawrence, Gary W. Reuther, Nicholas J. Lawrence, <span class="NLM_string-name hlFld-ContribAuthor">Ernst SchÃ¶nbrunn</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (4)
                                     , 2228-2241. <a href="https://doi.org/10.1021/acs.jmedchem.0c01952" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01952</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01952%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BInsights%252Binto%252BJAK2%252BInhibition%252Bby%252BRuxolitinib%25252C%252BFedratinib%25252C%252Band%252BDerivatives%252BThereof%26aulast%3DDavis%26aufirst%3DRyan%2BR.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D17112020%26date%3D11022021%26volume%3D64%26issue%3D4%26spage%3D2228%26epage%3D2241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Eunsun Park, Sun Joo Lee, Heegyum Moon, Jongmi Park, Hyeonho Jeon, Ji Sun Hwang, Hayoung Hwang, Ki Bum Hong, Seung-Hee Han, Sun Choi, <span class="NLM_string-name hlFld-ContribAuthor">Soosung Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 958-979. <a href="https://doi.org/10.1021/acs.jmedchem.0c01026" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BBiological%252BEvaluation%252Bof%252BN-Methyl-pyrrolo%25255B2%25252C3-b%25255Dpyridine-5-carboxamide%252BDerivatives%252Bas%252BJAK1-Selective%252BInhibitors%26aulast%3DPark%26aufirst%3DEunsun%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D16062020%26date%3D11012021%26volume%3D64%26issue%3D2%26spage%3D958%26epage%3D979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brian S. Gerstenberger, Catherine Ambler, Eric P. Arnold, Mary-Ellen Banker, Matthew F. Brown, James D. Clark, Alpay Dermenci, Martin E. Dowty, Andrew Fensome, Susan Fish, Matthew M. Hayward, Martin Hegen, Brett D. Hollingshead, John D. Knafels, David W. Lin, Tsung H. Lin, Dafydd R. Owen, Eddine Saiah, Raman Sharma, Felix F. Vajdos, Li Xing, Xiaojing Yang, Xin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Stephen W. Wright</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13561-13577. <a href="https://doi.org/10.1021/acs.jmedchem.0c00948" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00948</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00948%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252BInhibitor%252B%252528PF-06826647%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DGerstenberger%26aufirst%3DBrian%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03062020%26date%3D25082020%26date%3D05082020%26volume%3D63%26issue%3D22%26spage%3D13561%26epage%3D13577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bettina Borreschmidt Hansen, Tue Heesgaard Jepsen, Mogens Larsen, Rikke Sindet, Thomas Vifian, Mia NÃ¸rreskov Burhardt, Jens Larsen, Jimmi Gerner Seitzberg, Martin A. Carnerup, Anders Jerre, Christina MÃ¸lck, Paola Lovato, Sanjay Rai, Venkatarathnam Reddy Nasipireddy, <span class="NLM_string-name hlFld-ContribAuthor">Andreas RitzÃ©n</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 7008-7032. <a href="https://doi.org/10.1021/acs.jmedchem.0c00359" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00359%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFragment-Based%252BDiscovery%252Bof%252BPyrazolopyridones%252Bas%252BJAK1%252BInhibitors%252Bwith%252BExcellent%252BSubtype%252BSelectivity%26aulast%3DHansen%26aufirst%3DBettina%2BBorreschmidt%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28022020%26date%3D08062020%26date%3D28052020%26volume%3D63%26issue%3D13%26spage%3D7008%26epage%3D7032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Satoru Noji, Yoshinori Hara, Tomoya Miura, Hiroshi Yamanaka, Katsuya Maeda, Akimi Hori, Hiroshi Yamamoto, Shingo Obika, Masafumi Inoue, Yasunori Hase, Takuya Orita, Satoki Doi, Tsuyoshi Adachi, Atsuo Tanimoto, Chika Oki, Yukari Kimoto, Yoshihiro Ogawa, Tamotsu Negoro, Hiromasa Hashimoto, <span class="NLM_string-name hlFld-ContribAuthor">Makoto Shiozaki</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 7163-7185. <a href="https://doi.org/10.1021/acs.jmedchem.0c00450" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00450</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00450%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BJanus%252BKinase%252BInhibitor%252BBearing%252Ba%252BHighly%252BThree-Dimensional%252BSpiro%252BScaffold%25253A%252BJTE-052%252B%252528Delgocitinib%252529%252Bas%252Ba%252BNew%252BDermatological%252BAgent%252Bto%252BTreat%252BInflammatory%252BSkin%252BDisorders%26aulast%3DNoji%26aufirst%3DSatoru%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17032020%26date%3D29062020%26date%3D08062020%26volume%3D63%26issue%3D13%26spage%3D7163%26epage%3D7185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qibin Su, Erica Banks, Geraldine Bebernitz, Kirsten Bell, Cassandra F. Borenstein, Huawei Chen, Claudio E. Chuaqui, Nanhua Deng, Andrew D. Ferguson, Sameer Kawatkar, Neil P. Grimster, Linette Ruston, Paul D. Lyne, Jon A. Read, Xianyou Peng, Xiaohui Pei, Stephen Fawell, Zhanlei Tang, Scott Throner, Melissa M. Vasbinder, Haoyu Wang, Jon Winter-Holt, Richard Woessner, Allan Wu, Wenzhan Yang, Michael Zinda, <span class="NLM_string-name hlFld-ContribAuthor">Jason G. Kettle</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4517-4527. <a href="https://doi.org/10.1021/acs.jmedchem.9b01392" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01392%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%2525282R%252529-N-%25255B3-%25255B2-%25255B%2525283-Methoxy-1-methyl-pyrazol-4-yl%252529amino%25255Dpyrimidin-4-yl%25255D-1H-indol-7-yl%25255D-2-%2525284-methylpiperazin-1-yl%252529propenamide%252B%252528AZD4205%252529%252Bas%252Ba%252BPotent%252Band%252BSelective%252BJanus%252BKinase%252B1%252BInhibitor%26aulast%3DSu%26aufirst%3DQibin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D22082019%26date%3D28042020%26date%3D16042020%26volume%3D63%26issue%3D9%26spage%3D4517%26epage%3D4527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Minjian Yang, Bingzhong Tao, Chengjuan Chen, Wenqiang Jia, Shaolei Sun, Tiantai Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojian Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (12)
                                     , 5002-5012. <a href="https://doi.org/10.1021/acs.jcim.9b00798" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00798%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMachine%252BLearning%252BModels%252BBased%252Bon%252BMolecular%252BFingerprints%252Band%252Ban%252BExtreme%252BGradient%252BBoosting%252BMethod%252BLead%252Bto%252Bthe%252BDiscovery%252Bof%252BJAK2%252BInhibitors%26aulast%3DYang%26aufirst%3DMinjian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15092019%26date%3D04122019%26date%3D20112019%26volume%3D59%26issue%3D12%26spage%3D5002%26epage%3D5012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin, Yanlei Zhang, Steven Spergel, James Kempson, John S. Tokarski, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, David Shuster, Kathleen Gillooly, Xiaoxia Yang, Elizabeth Heimrich, Kim W. McIntyre, Charu Chaudhry, Javed Khan, Max Ruzanov, Jeffrey Tredup, Dawn Mulligan, Dianlin Xie, Huadong Sun, Christine Huang, Celia DâArienzo, Nelly Aranibar, Manoj Chiney, Anjaneya Chimalakonda, William J. Pitts, Louis Lombardo, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8973-8995. <a href="https://doi.org/10.1021/acs.jmedchem.9b00444" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHighly%252BSelective%252BInhibition%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%25253A%252BDiscovery%252Bof%252Bthe%252BAllosteric%252BInhibitor%252BBMS-986165%26aulast%3DWrobleski%26aufirst%3DStephen%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D18072019%26volume%3D62%26issue%3D20%26spage%3D8973%26epage%3D8995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Steven H. Spergel, Michael E. Mertzman, James Kempson, Junqing Guo, Sylwia Stachura, Lauren Haque, Jonathan S. Lippy, Rosemary F. Zhang, Michael Galella, Sidney Pitt, Guoxiang Shen, Aberra Fura, Kathleen Gillooly, Kim W. McIntyre, Vicky Tang, John Tokarski, John S. Sack, Javed Khan, Percy H. Carter, Joel C. Barrish, Steven G. Nadler, Luisa M. Salter-Cid, Gary L. Schieven, Stephen T. Wrobleski, <span class="NLM_string-name hlFld-ContribAuthor">William J. Pitts</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 306-311. <a href="https://doi.org/10.1021/acsmedchemlett.8b00508" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00508%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BJAK1%25252F3%252BInhibitor%252Band%252BUse%252Bof%252Ba%252BProdrug%252BTo%252BDemonstrate%252BEfficacy%252Bin%252Ba%252BModel%252Bof%252BRheumatoid%252BArthritis%26aulast%3DSpergel%26aufirst%3DSteven%2BH.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D26102018%26date%3D07022019%26date%3D13022019%26volume%3D10%26issue%3D3%26spage%3D306%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marian C. Bryan, <span class="NLM_string-name hlFld-ContribAuthor">Naomi S. Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9030-9058. <a href="https://doi.org/10.1021/acs.jmedchem.8b00667" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDisorders%25253A%252BRecent%252BAdvances%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26042018%26date%3D15062018%26date%3D05062018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hui Peng, Wenkun Luo, Huanfeng Jiang, <span class="NLM_string-name hlFld-ContribAuthor">Biaolin Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Tandem Achmatowicz Rearrangement and Acetalization of 1-[5-(Hydroxyalkyl)-furan-2-yl]-cyclobutanols Leading to Dispiroacetals and Subsequent Ring-Expansion to Form 6,7-Dihydrobenzofuran-4(5H)-ones. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (20)
                                     , 12869-12879. <a href="https://doi.org/10.1021/acs.joc.8b01765" title="DOI URL">https://doi.org/10.1021/acs.joc.8b01765</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b01765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b01765%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTandem%252BAchmatowicz%252BRearrangement%252Band%252BAcetalization%252Bof%252B1-%25255B5-%252528Hydroxyalkyl%252529-furan-2-yl%25255D-cyclobutanols%252BLeading%252Bto%252BDispiroacetals%252Band%252BSubsequent%252BRing-Expansion%252Bto%252BForm%252B6%25252C7-Dihydrobenzofuran-4%2525285H%252529-ones%26aulast%3DPeng%26aufirst%3DHui%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D11072018%26date%3D01102018%26date%3D21092018%26volume%3D83%26issue%3D20%26spage%3D12869%26epage%3D12879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Neil P. Grimster, Erica Anderson, Marat Alimzhanov, Geraldine Bebernitz, Kirsten Bell, Claudio Chuaqui, Tracy Deegan, Andrew D. Ferguson, Thomas Gero, Andreas Harsch, Dennis Huszar, Aarti Kawatkar, Jason G. Kettle, Paul Lyne, Jon A. Read, Caroline Rivard Costa, Linette Ruston, Patricia Schroeder, Jie Shi, Qibin Su, Scott Throner, Dorin Toader, Melissa Vasbinder, Richard Woessner, Haixia Wang, Allan Wu, Minwei Ye, Weijia Zheng, <span class="NLM_string-name hlFld-ContribAuthor">Michael Zinda</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5235-5244. <a href="https://doi.org/10.1021/acs.jmedchem.8b00076" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00076%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252Ba%252BNovel%252BSeries%252Bof%252BHighly%252BSelective%252BJAK1%252BKinase%252BInhibitors%26aulast%3DGrimster%26aufirst%3DNeil%2BP.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16012018%26date%3D13062018%26date%3D01062018%26volume%3D61%26issue%3D12%26spage%3D5235%26epage%3D5244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nazarii Sabat, Lenka PoÅ¡tovÃ¡ SlavÄtÃ­nskÃ¡, Blanka KlepetÃ¡ÅovÃ¡, <span class="NLM_string-name hlFld-ContribAuthor">Michal Hocek</span>. </span><span class="cited-content_cbyCitation_article-title">CâH Imidation of 7-Deazapurines. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (4)
                                     , 4674-4678. <a href="https://doi.org/10.1021/acsomega.8b00520" title="DOI URL">https://doi.org/10.1021/acsomega.8b00520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b00520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b00520%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DC%2525E2%252580%252593H%252BImidation%252Bof%252B7-Deazapurines%26aulast%3DSabat%26aufirst%3DNazarii%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19032018%26date%3D20042018%26volume%3D3%26issue%3D4%26spage%3D4674%26epage%3D4678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gideon A.  Gyebi</span>, <span class="hlFld-ContribAuthor ">Oludare M.  Ogunyemi</span>, <span class="hlFld-ContribAuthor ">Ibrahim M.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Saheed O.  Afolabi</span>, <span class="hlFld-ContribAuthor ">Joseph O.  Adebayo</span>. </span><span class="cited-content_cbyCitation_article-title">Dual targeting of cytokine storm and viral replication in COVID-19 by plant-derived steroidal pregnanes: An in silico perspective. </span><span class="cited-content_cbyCitation_journal-name">Computers in Biology and Medicine</span><span> <strong>2021,</strong> <em>134 </em>, 104406. <a href="https://doi.org/10.1016/j.compbiomed.2021.104406" title="DOI URL">https://doi.org/10.1016/j.compbiomed.2021.104406</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiomed.2021.104406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiomed.2021.104406%26sid%3Dliteratum%253Aachs%26jtitle%3DComputers%2520in%2520Biology%2520and%2520Medicine%26atitle%3DDual%252Btargeting%252Bof%252Bcytokine%252Bstorm%252Band%252Bviral%252Breplication%252Bin%252BCOVID-19%252Bby%252Bplant-derived%252Bsteroidal%252Bpregnanes%25253A%252BAn%252Bin%252Bsilico%252Bperspective%26aulast%3DGyebi%26aufirst%3DGideon%2BA.%26date%3D2021%26volume%3D134%26spage%3D104406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyun  Zheng</span>, <span class="hlFld-ContribAuthor ">Tianshuo  Zhong</span>, <span class="hlFld-ContribAuthor ">Xiao  Yi</span>, <span class="hlFld-ContribAuthor ">Qitao  Shen</span>, <span class="hlFld-ContribAuthor ">Chuanliu  Yin</span>, <span class="hlFld-ContribAuthor ">Lei  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Zhou</span>, <span class="hlFld-ContribAuthor ">Junyu  Chen</span>, <span class="hlFld-ContribAuthor ">Chuanming  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">IronâCatalyzed ThreeâComponent Cyanoalkylsulfonylation of 2,3âAllenoic Acids, Sulfur Dioxide, and Cycloketone Oxime Esters: Access to Cyanoalkylsulfonylated Butenolides. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>84 </em><a href="https://doi.org/10.1002/adsc.202100463" title="DOI URL">https://doi.org/10.1002/adsc.202100463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202100463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202100463%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DIron%2525E2%252580%252590Catalyzed%252BThree%2525E2%252580%252590Component%252BCyanoalkylsulfonylation%252Bof%252B2%25252C3%2525E2%252580%252590Allenoic%252BAcids%25252C%252BSulfur%252BDioxide%25252C%252Band%252BCycloketone%252BOxime%252BEsters%25253A%252BAccess%252Bto%252BCyanoalkylsulfonylated%252BButenolides%26aulast%3DZheng%26aufirst%3DXiangyun%26date%3D2021%26date%3D2021%26volume%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniya  Aynetdinova</span>, <span class="hlFld-ContribAuthor ">Mia C.  Callens</span>, <span class="hlFld-ContribAuthor ">Harry B.  Hicks</span>, <span class="hlFld-ContribAuthor ">Charmaine Y. X.  Poh</span>, <span class="hlFld-ContribAuthor ">Benjamin D. A.  Shennan</span>, <span class="hlFld-ContribAuthor ">Alistair M.  Boyd</span>, <span class="hlFld-ContribAuthor ">Zhong Hui  Lim</span>, <span class="hlFld-ContribAuthor ">Jamie A.  Leitch</span>, <span class="hlFld-ContribAuthor ">Darren J.  Dixon</span>. </span><span class="cited-content_cbyCitation_article-title">Installing the âmagic methylâ â CâH methylation in synthesis. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2021,</strong> <em>50 </em>
                                    (9)
                                     , 5517-5563. <a href="https://doi.org/10.1039/D0CS00973C" title="DOI URL">https://doi.org/10.1039/D0CS00973C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CS00973C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CS00973C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DInstalling%252Bthe%252B%2525E2%252580%25259Cmagic%252Bmethyl%2525E2%252580%25259D%252B%2525E2%252580%252593%252BC%2525E2%252580%252593H%252Bmethylation%252Bin%252Bsynthesis%26aulast%3DAynetdinova%26aufirst%3DDaniya%26date%3D2021%26date%3D2021%26volume%3D50%26issue%3D9%26spage%3D5517%26epage%3D5563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takuya  Miyano</span>, <span class="hlFld-ContribAuthor ">Alan D.  Irvine</span>, <span class="hlFld-ContribAuthor ">Reiko J.  Tanaka</span>. </span><span class="cited-content_cbyCitation_article-title">A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis. </span><span class="cited-content_cbyCitation_journal-name">Allergy</span><span> <strong>2021,</strong> <em>23 </em><a href="https://doi.org/10.1111/all.14870" title="DOI URL">https://doi.org/10.1111/all.14870</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/all.14870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fall.14870%26sid%3Dliteratum%253Aachs%26jtitle%3DAllergy%26atitle%3DA%252Bmathematical%252Bmodel%252Bto%252Bidentify%252Boptimal%252Bcombinations%252Bof%252Bdrug%252Btargets%252Bfor%252Bdupilumab%252Bpoor%252Bresponders%252Bin%252Batopic%252Bdermatitis%26aulast%3DMiyano%26aufirst%3DTakuya%26date%3D2021%26date%3D2021%26volume%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michela  Sperti</span>, <span class="hlFld-ContribAuthor ">Marta  Malavolta</span>, <span class="hlFld-ContribAuthor ">Gloria  Ciniero</span>, <span class="hlFld-ContribAuthor ">Simone  Borrelli</span>, <span class="hlFld-ContribAuthor ">Marco  CavagliÃ </span>, <span class="hlFld-ContribAuthor ">Stefano  Muscat</span>, <span class="hlFld-ContribAuthor ">Jack Adam  Tuszynski</span>, <span class="hlFld-ContribAuthor ">Antonella  Afeltra</span>, <span class="hlFld-ContribAuthor ">Domenico Paolo Emanuele  Margiotta</span>, <span class="hlFld-ContribAuthor ">Luca  Navarini</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibitors in immune-mediated rheumatic diseases: From a molecular perspective to clinical studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2021,</strong> <em>104 </em>, 107789. <a href="https://doi.org/10.1016/j.jmgm.2020.107789" title="DOI URL">https://doi.org/10.1016/j.jmgm.2020.107789</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2020.107789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2020.107789%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DJAK%252Binhibitors%252Bin%252Bimmune-mediated%252Brheumatic%252Bdiseases%25253A%252BFrom%252Ba%252Bmolecular%252Bperspective%252Bto%252Bclinical%252Bstudies%26aulast%3DSperti%26aufirst%3DMichela%26date%3D2021%26volume%3D104%26spage%3D107789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias R.  Bauer</span>, <span class="hlFld-ContribAuthor ">Paolo  Di Fruscia</span>, <span class="hlFld-ContribAuthor ">Simon C. C.  Lucas</span>, <span class="hlFld-ContribAuthor ">Iacovos N.  Michaelides</span>, <span class="hlFld-ContribAuthor ">Jennifer E.  Nelson</span>, <span class="hlFld-ContribAuthor ">R. Ian  Storer</span>, <span class="hlFld-ContribAuthor ">Benjamin C.  Whitehurst</span>. </span><span class="cited-content_cbyCitation_article-title">Put a ring on it: application of small aliphatic rings in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 448-471. <a href="https://doi.org/10.1039/D0MD00370K" title="DOI URL">https://doi.org/10.1039/D0MD00370K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00370K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00370K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPut%252Ba%252Bring%252Bon%252Bit%25253A%252Bapplication%252Bof%252Bsmall%252Baliphatic%252Brings%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DBauer%26aufirst%3DMatthias%2BR.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D448%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert M.  Borzilleri</span>, <span class="hlFld-ContribAuthor ">Amy C.  Hart</span>, <span class="hlFld-ContribAuthor ">Ryan  Moslin</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Stephen T.  Wrobleski</span>. </span><span class="cited-content_cbyCitation_article-title">JAK
              Family Inhibitors for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-86. <a href="https://doi.org/10.1002/0471266949.bmc279" title="DOI URL">https://doi.org/10.1002/0471266949.bmc279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc279%26sid%3Dliteratum%253Aachs%26atitle%3DJAK%252BFamily%252BInhibitors%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DBorzilleri%26aufirst%3DRobert%2BM.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D86%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ellen Q.  Wang</span>, <span class="hlFld-ContribAuthor ">Vu  Le</span>, <span class="hlFld-ContribAuthor ">Melissa  O'Gorman</span>, <span class="hlFld-ContribAuthor ">Sakambari  Tripathy</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Lisy  Wang</span>, <span class="hlFld-ContribAuthor ">Bimal K.  Malhotra</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Clinical Pharmacology</span><span> <strong>2021,</strong> <em>3 </em><a href="https://doi.org/10.1002/jcph.1858" title="DOI URL">https://doi.org/10.1002/jcph.1858</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcph.1858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcph.1858%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DEffects%252Bof%252BHepatic%252BImpairment%252Bon%252Bthe%252BPharmacokinetics%252Bof%252BAbrocitinib%252Band%252BIts%252BMetabolites%26aulast%3DWang%26aufirst%3DEllen%2BQ.%26date%3D2021%26date%3D2021%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erika L.  Crowley</span>, <span class="hlFld-ContribAuthor ">Novin  Nezamololama</span>, <span class="hlFld-ContribAuthor ">Kim  Papp</span>, <span class="hlFld-ContribAuthor ">Melinda J.  Gooderham</span>. </span><span class="cited-content_cbyCitation_article-title">Abrocitinib for the treatment of atopic dermatitis. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Clinical Immunology</span><span> <strong>2020,</strong> <em>16 </em>
                                    (10)
                                     , 955-962. <a href="https://doi.org/10.1080/1744666X.2021.1828068" title="DOI URL">https://doi.org/10.1080/1744666X.2021.1828068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1744666X.2021.1828068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1744666X.2021.1828068%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Clinical%2520Immunology%26atitle%3DAbrocitinib%252Bfor%252Bthe%252Btreatment%252Bof%252Batopic%252Bdermatitis%26aulast%3DCrowley%26aufirst%3DErika%2BL.%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D10%26spage%3D955%26epage%3D962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maryanne  Covington</span>, <span class="hlFld-ContribAuthor ">Xin  He</span>, <span class="hlFld-ContribAuthor ">Monika  Scuron</span>, <span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Robert  Collins</span>, <span class="hlFld-ContribAuthor ">Ashish  Juvekar</span>, <span class="hlFld-ContribAuthor ">Niu  Shin</span>, <span class="hlFld-ContribAuthor ">Margaret  Favata</span>, <span class="hlFld-ContribAuthor ">Karen  Gallagher</span>, <span class="hlFld-ContribAuthor ">Sarala  Sarah</span>, <span class="hlFld-ContribAuthor ">Chu-biao  Xue</span>, <span class="hlFld-ContribAuthor ">Michael  Peel</span>, <span class="hlFld-ContribAuthor ">Krista  Burke</span>, <span class="hlFld-ContribAuthor ">Julian  Oliver</span>, <span class="hlFld-ContribAuthor ">Brittany  Fay</span>, <span class="hlFld-ContribAuthor ">Wenqing  Yao</span>, <span class="hlFld-ContribAuthor ">Taisheng  Huang</span>, <span class="hlFld-ContribAuthor ">Peggy  Scherle</span>, <span class="hlFld-ContribAuthor ">Sharon  Diamond</span>, <span class="hlFld-ContribAuthor ">Robert  Newton</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Paul  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2020,</strong> <em>885 </em>, 173505. <a href="https://doi.org/10.1016/j.ejphar.2020.173505" title="DOI URL">https://doi.org/10.1016/j.ejphar.2020.173505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2020.173505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2020.173505%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DPreclinical%252Bcharacterization%252Bof%252Bitacitinib%252B%252528INCB039110%252529%25252C%252Ba%252Bnovel%252Bselective%252Binhibitor%252Bof%252BJAK1%25252C%252Bfor%252Bthe%252Btreatment%252Bof%252Binflammatory%252Bdiseases%26aulast%3DCovington%26aufirst%3DMaryanne%26date%3D2020%26volume%3D885%26spage%3D173505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Hua  Zhong</span>, <span class="hlFld-ContribAuthor ">Wenfeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Wen</span>, <span class="hlFld-ContribAuthor ">Zhujun  Yi</span>, <span class="hlFld-ContribAuthor ">Peizhi  Li</span>, <span class="hlFld-ContribAuthor ">Jianping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">STAT5a induces endotoxin tolerance by alleviating pyroptosis in kupffer cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular Immunology</span><span> <strong>2020,</strong> <em>122 </em>, 28-37. <a href="https://doi.org/10.1016/j.molimm.2020.03.016" title="DOI URL">https://doi.org/10.1016/j.molimm.2020.03.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molimm.2020.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molimm.2020.03.016%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Immunology%26atitle%3DSTAT5a%252Binduces%252Bendotoxin%252Btolerance%252Bby%252Balleviating%252Bpyroptosis%252Bin%252Bkupffer%252Bcells%26aulast%3DWang%26aufirst%3DTao%26date%3D2020%26volume%3D122%26spage%3D28%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xinying  Cheng</span>, <span class="hlFld-ContribAuthor ">Qiuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112155. <a href="https://doi.org/10.1016/j.ejmech.2020.112155" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112155%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJanus%252Bkinases%252B%252528JAKs%252529%25253A%252BThe%252Befficient%252Btherapeutic%252Btargets%252Bfor%252Bautoimmune%252Bdiseases%252Band%252Bmyeloproliferative%252Bdisorders%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2020%26volume%3D192%26spage%3D112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farzan  Solimani</span>, <span class="hlFld-ContribAuthor ">Katharina  Meier</span>, <span class="hlFld-ContribAuthor ">Kamran  Ghoreschi</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Topical and Systemic JAK Inhibitors in Dermatology. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2019,</strong> <em>10 </em><a href="https://doi.org/10.3389/fimmu.2019.02847" title="DOI URL">https://doi.org/10.3389/fimmu.2019.02847</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2019.02847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2019.02847%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DEmerging%252BTopical%252Band%252BSystemic%252BJAK%252BInhibitors%252Bin%252BDermatology%26aulast%3DSolimani%26aufirst%3DFarzan%26date%3D2019%26date%3D2019%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Hart S.  Dengler</span>, <span class="hlFld-ContribAuthor ">Naomi S.  Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (20)
                                     , 126658. <a href="https://doi.org/10.1016/j.bmcl.2019.126658" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126658%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInhaled%252BJanus%252BKinase%252B%252528JAK%252529%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Basthma%26aulast%3DZak%26aufirst%3DMark%26date%3D2019%26volume%3D29%26issue%3D20%26spage%3D126658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashley  Jarvis</span>, <span class="hlFld-ContribAuthor ">Gilles  Ouvry</span>. </span><span class="cited-content_cbyCitation_article-title">Essential ingredients for rational drug design. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (20)
                                     , 126674. <a href="https://doi.org/10.1016/j.bmcl.2019.126674" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126674%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DEssential%252Bingredients%252Bfor%252Brational%252Bdrug%252Bdesign%26aulast%3DJarvis%26aufirst%3DAshley%26date%3D2019%26volume%3D29%26issue%3D20%26spage%3D126674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Helen  He</span>, <span class="hlFld-ContribAuthor ">Emma  Guttman-Yassky</span>. </span><span class="cited-content_cbyCitation_article-title">JAK Inhibitors for Atopic Dermatitis: An Update. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Clinical Dermatology</span><span> <strong>2019,</strong> <em>20 </em>
                                    (2)
                                     , 181-192. <a href="https://doi.org/10.1007/s40257-018-0413-2" title="DOI URL">https://doi.org/10.1007/s40257-018-0413-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40257-018-0413-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40257-018-0413-2%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Clinical%2520Dermatology%26atitle%3DJAK%252BInhibitors%252Bfor%252BAtopic%252BDermatitis%25253A%252BAn%252BUpdate%26aulast%3DHe%26aufirst%3DHelen%26date%3D2019%26date%3D2018%26volume%3D20%26issue%3D2%26spage%3D181%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anniina  T. Virtanen</span>, <span class="hlFld-ContribAuthor ">Teemu  Haikarainen</span>, <span class="hlFld-ContribAuthor ">Juuli  Raivola</span>, <span class="hlFld-ContribAuthor ">Olli  Silvennoinen</span>. </span><span class="cited-content_cbyCitation_article-title">Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">BioDrugs</span><span> <strong>2019,</strong> <em>33 </em>
                                    (1)
                                     , 15-32. <a href="https://doi.org/10.1007/s40259-019-00333-w" title="DOI URL">https://doi.org/10.1007/s40259-019-00333-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40259-019-00333-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40259-019-00333-w%26sid%3Dliteratum%253Aachs%26jtitle%3DBioDrugs%26atitle%3DSelective%252BJAKinibs%25253A%252BProspects%252Bin%252BInflammatory%252Band%252BAutoimmune%252BDiseases%26aulast%3DT.%2BVirtanen%26aufirst%3DAnniina%26date%3D2019%26date%3D2019%26volume%3D33%26issue%3D1%26spage%3D15%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimo  Gadina</span>, <span class="hlFld-ContribAuthor ">Mimi T  Le</span>, <span class="hlFld-ContribAuthor ">Daniella M  Schwartz</span>, <span class="hlFld-ContribAuthor ">Olli  Silvennoinen</span>, <span class="hlFld-ContribAuthor ">Shingo  Nakayamada</span>, <span class="hlFld-ContribAuthor ">Kunihiro  Yamaoka</span>, <span class="hlFld-ContribAuthor ">John J  OâShea</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases to jakinibs: from basic insights to clinical practice. </span><span class="cited-content_cbyCitation_journal-name">Rheumatology</span><span> <strong>2019,</strong> <em>58 </em>
                                    (Supplement_1)
                                     , i4-i16. <a href="https://doi.org/10.1093/rheumatology/key432" title="DOI URL">https://doi.org/10.1093/rheumatology/key432</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/rheumatology/key432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Frheumatology%2Fkey432%26sid%3Dliteratum%253Aachs%26jtitle%3DRheumatology%26atitle%3DJanus%252Bkinases%252Bto%252Bjakinibs%25253A%252Bfrom%252Bbasic%252Binsights%252Bto%252Bclinical%252Bpractice%26aulast%3DGadina%26aufirst%3DMassimo%26date%3D2019%26date%3D2019%26volume%3D58%26issue%3DSupplement_1%26spage%3Di4%26epage%3Di16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charles J.  Malemud</span>. </span><span class="cited-content_cbyCitation_article-title">Defective JAK-STAT Pathway Signaling Contributes to Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmacology Reports</span><span> <strong>2018,</strong> <em>4 </em>
                                    (5)
                                     , 358-366. <a href="https://doi.org/10.1007/s40495-018-0151-4" title="DOI URL">https://doi.org/10.1007/s40495-018-0151-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40495-018-0151-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40495-018-0151-4%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmacology%2520Reports%26atitle%3DDefective%252BJAK-STAT%252BPathway%252BSignaling%252BContributes%252Bto%252BAutoimmune%252BDiseases%26aulast%3DMalemud%26aufirst%3DCharles%2BJ.%26date%3D2018%26date%3D2018%26volume%3D4%26issue%3D5%26spage%3D358%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimo  Gadina</span>, <span class="hlFld-ContribAuthor ">Catrina  Johnson</span>, <span class="hlFld-ContribAuthor ">Daniella  Schwartz</span>, <span class="hlFld-ContribAuthor ">Michael  Bonelli</span>, <span class="hlFld-ContribAuthor ">Sarfaraz  Hasni</span>, <span class="hlFld-ContribAuthor ">Yuka  Kanno</span>, <span class="hlFld-ContribAuthor ">Paul  Changelian</span>, <span class="hlFld-ContribAuthor ">Arian  Laurence</span>, <span class="hlFld-ContribAuthor ">John J.  O'Shea</span>. </span><span class="cited-content_cbyCitation_article-title">Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Leukocyte Biology</span><span> <strong>2018,</strong> <em>104 </em>
                                    (3)
                                     , 499-514. <a href="https://doi.org/10.1002/JLB.5RI0218-084R" title="DOI URL">https://doi.org/10.1002/JLB.5RI0218-084R</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/JLB.5RI0218-084R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2FJLB.5RI0218-084R%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Leukocyte%2520Biology%26atitle%3DTranslational%252Band%252Bclinical%252Badvances%252Bin%252BJAK-STAT%252Bbiology%25253A%252BThe%252Bpresent%252Band%252Bfuture%252Bof%252Bjakinibs%26aulast%3DGadina%26aufirst%3DMassimo%26date%3D2018%26date%3D2018%26volume%3D104%26issue%3D3%26spage%3D499%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Peeva</span>, <span class="hlFld-ContribAuthor ">Martin R.  Hodge</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Kieras</span>, <span class="hlFld-ContribAuthor ">Michael L.  Vazquez</span>, <span class="hlFld-ContribAuthor ">Kosalaram  Goteti</span>, <span class="hlFld-ContribAuthor ">Sanela G.  Tarabar</span>, <span class="hlFld-ContribAuthor ">Christine W.  Alvey</span>, <span class="hlFld-ContribAuthor ">Christopher  Banfield</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Clinical Pharmacology</span><span> <strong>2018,</strong> <em>84 </em>
                                    (8)
                                     , 1776-1788. <a href="https://doi.org/10.1111/bcp.13612" title="DOI URL">https://doi.org/10.1111/bcp.13612</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcp.13612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcp.13612%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DEvaluation%252Bof%252Ba%252BJanus%252Bkinase%252B1%252Binhibitor%25252C%252BPF-04965842%25252C%252Bin%252Bhealthy%252Bsubjects%25253A%252BA%252Bphase%252B1%25252C%252Brandomized%25252C%252Bplacebo-controlled%25252C%252Bdose-escalation%252Bstudy%26aulast%3DPeeva%26aufirst%3DElena%26date%3D2018%26date%3D2018%26volume%3D84%26issue%3D8%26spage%3D1776%26epage%3D1788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Tofacitinib (<b>1</b>), baricitinib (<b>2</b>), and ruxolitinib (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure of <b>25</b> in complex with JAK1. The ligand <b>25</b> is shown in yellow. Hydrogen bond interactions of the core pyrrolopyrimidine ring with hinge residues Leu959, Glu957, and the NH group with Asn1008 are highlighted in red. The structure is of sufficient resolution (2.1 Ã) to observe a bound water molecule (light pink) hydrogen bonded to N-3 of the core ring and in position to form hydrogen bond with Glu966 residue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of <b>25</b> in complex with JAK2. The ligand <b>25</b> is shown in magenta. Hydrogen bond interactions of the core pyrrolopyrimidine ring with hinge residues Leu932, Glu930, and the NH group with Asn981 and Arg980 are highlighted in red. The structure is of sufficient resolution (1.8 Ã) to observe a bound water molecule (light pink) hydrogen bonded to N-3 of the core ring and in position to form hydrogen bond to Asp939 through a network of water molecules. For clarity, the network of water molecules is not depicted. Another water molecule is also observed forming hydrogen bond interaction with the sulfur atom of the ligand and the NH backbone of the Lys857 residue in the P-loop.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Orientations of the P-loops in JAK1 (cyan) and JAK2 (green) in the ligand <b>25</b> bound X-ray structures. The JAK1 bound ligand is shown in yellow, while the JAK2 bound ligand is shown in magenta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Torsional profile of the dihedral (a) S(O<sub>2</sub>)âCâCâC and (b) NâS(O<sub>2</sub>)âCâC calculated from B3LYP/6-31++G basis set. Green and blue arrows indicate observed dihedrals in the X-ray bound state of <b>25</b> in JAK1 and JAK2, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Conformational preference for sulfamides. N<sup>1</sup> showing the s-<i>cis</i> relationship with the oxygen of the sulfone (shown in bold), while N<sup>2</sup> has a s-<i>trans</i> relationship with that same oxygen. (b) Example from a CSD entry (HIXNUX) showing the s-<i>cis</i> and s-<i>trans</i> relationship in sulfamides. Both nitrogens have pyramidal character.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibition of cytokine-induced STAT phosphorylation (pSTAT) in whole blood of rats dosed orally with <b>25.</b> NaÃ¯ve Lewis rats were given a single dose of <b>25</b> at 50, 15, or 5 mg/kg, and peripheral blood was taken at 0.25, 0.5, 2, 4, 8, and 24 h post dose. STAT phosphorylation was assayed at each time point by stimulation with relevant cytokines (A) IFNÎ³, (B) IL-21, and (C) IL-6, then subsequent measurement of appropriate pSTATs was performed. Intracellular STAT3 and STAT1 phosphorylation was determined within a CD3+ gate representing the T cell population. Data are presented as compared to maximal response in vehicle-dosed animals.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Rats with AIA were treated with 15, 5, 1, or 0.5 mg/kg of <b>25</b> or vehicle control. A significant reduction of hind paw swelling was seen on days 3â7 (15 mg/kg), days 4â7 (5 mg/kg), and days 6 and 7 (1 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. PK/PD modeling of exposure (<i>C</i><sub>ave</sub>) and its AUC of effect of <b>25</b> after 7 days of dosing in the rat AIA model. The unbound EC<sub>ave</sub>50 concentration was determined to be 1.3 Î¼M.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Extent of cytokine inhibition resulting from an expected efficacious dose of <b>25</b> (200 mg QD) in human (p-STAT abbreviated as ST).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Sulfonamide and Sulfamide Analogs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span><b>44</b>, MeNH<sub>2</sub>, THF, AcOH, rt then NaBH<sub>4</sub>, 0 Â°C to rt.</p><p><span class="fn-label">Scheme b</span><b><i>cis</i>-45</b>, <b>46a</b>, DIPEA, <i>i</i>-PrOH, 75 Â°C.</p><p><span class="fn-label">Scheme c</span><b>46b</b>, <b><i>cis</i>-45</b>, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, 95 Â°C.</p><p><span class="fn-label">Scheme d</span><b>47a</b>, HBr, AcOH, EtOAc, rt.</p><p><span class="fn-label">Scheme e</span><b>47b</b>, Pd(OH)<sub>2</sub>, cyclohexene, EtOH, 78 Â°C.</p><p><span class="fn-label">Scheme f</span>RSO<sub>2</sub>Cl, TEA or DIPEA.</p><p><span class="fn-label">Scheme g</span>aq OH<sup>â</sup> or CO<sub>3</sub><sup>2â</sup>/ROH.</p><p><span class="fn-label">Scheme h</span><b>48b</b>Â·HCl, LiHDMS, TMSCl, rt then RSO<sub>2</sub>Cl, rt.</p><p><span class="fn-label">Scheme i</span>ClSO<sub>2</sub>NCO, 2-bromoethanol, DCM, 0 Â°C then <b>48a</b>Â·2HBr, TEA, rt.</p><p class="last"><span class="fn-label">Scheme j</span>R<sup>1</sup>R<sup>2</sup>NH, TEA or DIPEA, MeCN, 100 Â°C (sealed tube).</p></p></figure><figure data-id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/medium/jm-2017-015983_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Sulfone and Reverse Sulfonamide Analogs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01598/20180201/images/large/jm-2017-015983_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01598&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span><b>52</b>Â·HCl, Boc<sub>2</sub>O, TEA, DCM, 0 Â°C to rt.</p><p><span class="fn-label">Scheme b</span>LiAlH<sub>4</sub>, THF, 0 to 66 Â°C.</p><p><span class="fn-label">Scheme c</span><b>46a</b>, <b>53</b>, TEA, cat. KI.</p><p><span class="fn-label">Scheme d</span><i>p</i>-TsCl, DMAP, DCM, 0 Â°C to rt.</p><p><span class="fn-label">Scheme e</span>KSAc, DMF, 55 Â°C.</p><p><span class="fn-label">Scheme f</span>30% aq H<sub>2</sub>O<sub>2</sub>, HCO<sub>2</sub>H.</p><p><span class="fn-label">Scheme g</span>SOCl<sub>2</sub>, cat. DMF, DCM, 0 to 75 Â°C.</p><p><span class="fn-label">Scheme h</span>R<sup>3</sup>R<sup>4</sup>NH, TEA or DIPEA.</p><p><span class="fn-label">Scheme i</span>aq OH<sup>â</sup> or CO<sub>3</sub><sup>2â</sup>/ROH.</p><p><span class="fn-label">Scheme j</span>K<sub>2</sub>CO<sub>3</sub>, MeOH, 0 Â°C then R<sup>2</sup>-X, rt.</p><p><span class="fn-label">Scheme k</span>Oxone, THF, EtOH, H<sub>2</sub>O.</p><p class="last"><span class="fn-label">Scheme l</span>R<sup>2</sup>SH, DBU, NMP, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i104">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leonard, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">JAKS and STATS: biological implications</span> <span class="citation_source-journal">Annu. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">â</span> <span class="NLM_lpage">322</span><span class="refDoi">Â DOI: 10.1146/annurev.immunol.16.1.293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1146%2Fannurev.immunol.16.1.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=9597132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADyaK1cXislygurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=293-322&author=W.+J.+Leonardauthor=J.+J.+O%E2%80%99Shea&title=JAKS+and+STATS%3A+biological+implications&doi=10.1146%2Fannurev.immunol.16.1.293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">JAKS and STATS: Biological implications</span></div><div class="casAuthors">Leonard, Warren J.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">293-322</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 185 refs.  Cytokines and interferons are mols. that play central roles in the regulation of a wide array of cellular functions in the lympho-hematopoietic system.  These factors stimulate proliferation, differentiation, and survival signals, as well as specialized functions in host resistance to pathogens.  Although cytokines are known to activate multiple signaling pathways that together mediate these important functions, one of these pathways, the Jak-STAT pathway, is the focus of this chapter.  This pathway is triggered by both cytokines and interferons, and it very rapidly allows the transduction of an extracellular signal into the nucleus.  The pathway uses a novel mechanism in which cytosolic latent transcription factors, known as signal transducers and activators of transcription (STATs), are tyrosine phosphorylated by Janus family tyrosine kinases (Jaks), allowing STAT protein dimerization and nuclear translocation.  STATs then can modulate the expression of target genes.  The basic biol. of this system, including the range of known Jaks and STATs, is discussed, as are the defects in animals and human lacking some of these signaling mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkrO-nJd5D_LVg90H21EOLACvtfcHk0lhe2QBZUYMBdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislygurs%253D&md5=ac5eeeb0159c2c8769e2cb28720cdf98</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.16.1.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.16.1.293%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAKS%2520and%2520STATS%253A%2520biological%2520implications%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1998%26volume%3D16%26spage%3D293%26epage%3D322%26doi%3D10.1146%2Fannurev.immunol.16.1.293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">â</span> <span class="NLM_lpage">287</span><span class="refDoi">Â DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lhe2QBZUYMBdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1002%2Fjlb.60.4.441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=8864127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1996&pages=441-452&author=J.+A.+Johnstonauthor=C.+M.+Baconauthor=M.+C.+Riedyauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+IL-2+and+related+cytokines%3A+JAKs%2C+STATs%2C+and+relationship+to+immunodeficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span></div><div class="casAuthors">Johnston, James A.; Bacon, Chris M.; Riedy, M. C.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 153 refs.  Cytokines that bind to the interleukin-2 (IL-2) receptor common gamma chain (Î³c), including IL-2, IL-4, IL-7, IL-9, and IL-15, are important for the growth and differentiation of T and B lymphocytes, natural killer cells, macrophages, and monocytes.  These cytokines have overlapping biol. effects that in part result from the use of the shared receptor subunit Î³c.  Recently it has become clear that these cytokines activate a no. of important intracellular signaling mols., including the Janus kinases JAK1 and JAK3 and members of the transcription factor family of signal transducers and activators of transcription (STATs).  The discovery of these signaling pathways has led to important new insights into their role of lymphocyte maturation, as it has emerged that mutations in the genes encoding both Î³c and JAK3 result in similar forms of severe combined immunodeficiency (SCID).  In this review we examine the structure and function of cytokine receptors and the signaling pathways involved in their regulation of gene expression.  Furthermore, we discuss recent advances that have led to a better understanding of how cytokines elicit intracellular responses, as well as their role in normal lymphoid development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBS-4Fw4Io7Vg90H21EOLACvtfcHk0lhe2QBZUYMBdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D&md5=6ccea65ed0126878728f639506a565ac</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1002%2Fjlb.60.4.441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlb.60.4.441%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DBacon%26aufirst%3DC.%2BM.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520IL-2%2520and%2520related%2520cytokines%253A%2520JAKs%252C%2520STATs%252C%2520and%2520relationship%2520to%2520immunodeficiency%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D1996%26volume%3D60%26spage%3D441%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plenge, R.</span><span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">â</span> <span class="NLM_lpage">550</span><span class="refDoi">Â DOI: 10.1016/j.immuni.2012.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.immuni.2012.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=22520847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease&doi=10.1016%2Fj.immuni.2012.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease</span></div><div class="casAuthors">O'Shea, John J.; Plenge, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">542-550</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, a landmark in cell biol., provided a simple mechanism for gene regulation that dramatically advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleukins.  As we learn more about the complexities of immune responses, new insights into the functions of this pathway continue to be revealed, aided by technol. that permits genome-wide views.  As we celebrate the 20th anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this knowledge has rapidly been translated to human immune disease.  Not only have genome-wide assocn. studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc6dj5Zf9fdLVg90H21EOLACvtfcHk0lhsJUmt08InCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D&md5=de187a0555549f9f00f5a41052c05352</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2012.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2012.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550%26doi%3D10.1016%2Fj.immuni.2012.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Shuai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span> </span><span class="NLM_article-title">Regulation of JAK-STAT signaling in the immune system</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">â</span> <span class="NLM_lpage">911</span><span class="refDoi">Â DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signaling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1eR"><div class="casContent"><span class="casTitleNuber">1e</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lhsJUmt08InCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit1e&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signaling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Mavers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruderman, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, H.</span><span> </span><span class="NLM_article-title">Intracellular signal pathways: potential for therapies</span> <span class="citation_source-journal">Curr. Rheumatol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">â</span> <span class="NLM_lpage">385</span><span class="refDoi">Â DOI: 10.1007/s11926-009-0054-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1007%2Fs11926-009-0054-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=19772834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFeku7jE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=378-385&author=M.+Maversauthor=E.+M.+Rudermanauthor=H.+Perlman&title=Intracellular+signal+pathways%3A+potential+for+therapies&doi=10.1007%2Fs11926-009-0054-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular signal pathways: potential for therapies</span></div><div class="casAuthors">Mavers, Melissa; Ruderman, Eric M.; Perlman, Harris</div><div class="citationInfo"><span class="NLM_cas:title">Current Rheumatology Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">378-385</span>CODEN:
                <span class="NLM_cas:coden">CRRUCI</span>;
        ISSN:<span class="NLM_cas:issn">1523-3774</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Drawbacks to current therapies for rheumatoid arthritis and the high cost of many of these drugs have lead to the investigation of novel approaches for treatment of this disease.  One such tactic is the targeting of proteins involved in intracellular signal transduction.  Inhibitors of p38 kinase have largely failed in clin. trials, due to both lack of efficacy and adverse events.  The degree of adverse events may reflect off-target effects or, conversely, may be a mechanism-related event subsequent to successful inhibition of p38.  Drugs targeting Janus kinases or spleen tyrosine kinase have shown greater success in clin. trials.  A thorough anal. of specificity, as well as publication of both pos. and neg. results, must be the goal of continuing trials of these and other inhibitors of signal transduction mols.  The success of many clin. trials in this novel class of drugs provides optimism that more cost-effective and improved therapies will soon be available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBrleay_ctfrVg90H21EOLACvtfcHk0lhsJUmt08InCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFeku7jE&md5=f3a18d64ac9620db5e43ca55df40c83b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs11926-009-0054-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11926-009-0054-9%26sid%3Dliteratum%253Aachs%26aulast%3DMavers%26aufirst%3DM.%26aulast%3DRuderman%26aufirst%3DE.%2BM.%26aulast%3DPerlman%26aufirst%3DH.%26atitle%3DIntracellular%2520signal%2520pathways%253A%2520potential%2520for%2520therapies%26jtitle%3DCurr.%2520Rheumatol.%2520Rep.%26date%3D2009%26volume%3D11%26spage%3D378%26epage%3D385%26doi%3D10.1007%2Fs11926-009-0054-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Schindler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, T.</span><span> </span><span class="NLM_article-title">JAK-STAT Signaling: from interferons to cytokines</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">20059</span><span class="NLM_x">â</span> <span class="NLM_lpage">20063</span><span class="refDoi">Â DOI: 10.1074/jbc.R700016200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1074%2Fjbc.R700016200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=17502367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsFWntr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=20059-20063&author=C.+Schindlerauthor=D.+E.+Levyauthor=T.+Decker&title=JAK-STAT+Signaling%3A+from+interferons+to+cytokines&doi=10.1074%2Fjbc.R700016200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">JAK-STAT Signaling: From Interferons to Cytokines</span></div><div class="casAuthors">Schindler, Christian; Levy, David E.; Decker, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">20059-20063</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  The early availability of recombinant interferons (IFNs) afforded an opportunity to study how cytokines induce gene expression, culminating in the identification of JAK-STAT signaling paradigm.  Subsequent studies identified 7 STATs and 4 JAKs, providing an insight how IFNs and other members of the four-helix bundle cytokine family transduce their biol. responses.  Here, the authors briefly summarize this signaling paradigm and then focus on STAT-dependent transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3j1nH6yBhbVg90H21EOLACvtfcHk0lhsJUmt08InCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsFWntr8%253D&md5=9bbfc21b9afc22cd65dbd9a8605f7a03</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R700016200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R700016200%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DC.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDecker%26aufirst%3DT.%26atitle%3DJAK-STAT%2520Signaling%253A%2520from%2520interferons%2520to%2520cytokines%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D20059%26epage%3D20063%26doi%3D10.1074%2Fjbc.R700016200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Cytokines and their role in lymphoid development, differentiation and homeostasis</span> <span class="citation_source-journal">Curr. Opin. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">â</span> <span class="NLM_lpage">506</span><span class="refDoi">Â DOI: 10.1097/00130832-200212000-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1097%2F00130832-200212000-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=14752332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=495-506&author=S.+R.+Hofmannauthor=R.+Ettingerauthor=Y.-J.+Zhouauthor=M.+Gadinaauthor=P.+Lipskyauthor=R.+Siegelauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Shea&title=Cytokines+and+their+role+in+lymphoid+development%2C+differentiation+and+homeostasis&doi=10.1097%2F00130832-200212000-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines and their role in lymphoid development, differentiation and homeostasis</span></div><div class="casAuthors">Hofmann Sigrun R; Ettinger Rachel; Zhou Yong-Jie; Gadina Massimo; Lipsky Peter; Siegel Richard; Candotti Fabio; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-506</span>
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The development of lymphoid tissues as well as the ultimate differentiation of naive and memory T cells are dependent on cytokines.  In this review, we will focus on recent advances in the understanding of molecular mechanisms that regulate lymphoid development, homeostasis and tolerance.  RECENT FINDINGS:  Cytokines play a critical role in the development and differentiation of lymphoid cells.  In addition, newer data indicate important roles of interleukin-7 and interleukin-15 in lymphoid homeostasis and memory.  Furthermore, a new family of heterodimeric cytokines comprising interleukin-12, interleukin-23 and -27 is important for differentiation of helper T cells and cell-mediated immunity.  Finally the importance of tumor necrosis factor superfamily members in the development of lymphoid organs has recently been elucidated and will be discussed in detail.  SUMMARY:  New cytokines and receptors continue to be identified.  The discovery and characterization of cytokines, their receptors and signaling molecules will provide a more complete understanding of normal lymphoid development, differentiation and function.  In addition, this knowledge should improve our understanding of the pathogenesis of immunological diseases and hopefully will provide new treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTci7HKMzLxgUNHe_gFldTbfW6udTcc2ebexet63XBOCLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D&md5=9480ae8620e9053745c038149a08a607</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1097%2F00130832-200212000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200212000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DEttinger%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.-J.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DCytokines%2520and%2520their%2520role%2520in%2520lymphoid%2520development%252C%2520differentiation%2520and%2520homeostasis%26jtitle%3DCurr.%2520Opin.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2002%26volume%3D2%26spage%3D495%26epage%3D506%26doi%3D10.1097%2F00130832-200212000-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Levy, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darnell, J. E.,  Jr</span><span> </span><span class="NLM_article-title">STATS: Transcriptional control and biological impact</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">â</span> <span class="NLM_lpage">662</span><span class="refDoi">Â DOI: 10.1038/nrm909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1038%2Fnrm909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=12209125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslansrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=651-662&author=D.+E.+Levyauthor=J.+E.+Darnell&title=STATS%3A+Transcriptional+control+and+biological+impact&doi=10.1038%2Fnrm909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Stats: transcriptional control and biological impact</span></div><div class="casAuthors">Levy, David E.; Darnell, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">651-662</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Extracellular proteins bound to cell-surface receptors can change nuclear gene expression patterns in minutes, with far-reaching consequences for development, cell growth, and homeostasis.  The signal transducer and activator of transcription (STAT) proteins are among the most well studied of the latent cytoplasmic signal-dependent transcription factor pathways.  In addn. to several roles in normal cell decisions, dysregulation of STAT function contributes to human disease, making the study of these proteins an important topic of current research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGqYF32j262LVg90H21EOLACvtfcHk0ljDDAwfOz1NuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslansrw%253D&md5=4a04359c59e54b12d8a67efb6ef42e4c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrm909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm909%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26atitle%3DSTATS%253A%2520Transcriptional%2520control%2520and%2520biological%2520impact%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D651%26epage%3D662%26doi%3D10.1038%2Fnrm909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meraz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, K. C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennica, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, R. D.</span><span> </span><span class="NLM_article-title">Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the JAKs in cytokine-induced biologic responses</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">383</span><span class="refDoi">Â DOI: 10.1016/S0092-8674(00)81166-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2FS0092-8674%2800%2981166-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=9590172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFCjtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=373-383&author=S.+J.+Rodigauthor=M.+A.+Merazauthor=J.+M.+Whiteauthor=P.+A.+Lampeauthor=J.+K.+Rileyauthor=C.+D.+Arthurauthor=K.+L.+Kingauthor=K.+C.+F.+Sheehanauthor=L.+Yinauthor=D.+Pennicaauthor=E.+M.+Johnsonauthor=R.+D.+Schreiber&title=Disruption+of+the+Jak1+gene+demonstrates+obligatory+and+nonredundant+roles+of+the+JAKs+in+cytokine-induced+biologic+responses&doi=10.1016%2FS0092-8674%2800%2981166-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses</span></div><div class="casAuthors">Rodig, Scott J.; Meraz, Marco A.; White, J. Michael; Lampe, Pat A.; Riley, Joan K.; Arthur, Cora D.; King, Kathleen L.; Sheehan, Kathleen C. F.; Yin, Li; Pennica, Diane; Johnson, Eugene M., Jr.; Schreiber, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">373-383</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Herein we report the generation of mice lacking the ubiquitously expressed Janus kinase, Jak1.  Jak1-/- mice are runted at birth, fail to nurse, and die perinatally.  Although Jak1-/- cells are responsive to many cytokines, they fail to manifest biol. responses to cytokines that bind to three distinct families of cytokine receptors.  These include all class II cytokine receptors, cytokine receptors that utilize the Î³c subunit for signaling, and the family of cytokine receptors that depend on the gp130 subunit for signaling.  Our results thus demonstrate that Jak1 plays an essential and nonredundant role in promoting biol. responses induced by a select subset of cytokine receptors, including those in which Jak utilization was thought to be nonspecific.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxGavQ7H-weLVg90H21EOLACvtfcHk0ljDDAwfOz1NuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFCjtLs%253D&md5=c96007f46457346d3446a6ed2c2e0e07</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981166-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981166-6%26sid%3Dliteratum%253Aachs%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DMeraz%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DLampe%26aufirst%3DP.%2BA.%26aulast%3DRiley%26aufirst%3DJ.%2BK.%26aulast%3DArthur%26aufirst%3DC.%2BD.%26aulast%3DKing%26aufirst%3DK.%2BL.%26aulast%3DSheehan%26aufirst%3DK.%2BC.%2BF.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DPennica%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DDisruption%2520of%2520the%2520Jak1%2520gene%2520demonstrates%2520obligatory%2520and%2520nonredundant%2520roles%2520of%2520the%2520JAKs%2520in%2520cytokine-induced%2520biologic%2520responses%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D373%26epage%3D383%26doi%3D10.1016%2FS0092-8674%2800%2981166-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kaur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaushal, S.</span><span> </span><span class="NLM_article-title">Systematic review of tofacitinib: A new drug for the management of rheumatoid arthritis</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1074</span><span class="NLM_x">â</span> <span class="NLM_lpage">1086</span><span class="refDoi">Â DOI: 10.1016/j.clinthera.2014.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.clinthera.2014.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=25047498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2014&pages=1074-1086&author=K.+Kaurauthor=S.+Kalraauthor=S.+Kaushal&title=Systematic+review+of+tofacitinib%3A+A+new+drug+for+the+management+of+rheumatoid+arthritis&doi=10.1016%2Fj.clinthera.2014.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis</span></div><div class="casAuthors">Kaur, Kirandeep; Kalra, Sonesh; Kaushal, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1074-1086</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The goal of this study was to review and summarize the efficacy and safety of use of tofacitinib for treating rheumatoid arthritis (RA).  A systematic literature review was conducted to identify English-language articles published through May 2013 within PubMed, ClinicalTrials.gov, and Cochrane Library reporting results from Phase II and Phase III tofacitinib randomized clin. trials.  Tofacitinib must have been used as monotherapy or in combination therapy with disease-modifying antirheumatic drugs (DMARDs) in the treatment of RA.  Study outcomes had to include at least 1 of the following: American College of Rheumatol. (ACR) 20%, 50%, or 70% response rates; tender/swollen joint count; health assessment questionnaire of disability; radiog. outcomes; and drug persistence.  Eight studies (4 Phase II and 4 Phase III trials) were included in the review.  Patients with active RA and who were nonresponders to a biol. agent or the nonbiol. DMARD methotrexate were included in these studies.  The results of the Phase II trials show that tofacitinib at doses â¥3 mg BID was efficacious among the nonresponders.  The results of the Phase III trials, comparing tofacitinib 5 and 10 mg with placebo, show that tofacitinib led to a significant improvement in ACR20 response (P < 0.0001), Health Assessment Questionnaire-Disability Index (P < 0.0001) scores, and ACR50 response (P < 0.0001) after 3 mo.  The efficacy of tofacitinib was numerically similar to adalimumab.  The most common adverse events were infections, infestations, increases in LDL-C and HDL-C levels, and a decrease in neutrophil counts.  Tofacitinib is an efficacious drug for the management of moderate to severe RA among patients with an inadequate response to methotrexate and tumor necrosis factor inhibitors.  Long-term studies can help in understanding the risk/benefit profile of tofacitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNhogMT16YO7Vg90H21EOLACvtfcHk0ljZqmcHVGbCvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI&md5=8ffd0a6e85f9b9880cc80462337ddc7f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2014.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2014.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DK.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DKaushal%26aufirst%3DS.%26atitle%3DSystematic%2520review%2520of%2520tofacitinib%253A%2520A%2520new%2520drug%2520for%2520the%2520management%2520of%2520rheumatoid%2520arthritis%26jtitle%3DClin.%2520Ther.%26date%3D2014%26volume%3D36%26spage%3D1074%26epage%3D1086%26doi%3D10.1016%2Fj.clinthera.2014.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">â</span> <span class="NLM_lpage">5307</span><span class="refDoi">Â DOI: 10.4049/jimmunol.0902819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-5307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050&doi=10.4049%2Fjimmunol.0902819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0ljZqmcHVGbCvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D5307%26doi%3D10.4049%2Fjimmunol.0902819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Ruxolitinib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">â</span> <span class="NLM_lpage">104</span><span class="refDoi">Â DOI: 10.1038/nrd3652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1038%2Fnrd3652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=22293561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=103-104&author=R.+A.+Mesaauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Ruxolitinib&doi=10.1038%2Fnrd3652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib</span></div><div class="casAuthors">Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-104</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Nov. 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-mol. inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf2yAGCsbIA7Vg90H21EOLACvtfcHk0ljZqmcHVGbCvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D&md5=5bcfbd15f4478268330ffc4c8855762d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd3652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3652%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DRuxolitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D103%26epage%3D104%26doi%3D10.1038%2Fnrd3652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schwartz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J.</span><span> </span><span class="NLM_article-title">Type 1/11 cytokines, JAKs, and new design strategies for treating autoimmune diseases</span> <span class="citation_source-journal">Nat. Rev. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">â</span> <span class="NLM_lpage">36</span><span class="refDoi">Â DOI: 10.1038/nrrheum.2015.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1038%2Fnrrheum.2015.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=26633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=25-36&author=D.+Schwartzauthor=M.+Bonelliauthor=M.+Gadinaauthor=J.+O%E2%80%99Shea&title=Type+1%2F11+cytokines%2C+JAKs%2C+and+new+design+strategies+for+treating+autoimmune+diseases&doi=10.1038%2Fnrrheum.2015.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Bonelli, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cytokines are major drivers of autoimmunity, and biol. agents targeting cytokines have revolutionized the treatment of immune-mediated diseases.  Despite the effectiveness of these drugs, they do not induce complete remission in all patients, prompting the development of alternative strategies - including targeting of intracellular signal transduction pathways downstream of cytokines.  Many cytokines that bind type I and type II cytokine receptors are crit. regulators of immune-mediated diseases and employ the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway to exert their effect.  Pharmacol. inhibition of JAKs blocks the actions of type I/II cytokines, and within the past 3 years therapeutic JAK inhibitors, or Jakinibs, have become available to rheumatologists.  Jakinibs have proven effective for the treatment of rheumatoid arthritis and other inflammatory diseases.  Adverse effects of these agents are largely related to their mode of action and include infections and hyperlipidemia.  Jakinibs are currently being investigated for a no. of new indications, and second-generation selective Jakinibs are being developed and tested.  Targeting STATs could be a future avenue for the treatment of rheumatol. diseases, although substantial challenges remain.  Nonetheless, the ability to therapeutically target intracellular signalling pathways has already created a new paradigm for the treatment of rheumatol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdr1Dh92dnLVg90H21EOLACvtfcHk0liiILlmEU5z_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ&md5=e06f7ab6424f1fbdbf481c75fa9ebd23</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.167%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DType%25201%252F11%2520cytokines%252C%2520JAKs%252C%2520and%2520new%2520design%2520strategies%2520for%2520treating%2520autoimmune%2520diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D25%26epage%3D36%26doi%3D10.1038%2Fnrrheum.2015.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Keystone, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beattie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berclaz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus-Gort, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macias, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M.</span><span> </span><span class="NLM_article-title">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have an inadequate response to methotrexate</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">â</span> <span class="NLM_lpage">340</span><span class="refDoi">Â DOI: 10.1136/annrheumdis-2014-206478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1136%2Fannrheumdis-2014-206478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=25431052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2015&pages=333-340&author=E.+C.+Keystoneauthor=P.+Taylorauthor=E.+Drescherauthor=D.+Schlichtingauthor=D.+Beattieauthor=P.+Berclazauthor=C.+Leeauthor=R.+Fidelus-Gortauthor=M.+Luchiauthor=T.+Rooneyauthor=W.+Maciasauthor=M.+Genovese&title=Safety+and+efficacy+of+baricitinib+at+24+weeks+in+patients+with+rheumatoid+arthritis+who+have+an+inadequate+response+to+methotrexate&doi=10.1136%2Fannrheumdis-2014-206478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate</span></div><div class="casAuthors">Keystone, Edward C.; Taylor, Peter C.; Drescher, Edit; Schlichting, Douglas E.; Beattie, Scott D.; Berclaz, Pierre-Yves; Lee, Chin H.; Fidelus-Gort, Rosanne K.; Luchi, Monica E.; Rooney, Terence P.; Macias, William L.; Genovese, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">333-340</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate.  Methods In this phase IIb study, 301 patients were randomized 2:1:1:1:1 to receive once daily doses of placebo or 1, 2, 4 or 8 mg baricitinib for 12 wk.  Patients assigned to 2, 4 and 8 mg baricitinib continued blinded treatment for an addnl. 12 wk.  Patients assigned to placebo or 1 mg baricitinib were reassigned to 2 mg twice daily or 4 mg once daily baricitinib between weeks 12-24.  The primary endpoint was the proportion of patients in the combined 4 and 8 mg groups achieving an American College of Rheumatol. 20% (ACR20) response vs. placebo at week 12.  Results Significantly more patients in the combined baricitinib 4 and 8 mg groups compared with placebo achieved an ACR20 response at week 12 (76% vs 41%, p<0.001).  At week 12, significant differences vs. placebo were also obsd. in patients achieving ACR50, ACR70 and remission as measured by Disease Activity Score for 28-joint counts, Clin. Disease Activity Index and Simplified Disease Activity Index.  Patients receiving 2, 4, or 8 mg baricitinib maintained or improved in all measures through 24 wk.  Similar proportions of patients experienced at least one adverse event in the placebo and baricitinib groups.  Serious infections developed in three patients receiving baricitinib.  No cases of tuberculosis, herpes zoster, opportunistic infections or deaths were reported.  Dose-dependent decreases in Hb were obsd. with baricitinib.  Conclusions Baricitinib improved the signs and symptoms of RA in methotrexate inadequate responders with active disease.  Baricitinib was well tolerated with no unexpected safety findings through week 24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz3lYB7HU_KbVg90H21EOLACvtfcHk0liiILlmEU5z_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D&md5=2f13c96c1c1dc5f68e69cd3e6da457b7</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-206478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-206478%26sid%3Dliteratum%253Aachs%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DTaylor%26aufirst%3DP.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DSchlichting%26aufirst%3DD.%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBerclaz%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFidelus-Gort%26aufirst%3DR.%26aulast%3DLuchi%26aufirst%3DM.%26aulast%3DRooney%26aufirst%3DT.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DGenovese%26aufirst%3DM.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520baricitinib%2520at%252024%2520weeks%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520who%2520have%2520an%2520inadequate%2520response%2520to%2520methotrexate%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2015%26volume%3D74%26spage%3D333%26epage%3D340%26doi%3D10.1136%2Fannrheumdis-2014-206478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Strober, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonanno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harness, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, K.</span><span> </span><span class="NLM_article-title">Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">992</span><span class="NLM_x">â</span> <span class="NLM_lpage">999</span><span class="refDoi">Â DOI: 10.1111/bjd.12517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1111%2Fbjd.12517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=23855761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslakurzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=992-999&author=B.+Stroberauthor=M.+Buonannoauthor=J.+D.+Clarkauthor=T.+Kawabataauthor=H.+Tanauthor=R.+Wolkauthor=H.+Valdezauthor=R.+G.+Langleyauthor=J.+Harnessauthor=A.+Menterauthor=K.+Papp&title=Effect+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+on+haematological+parameters+during+12+weeks+of+psoriasis+treatment&doi=10.1111%2Fbjd.12517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment</span></div><div class="casAuthors">Strober, B.; Buonanno, M.; Clark, J. D.; Kawabata, T.; Tan, H.; Wolk, R.; Valdez, H.; Langley, R. G.; Harness, J.; Menter, A.; Papp, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">992-999</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : The Janus kinase (JAK) inhibitor, tofacitinib, has shown efficacy for the treatment of psoriasis in a phase IIb trial (A3921047; NCT00678210).  Objectives : To report haematol. data from the phase IIb trial, given the importance of JAK-dependent signalling in haematopoiesis.  Methods : Patients with moderate-to-severe chronic plaque psoriasis were randomized to receive tofacitinib 2, 5 or 15 mg, or placebo, twice daily over 12 wk.  Blood samples were collected at screening, baseline, weeks 2, 4, 8 and 12 during treatment, and weeks 14 and 16 during off-treatment follow-up.  Results : Baseline haematol. was similar across patients receiving tofacitinib 2 mg (n = 49), 5 mg (n = 49) or 15 mg (n = 49), or placebo (n = 50).  Tofacitinib conferred dose-dependent decreases in Hb, haematocrit and red blood cell counts, while reticulocyte counts initially declined, before recovering by week 8, and exceeding baseline levels after treatment cessation.  With regard to white blood cells, tofacitinib had no clear dose-dependent effects on basophils or monocytes, but appeared to be assocd. with transient or reversible dose-dependent decreases in neutrophil and eosinophil counts and transient increases in lymphocyte counts, which were primarily attributable to increases in B-cell counts.  Natural killer cell counts declined with tofacitinib.  Conclusions : Tofacitinib conferred tolerable, dose-dependent changes in haematol. parameters during short-term administration in patients with psoriasis.  The effects did not appear to be progressive, and were often transient or reversible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXc7wLFiJmW7Vg90H21EOLACvtfcHk0liiILlmEU5z_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslakurzP&md5=c8427f4813dc663ef97a2fce48f6fd08</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fbjd.12517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.12517%26sid%3Dliteratum%253Aachs%26aulast%3DStrober%26aufirst%3DB.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DKawabata%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DHarness%26aufirst%3DJ.%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DPapp%26aufirst%3DK.%26atitle%3DEffect%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520on%2520haematological%2520parameters%2520during%252012%2520weeks%2520of%2520psoriasis%2520treatment%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2013%26volume%3D169%26spage%3D992%26epage%3D999%26doi%3D10.1111%2Fbjd.12517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovich, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">â</span> <span class="NLM_lpage">157</span><span class="refDoi">Â DOI: 10.1016/0092-8674(93)90167-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2F0092-8674%2893%2990167-O" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=147-157&author=M.+Noguchiauthor=H.+Yiauthor=H.+M.+Rosenblattauthor=A.+H.+Filipovichauthor=S.+Adelsteinauthor=W.+S.+Modiauthor=O.+W.+McBrideauthor=W.+J.+Leonard&title=Interleukin-2+receptor+gamma+chain+mutation+results+in+X-linked+severe+combined+immunodeficiency+in+humans&doi=10.1016%2F0092-8674%2893%2990167-O"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2893%2990167-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252893%252990167-O%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DRosenblatt%26aufirst%3DH.%2BM.%26aulast%3DFilipovich%26aufirst%3DA.%2BH.%26aulast%3DAdelstein%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DW.%2BS.%26aulast%3DMcBride%26aufirst%3DO.%2BW.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DInterleukin-2%2520receptor%2520gamma%2520chain%2520mutation%2520results%2520in%2520X-linked%2520severe%2520combined%2520immunodeficiency%2520in%2520humans%26jtitle%3DCell%26date%3D1993%26volume%3D73%26spage%3D147%26epage%3D157%26doi%3D10.1016%2F0092-8674%2893%2990167-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzuti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koslov, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckius, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beals, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagouras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magna, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltarelli, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelms, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Des Etages, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finco-Kent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paniagua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">â</span> <span class="NLM_lpage">878</span><span class="refDoi">Â DOI: 10.1126/science.1087061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=C.+Shang-Poaauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=S.+G.+Des+Etagesauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.+S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.+J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor&doi=10.1126%2Fscience.1087061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0li-S-ThWn8oJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%2BEtages%26aufirst%3DS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878%26doi%3D10.1126%2Fscience.1087061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5023</span><span class="NLM_x">â</span> <span class="NLM_lpage">5038</span><span class="refDoi">Â DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0li-S-ThWn8oJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">â</span> <span class="NLM_lpage">8484</span><span class="refDoi">Â DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=S.-P.+Changauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lhNhM0M03K-1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DS.-P.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrick, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saabye, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span> </span><span class="NLM_article-title">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span> <span class="citation_source-journal">J. Inflammation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="refDoi">Â DOI: 10.1186/1476-9255-7-41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41&author=D.+M.+Meyerauthor=M.+I.+Jessonauthor=X.+Liauthor=M.+M.+Elrickauthor=C.+L.+Funckes-Shippyauthor=J.+D.+Warnerauthor=C.+J.+Grossauthor=M.+E.+Dowtyauthor=S.+K.+Ramaiahauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+L.+Barksauthor=N.+Kishoreauthor=D.+L.+Morris&title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+the+JAK1%2FJAK3+inhibitor%2C+CP-690%2C550%2C+in+rat+adjuvant-induced+arthritis&doi=10.1186%2F1476-9255-7-41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Meyer Debra M; Jesson Michael I; Li Xiong; Elrick Mollisa M; Funckes-Shippy Christie L; Warner James D; Gross Cindy J; Dowty Martin E; Ramaiah Shashi K; Hirsch Jeffrey L; Saabye Matthew J; Barks Jennifer L; Kishore Nandini; Morris Dale L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of inflammation (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors.  CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.  In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment.  These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment.  METHODS:  Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays.  The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays.  In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model.  RESULTS:  CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays.  Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment.  Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease.  At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels.  The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2.  CONCLUSION:  Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2.  In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550.  Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17.  Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2.  Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-l9vqy6452oNpW7w2tapOfW6udTcc2eZ31X775NmZErntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D&md5=1190d7c5509fde79a7b56024a3aec9d9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DElrick%26aufirst%3DM.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DGross%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DBarks%26aufirst%3DJ.%2BL.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DAnti-inflammatory%2520activity%2520and%2520neutrophil%2520reductions%2520mediated%2520by%2520the%2520JAK1%252FJAK3%2520inhibitor%252C%2520CP-690%252C550%252C%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DJ.%2520Inflammation%26date%3D2010%26volume%3D7%26spage%3D41%26doi%3D10.1186%2F1476-9255-7-41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Menet, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Rompaey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geney, R.</span><span> </span><span class="NLM_article-title">Advances in the discovery of selective JAK inhibitors</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">â</span> <span class="NLM_lpage">223</span><span class="refDoi">Â DOI: 10.1016/B978-0-444-62652-3.00004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2FB978-0-444-62652-3.00004-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=23384668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=153-223&author=C.+J.+Menetauthor=L.+Van+Rompaeyauthor=R.+Geney&title=Advances+in+the+discovery+of+selective+JAK+inhibitors&doi=10.1016%2FB978-0-444-62652-3.00004-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery of selective JAK inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Van Rompaey, Luc; Geney, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-223</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses the advances in the discovery of selective JAK inhibitors.  JAK inhibitor includes JAK1, JAK2 and JAK3 and tyrosine kinase2.  Medicinal chem. and structural biol. fronts in designing and synthesizing selective or mixed JAK small-mol. inhibitors were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTg_zxiK5GGLVg90H21EOLACvtfcHk0lhNhM0M03K-1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D&md5=3d7e6f0481e3a891c84c49ece6421d74</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-62652-3.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-62652-3.00004-1%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGeney%26aufirst%3DR.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520selective%2520JAK%2520inhibitors%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D153%26epage%3D223%26doi%3D10.1016%2FB978-0-444-62652-3.00004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Menet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mammoliti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Ramos, M.</span><span> </span><span class="NLM_article-title">Progress toward JAK1-selective inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">â</span> <span class="NLM_lpage">235</span><span class="refDoi">Â DOI: 10.4155/fmc.14.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.4155%2Ffmc.14.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=25686006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=203-235&author=C.+Menetauthor=O.+Mammolitiauthor=M.+Lopez-Ramos&title=Progress+toward+JAK1-selective+inhibitors&doi=10.4155%2Ffmc.14.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Progress toward JAK1-selective inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Mammoliti, Oscar; Lopez-Ramos, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-235</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the JAK-STAT pathway was a landmark in cell biol.  The identification of these pathways has changed the landscape of treatment of rheumatoid arthritis and other autoimmune diseases.  The two first (unselective) JAK inhibitors have recently been approved by the US FDA for the treatment of myelofibrosis and rheumatoid arthritis and many other JAK inhibitors are currently in clin. development or at the discovery stage.  Research groups have demonstrated the different roles of JAK member and the therapeutic potential of targeting them selectively.  JAK1 plays a crit. and potentially dominant role in the transduction of Î³c cytokine (Î³c = common Î³ chain) and in IL-6 signaling.  In this review, we will discuss the state-of-the-art research that evokes JAK1 selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFBuFU-x0dWrVg90H21EOLACvtfcHk0li0dDGFNu_Gkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D&md5=ef6cf011f0078aaa4f83560c98524d1c</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.149%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DLopez-Ramos%26aufirst%3DM.%26atitle%3DProgress%2520toward%2520JAK1-selective%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D203%26epage%3D235%26doi%3D10.4155%2Ffmc.14.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Thorarensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fensome, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juba, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casimiro-Garcia, A.</span><span> </span><span class="NLM_article-title">ATP mediated kinome selectivity â The missing link in understanding the contribution of individual JAK kinases isoforms to cellular signaling</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1552</span><span class="NLM_x">â</span> <span class="NLM_lpage">1558</span><span class="refDoi">Â DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.-B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP+mediated+kinome+selectivity+%E2%80%93+The+missing+link+in+understanding+the+contribution+of+individual+JAK+kinases+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP%2520mediated%2520kinome%2520selectivity%2520%25E2%2580%2593%2520The%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520kinases%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">â</span> <span class="NLM_lpage">3108</span><span class="refDoi">Â DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28KI%29+and+the+concentration+of+inhibitor+which+causes+50%25+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0li0dDGFNu_Gkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528KI%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Reino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Ramos, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">970</span><span class="NLM_x">â</span> <span class="NLM_lpage">981</span><span class="refDoi">Â DOI: 10.1002/art.33419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1002%2Fart.33419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=22006202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVygt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=970-981&author=J.+M.+Kremerauthor=S.+Cohenauthor=B.+E.+Wilkinsonauthor=C.+A.+Connellauthor=J.+L.+Frenchauthor=J.+Gomez-Reinoauthor=D.+Grubenauthor=K.+S.+Kanikauthor=S.+Krishnaswamiauthor=V.+Pascual-Ramosauthor=G.+Wallensteinauthor=S.+H.+Zwillich&title=A+phase+2B+dose-ranging+study+of+the+oral+JAK+inhibitor+tofacitinib+%28CP-690%2C550%29+versus+placebo+in+combination+with+background+methotrexate+in+patients+with+active+rheumatoid+arthritis+and+inadequate+response+to+methotrexate+alone&doi=10.1002%2Fart.33419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone</span></div><div class="casAuthors">Kremer, Joel M.; Cohen, Stanley; Wilkinson, Bethanie E.; Connell, Carol A.; French, Jonathan L.; Gomez-Reino, Juan; Gruben, David; Kanik, Keith S.; Krishnaswami, Sriram; Pascual-Ramos, Virginia; Wallenstein, Gene; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">970-981</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP-690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy.  Methods. In this 24-wk, double-blind, phase IIb study, patients with active RA (n = 507) were randomized to receive placebo or tofacitinib (20 mg/day, 1 mg twice daily, 3 mg twice daily, 5 mg twice daily, 10 mg twice daily, or 15 mg twice daily).  All patients continued to receive a stable dosage of MTX.  The primary end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at week 12.  Results. At week 12, ACR20 response rates for patients receiving all tofacitinib dosages â¥3 mg twice daily (52.9% for 3 mg twice daily, 50.7% for 5 mg twice daily, 58.1% for 10 mg twice daily, 56.0% for 15 mg twice daily, and 53.8% for 20 mg/day) were significantly (P â¤ 0.05) greater than those for placebo (33.3%).  Improvements were sustained at week 24 for the ACR20, ACR50, and ACR70 responses, scores for the Health Assessment Questionnaire disability index, the 3-variable Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP), and a 3-variable DAS28-CRP of <2.6.  The most common treatment-emergent adverse events occurring in >10% of patients in any tofacitinib group were diarrhea, upper respiratory tract infection, and headache; 21 patients (4.1%) experienced serious adverse events.  Sporadic increases in transaminase levels, increases in cholesterol and serum creatinine levels, and decreases in neutrophil and Hb levels were obsd.  Conclusion. In patients with active RA in whom the response to MTX has been inadequate, the addn. of tofacitinib at a dosage â¥3 mg twice daily showed sustained efficacy and a manageable safety profile over 24 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGQK92I8twr7Vg90H21EOLACvtfcHk0li0dDGFNu_Gkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVygt78%253D&md5=69d74dbdde12d7d1b45fa3d3a413645a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fart.33419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33419%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DFrench%26aufirst%3DJ.%2BL.%26aulast%3DGomez-Reino%26aufirst%3DJ.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DPascual-Ramos%26aufirst%3DV.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DA%2520phase%25202B%2520dose-ranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520tofacitinib%2520%2528CP-690%252C550%2529%2520versus%2520placebo%2520in%2520combination%2520with%2520background%2520methotrexate%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520and%2520inadequate%2520response%2520to%2520methotrexate%2520alone%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D970%26epage%3D981%26doi%3D10.1002%2Fart.33419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Di, Li.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, Yi-An.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duckworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, S.</span><span> </span><span class="NLM_article-title">Mechanistics insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">448</span><span class="refDoi">Â DOI: 10.1016/j.ejmech.2012.06.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.ejmech.2012.06.043" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2012&pages=441-448&author=Li.+Diauthor=C.+Keeferauthor=D.+O.+Scottauthor=T.+Strelevitzauthor=G.+Changauthor=Yi-An.+Biauthor=Y.+Laiauthor=J.+Duckworthauthor=K.+Fennerauthor=M.+Troutmanauthor=S.+Obach&title=Mechanistics+insights+from+comparing+intrinsic+clearance+values+between+human+liver+microsomes+and+hepatocytes+to+guide+drug+design&doi=10.1016%2Fj.ejmech.2012.06.043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.06.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.06.043%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DLi.%26aulast%3DKeefer%26aufirst%3DC.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DStrelevitz%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DG.%26aulast%3DBi%26aufirst%3DYi-An.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DDuckworth%26aufirst%3DJ.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DTroutman%26aufirst%3DM.%26aulast%3DObach%26aufirst%3DS.%26atitle%3DMechanistics%2520insights%2520from%2520comparing%2520intrinsic%2520clearance%2520values%2520between%2520human%2520liver%2520microsomes%2520and%2520hepatocytes%2520to%2520guide%2520drug%2520design%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D57%26spage%3D441%26epage%3D448%26doi%3D10.1016%2Fj.ejmech.2012.06.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chrencik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gormley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommers, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenbrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, T. E.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">â</span> <span class="NLM_lpage">433</span><span class="refDoi">Â DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.-C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lgFN2wDR8V9Fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Andrews, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craik, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. L.</span><span> </span><span class="NLM_article-title">Functional group contributions to drug-receptor interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1648</span><span class="NLM_x">â</span> <span class="NLM_lpage">1657</span><span class="refDoi">Â DOI: 10.1021/jm00378a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00378a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADyaL2cXmt1aju7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1984&pages=1648-1657&author=P.+R.+Andrewsauthor=D.+J.+Craikauthor=J.+L.+Martin&title=Functional+group+contributions+to+drug-receptor+interactions&doi=10.1021%2Fjm00378a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Functional group contributions to drug-receptor interactions</span></div><div class="casAuthors">Andrews, P. R.; Craik, D. J.; Martin, J. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1648-57</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">To overcome the difficulties in estg. the potential bond strengths involved in the interaction between a drug and a reasonable matched receptor, 200 drugs and enzyme inhibitors chosen on the basis of their apparent tight binding to their corresponding receptor sites, were used to provide a statistical est. of the strength of noncovalent bonds assocd. with each functional groups in an av. drug-receptor environment.  Values are presented to det. the goodness of fit of a drug to its receptor by comparing the obsd. binding const. to the av. binding energy calcd. by summing the intrinsic binding energies of the component groups and then subtracting 2 entropy related terms.  Drugs such as diazepam  [439-14-5] that match their receptors well have a measured binding energy exceeding the calcd. av. value, whereas others such as buprenorphine  [52485-79-7] who match their receptor less than the av. have binding energies less the calcd. av. value.  In addn. the binding energies of 3 central nervous system active drugs and representative amino acids within a polypeptide mol. are also given.  General principles for the application of intrinsic binding energies in drug design and structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9jA81gwVWgbVg90H21EOLACvtfcHk0lgFN2wDR8V9Fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmt1aju7g%253D&md5=9b499aee3899f6ffc3ac7e558f28f93f</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm00378a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00378a021%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DP.%2BR.%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26aulast%3DMartin%26aufirst%3DJ.%2BL.%26atitle%3DFunctional%2520group%2520contributions%2520to%2520drug-receptor%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1984%26volume%3D27%26spage%3D1648%26epage%3D1657%26doi%3D10.1021%2Fjm00378a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schonherr, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cernak, T.</span><span> </span><span class="NLM_article-title">Profound methyl effects in drug discovery and a call for new methylation reactions</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">12256</span><span class="NLM_x">â</span> <span class="NLM_lpage">12267</span><span class="refDoi">Â DOI: 10.1002/anie.201303207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1002%2Fanie.201303207" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=12256-12267&author=H.+Schonherrauthor=T.+Cernak&title=Profound+methyl+effects+in+drug+discovery+and+a+call+for+new+methylation+reactions&doi=10.1002%2Fanie.201303207"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201303207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201303207%26sid%3Dliteratum%253Aachs%26aulast%3DSchonherr%26aufirst%3DH.%26aulast%3DCernak%26aufirst%3DT.%26atitle%3DProfound%2520methyl%2520effects%2520in%2520drug%2520discovery%2520and%2520a%2520call%2520for%2520new%2520methylation%2520reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D12256%26epage%3D12267%26doi%3D10.1002%2Fanie.201303207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamohan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geoghegan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knafels, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaila, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span> </span><span class="NLM_article-title">Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system</span> <span class="citation_source-journal">Acta Crystallogr., Sect. F: Struct. Biol. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">840</span><span class="NLM_x">â</span> <span class="NLM_lpage">845</span><span class="refDoi">Â DOI: 10.1107/S2053230X16016356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1107%2FS2053230X16016356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=27827355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWmt7zI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=840-845&author=N.+Caspersauthor=S.+Hanauthor=F.+Rajamohanauthor=L.+Hothauthor=K.+Geogheganauthor=T.+Subashiauthor=J.+Knafelsauthor=M.+Vazquezauthor=N.+Kailaauthor=C.+Croninauthor=E.+Johnsonauthor=R.+Kurumbail&title=Development+of+a+high-throughput+crystal+structure-determination+platform+for+JAK1+using+a+novel+metal-chelator+soaking+system&doi=10.1107%2FS2053230X16016356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system</span></div><div class="casAuthors">Caspers, Nicole L.; Han, Seungil; Rajamohan, Francis; Hoth, Lise R.; Geoghegan, Kieran F.; Subashi, Timothy A.; Vazquez, Michael L.; Kaila, Neelu; Cronin, Ciaran N.; Johnson, Eric; Kurumbail, Ravi G.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">840-845</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Crystals of phosphorylated JAK1 kinase domain were initially generated in complex with nucleotide (ADP) and magnesium.  The tightly bound Mg2+-ADP at the ATP-binding site proved recalcitrant to ligand displacement.  Addn. of a molar excess of EDTA helped to dislodge the divalent metal ion, promoting the release of ADP and allowing facile exchange with ATP-competitive small-mol. ligands.  Many kinases require the presence of a stabilizing ligand in the ATP site for crystn.  This procedure could be useful for developing co-crystn. systems with an exchangeable ligand to enable structure-based drug design of other protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1j6dvXhIlZbVg90H21EOLACvtfcHk0lgkJn9MEzPATQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWmt7zI&md5=b4c15c4bc3deb1e54710882a70607ec8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1107%2FS2053230X16016356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X16016356%26sid%3Dliteratum%253Aachs%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DRajamohan%26aufirst%3DF.%26aulast%3DHoth%26aufirst%3DL.%26aulast%3DGeoghegan%26aufirst%3DK.%26aulast%3DSubashi%26aufirst%3DT.%26aulast%3DKnafels%26aufirst%3DJ.%26aulast%3DVazquez%26aufirst%3DM.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DCronin%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DKurumbail%26aufirst%3DR.%26atitle%3DDevelopment%2520of%2520a%2520high-throughput%2520crystal%2520structure-determination%2520platform%2520for%2520JAK1%2520using%2520a%2520novel%2520metal-chelator%2520soaking%2520system%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2016%26volume%3D72%26spage%3D840%26epage%3D845%26doi%3D10.1107%2FS2053230X16016356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">232</span><span class="refDoi">Â DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+The+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0lh_ZvWjjBTgsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520The%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaines, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile-Woo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span> </span><span class="NLM_article-title">Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">â</span> <span class="NLM_lpage">4785</span><span class="refDoi">Â DOI: 10.1021/jm4004895</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=P.+Bir+Kohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroxyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2&doi=10.1021%2Fjm4004895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Hurley, Christopher A.; Ward, Stuart I.; Bergeron, Philippe; Barrett, Kathy; Balazs, Mercedesz; Blair, Wade S.; Bull, Richard; Chakravarty, Paroma; Chang, Christine; Crackett, Peter; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ellwood, Charles; Gaines, Simon; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Gribling, Peter; Hamman, Chris; Harstad, Eric; Hewitt, Peter; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Labadie, Sharada; Lee, Wyne P.; Liao, Jiangpeng; Liimatta, Marya; Mendonca, Rohan; Narukulla, Raman; Pulk, Rebecca; Reeve, Austin; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; van Abbema, Anne; Aliagas, Ignacio; Avitabile-Woo, Barbara; Xiao, Yisong; Yang, Jing; Kulagowski, Janusz J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4764-4785</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors.  X-ray structures of a C-2 hydroxyethyl analog in complex with both JAK1 and JAK2 revealed differential ligand/protein interactions between the two isoforms and offered an explanation for the obsd. selectivity.  Anal. of historical data from related mols. was used to develop a set of physicochem. compd. design parameters to impart desirable properties such as acceptable membrane permeability, potent whole blood activity, and a high degree of metabolic stability.  This work culminated in the identification of a highly JAK1 selective compd. (31) exhibiting favorable oral bioavailability across a range of preclin. species and robust efficacy in a rat CIA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP0DlLtJCYq7Vg90H21EOLACvtfcHk0lh_ZvWjjBTgsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D&md5=0b0d1950adebf325cc434344f57ca139</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroxyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785%26doi%3D10.1021%2Fjm4004895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupardus, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span> </span><span class="NLM_article-title">Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7627</span><span class="NLM_x">â</span> <span class="NLM_lpage">7633</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.bmcl.2012.10.008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7627-7633&author=S.+Labadieauthor=P.+S.+Dragovichauthor=K.+Barrettauthor=W.+S.+Blairauthor=P.+Bergeronauthor=C.+Changauthor=G.+Deshmukhauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=C.+A.+Hurleyauthor=A.+Johnsonauthor=J.+R.+Kennyauthor=P.+Bir+Kohliauthor=J.+J.+Kulagowskiauthor=M.+Liimattaauthor=P.+L.+Lupardusauthor=R.+Mendoncaauthor=J.+M.+Murrayauthor=R.+Pulkauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+Wardauthor=M.+Zak&title=Structure-based+discovery+of+C-2+substituted+imidazo-pyrrolopyridine+JAK1+inhibitors+with+improved+selectivity+over+JAK2&doi=10.1016%2Fj.bmcl.2012.10.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLupardus%26aufirst%3DP.%2BL.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%26aulast%3DZak%26aufirst%3DM.%26atitle%3DStructure-based%2520discovery%2520of%2520C-2%2520substituted%2520imidazo-pyrrolopyridine%2520JAK1%2520inhibitors%2520with%2520improved%2520selectivity%2520over%2520JAK2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7627%26epage%3D7633%26doi%3D10.1016%2Fj.bmcl.2012.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vasbinder, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alimzhanov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebernitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deegan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huszar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawatkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawatkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbacher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steuber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinda, M.</span><span> </span><span class="NLM_article-title">Identification of azabenzimidazoles as potent JAK1 selective inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">â</span> <span class="NLM_lpage">67</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.bmcl.2015.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=26614408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFagsLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=60-67&author=M.+M.+Vasbinderauthor=M.+Alimzhanovauthor=M.+Augustinauthor=G.+Bebernitzauthor=K.+Bellauthor=C.+Chuaquiauthor=T.+Deeganauthor=A.+D.+Fergusonauthor=K.+Goodwinauthor=D.+Huszarauthor=A.+Kawatkarauthor=S.+Kawatkarauthor=J.+Readauthor=J.+Shiauthor=S.+Steinbacherauthor=H.+Steuberauthor=Q.+Suauthor=D.+Toaderauthor=H.+Wangauthor=R.+Woessnerauthor=A.+Wuauthor=M.+Yeauthor=M.+Zinda&title=Identification+of+azabenzimidazoles+as+potent+JAK1+selective+inhibitors&doi=10.1016%2Fj.bmcl.2015.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of azabenzimidazoles as potent JAK1 selective inhibitors</span></div><div class="casAuthors">Vasbinder, Melissa M.; Alimzhanov, Marat; Augustin, Martin; Bebernitz, Geraldine; Bell, Kirsten; Chuaqui, Claudio; Deegan, Tracy; Ferguson, Andrew D.; Goodwin, Kelly; Huszar, Dennis; Kawatkar, Aarti; Kawatkar, Sameer; Read, Jon; Shi, Jie; Steinbacher, Stefan; Steuber, Holger; Su, Qibin; Toader, Dorin; Wang, Haixia; Woessner, Richard; Wu, Allan; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-67</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have identified a class of azabenzimidazoles as potent and selective JAK1 inhibitors.  Investigations into the SAR are presented along with the structural features required to achieve selectivity for JAK1 vs. other JAK family members.  An example from the series demonstrated highly selective inhibition of JAK1 vs. JAK2 and JAK3, along with inhibition of pSTAT3 in vivo, enabling it to serve as a JAK1 selective tool compd. to further probe the biol. of JAK1 selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQjKE058gZrVg90H21EOLACvtfcHk0lh11mV1yLAHGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFagsLrL&md5=49f2cc63e15dcdf539fb7195a9c6224a</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DVasbinder%26aufirst%3DM.%2BM.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DDeegan%26aufirst%3DT.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGoodwin%26aufirst%3DK.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DKawatkar%26aufirst%3DA.%26aulast%3DKawatkar%26aufirst%3DS.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSteuber%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520azabenzimidazoles%2520as%2520potent%2520JAK1%2520selective%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D60%26epage%3D67%26doi%3D10.1016%2Fj.bmcl.2015.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Simov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elwood, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibeau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunaydin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraybill, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span> </span><span class="NLM_article-title">Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1803</span><span class="NLM_x">â</span> <span class="NLM_lpage">1808</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2Fj.bmcl.2016.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=26927423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt12mtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1803-1808&author=V.+Simovauthor=S.+V.+Deshmukhauthor=C.+J.+Dinsmoreauthor=F.+Elwoodauthor=R.+B.+Fernandezauthor=Y.+Garciaauthor=C.+Gibeauauthor=H.+Gunaydinauthor=J.+Jungauthor=J.+D.+Katzauthor=B.+Kraybillauthor=B.+Lapointeauthor=S.+B.+Patelauthor=T.+Siuauthor=H.+Suauthor=J.+R.+Young&title=Structure-based+design+and+development+of+%28benz%29imidazole+pyridones+as+JAK1-selective+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2016.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors</span></div><div class="casAuthors">Simov, Vladimir; Deshmukh, Sujal V.; Dinsmore, Christopher J.; Elwood, Fiona; Fernandez, Rafael B.; Garcia, Yudith; Gibeau, Craig; Gunaydin, Hakan; Jung, Joon; Katz, Jason D.; Kraybill, Brian; Lapointe, Blair; Patel, Sangita B.; Siu, Tony; Su, Hua; Young, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1803-1808</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mammalian Janus Kinases (JAK1, JAK2, JAK3 and TYK2) are intracellular, nonreceptor tyrosine kinases whose activities have been assocd. in the literature and the clinic with a variety of hyperproliferative diseases and immunol. disorders.  At the onset of the program, it was hypothesized that a JAK1 selective compd. over JAK2 could lead to an improved therapeutic index relative to marketed nonselective JAK inhibitors by avoiding the clin. AEs, such as anemia, presumably assocd. with JAK2 inhibition.  During the course of the JAK1 program, a no. of diverse chem. scaffolds were identified from both uHTS campaigns and de novo scaffold design.  As part of this effort, a (benz)imidazole scaffold evolved via a scaffold-hopping exercise from a mature chem. series.  Concurrent crystallog.-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeRwubYziKxrVg90H21EOLACvtfcHk0li_jYGvlQzGGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt12mtLo%253D&md5=f863ad973f0f86993bb7f796821b5059</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DSimov%26aufirst%3DV.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DElwood%26aufirst%3DF.%26aulast%3DFernandez%26aufirst%3DR.%2BB.%26aulast%3DGarcia%26aufirst%3DY.%26aulast%3DGibeau%26aufirst%3DC.%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DKraybill%26aufirst%3DB.%26aulast%3DLapointe%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DSiu%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26atitle%3DStructure-based%2520design%2520and%2520development%2520of%2520%2528benz%2529imidazole%2520pyridones%2520as%2520JAK1-selective%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1803%26epage%3D1808%26doi%3D10.1016%2Fj.bmcl.2016.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Allen, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span> </span><span class="NLM_article-title">Research applications of the Cambridge Structural Database (CSD)</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">â</span> <span class="NLM_lpage">475</span><span class="refDoi">Â DOI: 10.1039/b309040j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1039%2Fb309040j" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=463-475&author=F.+H.+Allenauthor=R.+Taylor&title=Research+applications+of+the+Cambridge+Structural+Database+%28CSD%29&doi=10.1039%2Fb309040j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1039%2Fb309040j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb309040j%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DF.%2BH.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DResearch%2520applications%2520of%2520the%2520Cambridge%2520Structural%2520Database%2520%2528CSD%2529%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2004%26volume%3D33%26spage%3D463%26epage%3D475%26doi%3D10.1039%2Fb309040j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26"><span><span> </span><span class="NLM_article-title">CCDC Website database</span>: <a href="http://www.ccdc.cam.ac.uk/free_services/website/" class="extLink">http://www.ccdc.cam.ac.uk/free_services/website/</a> (acccessed December 9, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CCDC+Website+database%3A+http%3A%2F%2Fwww.ccdc.cam.ac.uk%2Ffree_services%2Fwebsite%2F+%28acccessed+December+9%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DCCDC%2520Website%2520database" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">24</span><span class="refDoi">Â DOI: 10.1021/ci7002494</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci7002494" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksV2isA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=1-24&author=K.+A.+Brameldauthor=B.+Kuhnauthor=D.+C.+Reuterauthor=M.+Stahl&title=Small+molecule+conformational+preferences+derived+from+crystal+structure+data.+A+medicinal+chemistry+focused+analysis&doi=10.1021%2Fci7002494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule conformational preferences derived from crystal structure data. a medicinal chemistry focused analysis</span></div><div class="casAuthors">Brameld, Ken A.; Kuhn, Bernd; Reuter, Deborah C.; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Based on torsion angle distributions of frequently occurring substructures, conformation preferences of druglike mols. are presented, accompanied by a review of the relevant literature.  First, the relevance of the Cambridge Structural Database (CSD) for drug design is demonstrated by comparing substructures present in compds. entering clin. trials with those found in the CSD and protein-bound ligands in the Protein Data Bank (PDB).  Next, we briefly highlight preferred conformations of elementary acyclic systems, followed by a discussion of sulfonamide conformations.  Due to their central role in medicinal chem., we discuss properties of aryl ring substituents in depth, including biaryl systems and systems of two aryl rings connected by two acyclic bonds.  For a subset of torsion motifs, we also compare torsion angle histograms derived from CSD structures with those derived from ligands in the PDB.  Furthermore, selected properties of some six- and seven-membered ring systems are discussed.  The article closes with a section on attractive sulfur-oxygen contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBrdvMrRvKirVg90H21EOLACvtfcHk0lgRjUnjnrnVMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksV2isA%253D%253D&md5=289969338dcb94a145ce736d19d05cf4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fci7002494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci7002494%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DReuter%26aufirst%3DD.%2BC.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DSmall%2520molecule%2520conformational%2520preferences%2520derived%2520from%2520crystal%2520structure%2520data.%2520A%2520medicinal%2520chemistry%2520focused%2520analysis%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26spage%3D1%26epage%3D24%26doi%3D10.1021%2Fci7002494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">vanAbbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkowycz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span> </span><span class="NLM_article-title">Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5901</span><span class="NLM_x">â</span> <span class="NLM_lpage">5921</span><span class="refDoi">Â DOI: 10.1021/jm300438j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300438j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5901-5921&author=J.+J.+Kulagowskiauthor=W.+Blairauthor=R.+J.+Bullauthor=C.+Changauthor=G.+Deshmukhauthor=H.+J.+Dykeauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=T.+K.+Harrisonauthor=P.+R.+Hewittauthor=M.+Liimattaauthor=C.+A.+Hurleyauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=K.+P.+Birauthor=R.+J.+Maxeyauthor=R.+Mendoncaauthor=K.+Mortaraauthor=J.+Murrayauthor=R.+Narukullaauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+vanAbbemaauthor=S.+I.+Wardauthor=B.+Waszkowyczauthor=M.+Zak&title=Identification+of+imidazo-pyrrolopyridines+as+novel+and+potent+JAK1+inhibitors&doi=10.1021%2Fjm300438j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors</span></div><div class="casAuthors">Kulagowski, Janusz J.; Blair, Wade; Bull, Richard J.; Chang, Christine; Deshmukh, Gauri; Dyke, Hazel J.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Harrison, Trevor K.; Hewitt, Peter R.; Liimatta, Marya; Hurley, Christopher A.; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Bir Kohli, Pawan; Maxey, Robert J.; Mendonca, Rohan; Mortara, Kyle; Murray, Jeremy; Narukulla, Raman; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Waszkowycz, Bohdan; Zak, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5901-5921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), by specific targeting of the JAK1 pathway.  Examn. of the preferred binding conformation of clin. effective, pan-JAK inhibitor 1 led to identification of a novel, tricyclic hinge binding scaffold 3.  Exploration of SAR through a series of cycloamino and cycloalkylamino analogs demonstrated this template to be highly tolerant of substitution, with a predisposition to moderate selectivity for the JAK1 isoform over JAK2.  This study culminated in the identification of subnanomolar JAK1 inhibitors such as 22 and 49, having excellent cell potency, good rat pharmacokinetic characteristics, and excellent kinase selectivity.  Detn. of the binding modes of the series in JAK1 and JAK2 by X-ray crystallog. supported the design of analogs to enhance affinity and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpamrk0bG1MK7Vg90H21EOLACvtfcHk0lgRjUnjnrnVMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D&md5=d91bc0e24abf14adcf44caf61e3e879f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300438j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300438j%26sid%3Dliteratum%253Aachs%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDyke%26aufirst%3DH.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHarrison%26aufirst%3DT.%2BK.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DBir%26aufirst%3DK.%2BP.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DvanAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DZak%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520imidazo-pyrrolopyridines%2520as%2520novel%2520and%2520potent%2520JAK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5901%26epage%3D5921%26doi%3D10.1021%2Fjm300438j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="note"><p class="first last">PetaChem, LLC, 26040 Elena Road, Los Altos Hills, CA 94022. Conformational Analysis: All quantum mechanical calculations were performed with the PetaChem software utilizing the B3LYP density functional with the 6-31G++ basis set in the gas phase. Dihedral scans were performed using a series of constrained optimizations, whereby the specified dihedral angle was kept frozen at a given value, with full optimization of the remaining geometric parameters subject to the given dihedral constraint. Total energies for a given system were then converted into relative energies (kilocalories per mole) for graphical depiction.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="note"><p class="first last">This dihedral value is dependent on the pyramidalization of the nitrogen in small-molecule X-ray structures. Sulfonamide nitrogen atoms are generally depicted as slightly less pyramidal with an N-plane distance between 0.25 and 0.4 Ã but often lower.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, J.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C.</span><span> </span><span class="NLM_article-title">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1505</span><span class="NLM_x">â</span> <span class="NLM_lpage">1515</span><span class="refDoi">Â DOI: 10.1136/ard.2007.076430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1136%2Fard.2007.076430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=18055474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=1505-1515&author=M.+Hegenauthor=J.+Keithauthor=M.+Collinsauthor=C.+Nickerson-Nutter&title=Utility+of+animal+models+for+identification+of+potential+therapeutics+for+rheumatoid+arthritis&doi=10.1136%2Fard.2007.076430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span></div><div class="casAuthors">Hegen, M.; Keith, J. C., Jr.; Collins, M.; Nickerson-Nutter, C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1505-1515</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Animal models of rheumatoid arthritis (RA) are widely used for testing potential new therapies for RA.  However, the question of which animal model is most predictive of therapeutic efficacy in human RA commonly arises in data evaluation.  A retrospective review of the animal models used to evaluate approved, pending RA therapies, and compds. that were discontinued during phase II or III clin. trials found that the three most commonly used models were adjuvant-induced arthritis (AIA) in rats and collagen-induced arthritis (CIA) in rats and mice.  Limited data were found for more recently developed genetically modified animal models.  Examn. of the efficacy of various compds. in these animal models revealed that a compd.'s therapeutic efficacy, rather than prophylactic efficacy, in AIA and CIA models was more predictive of clin. efficacy in human RA than data from either model alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruwo5lHLFB3bVg90H21EOLACvtfcHk0lgRjUnjnrnVMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP&md5=417b41682141901273229dacb8f63283</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1136%2Fard.2007.076430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2007.076430%26sid%3Dliteratum%253Aachs%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DKeith%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%26atitle%3DUtility%2520of%2520animal%2520models%2520for%2520identification%2520of%2520potential%2520therapeutics%2520for%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2008%26volume%3D67%26spage%3D1505%26epage%3D1515%26doi%3D10.1136%2Fard.2007.076430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span> </span><span class="NLM_article-title">Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">â</span> <span class="NLM_lpage">173</span><span class="refDoi">Â DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+clinical+translation+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+in+rheumatoid+arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of â¼100 nM.  Tofacitinib potency (ED50) in clin. studies was â¼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of â¼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within â¼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0lh7F1fEkIeNIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520clinical%2520translation%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Vanhoutte, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Aa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">vanât Klooster, G.</span><span> </span><span class="NLM_article-title">Selective JAK1 inhibition in the treatment of rheumatoid arthritis: Proof of concept with GLPG0634</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">2489</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=2489&author=F.+Vanhoutteauthor=M.+Mazurauthor=A.+Van+der+Aaauthor=P.+Wigerinckauthor=G.+van%E2%80%99t+Klooster&title=Selective+JAK1+inhibition+in+the+treatment+of+rheumatoid+arthritis%3A+Proof+of+concept+with+GLPG0634"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DMazur%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3Dvan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DSelective%2520JAK1%2520inhibition%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%253A%2520Proof%2520of%2520concept%2520with%2520GLPG0634%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D62%26spage%3D2489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Patil, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonde, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kekan, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathe, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, A.</span><span> </span><span class="NLM_article-title">An Improved and Efficient process for the preparation of tofacitinib citrate</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1714</span><span class="NLM_x">â</span> <span class="NLM_lpage">1720</span><span class="refDoi">Â DOI: 10.1021/op500274j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op500274j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=1714-1720&author=Y.+S.+Patilauthor=N.+L.+Bondeauthor=A.+S.+Kekanauthor=D.+G.+Satheauthor=A.+Das&title=An+Improved+and+Efficient+process+for+the+preparation+of+tofacitinib+citrate&doi=10.1021%2Fop500274j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fop500274j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop500274j%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DY.%2BS.%26aulast%3DBonde%26aufirst%3DN.%2BL.%26aulast%3DKekan%26aufirst%3DA.%2BS.%26aulast%3DSathe%26aufirst%3DD.%2BG.%26aulast%3DDas%26aufirst%3DA.%26atitle%3DAn%2520Improved%2520and%2520Efficient%2520process%2520for%2520the%2520preparation%2520of%2520tofacitinib%2520citrate%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D1714%26epage%3D1720%26doi%3D10.1021%2Fop500274j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Montero, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewynter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agoh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaunay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbach, J.-L.</span><span> </span><span class="NLM_article-title">Selective synthesis of sulfonylureas and carboxysulfamides. A novel route to oxazolidinones</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3091</span><span class="NLM_x">â</span> <span class="NLM_lpage">3094</span><span class="refDoi">Â DOI: 10.1016/S0040-4039(00)88103-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1016%2FS0040-4039%2800%2988103-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1983&pages=3091-3094&author=J.-L.+Monteroauthor=G.+Dewynterauthor=B.+Agohauthor=B.+Delaunayauthor=J.-L.+Imbach&title=Selective+synthesis+of+sulfonylureas+and+carboxysulfamides.+A+novel+route+to+oxazolidinones&doi=10.1016%2FS0040-4039%2800%2988103-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2988103-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252988103-4%26sid%3Dliteratum%253Aachs%26aulast%3DMontero%26aufirst%3DJ.-L.%26aulast%3DDewynter%26aufirst%3DG.%26aulast%3DAgoh%26aufirst%3DB.%26aulast%3DDelaunay%26aufirst%3DB.%26aulast%3DImbach%26aufirst%3DJ.-L.%26atitle%3DSelective%2520synthesis%2520of%2520sulfonylureas%2520and%2520carboxysulfamides.%2520A%2520novel%2520route%2520to%2520oxazolidinones%26jtitle%3DTetrahedron%2520Lett.%26date%3D1983%26volume%3D24%26spage%3D3091%26epage%3D3094%26doi%3D10.1016%2FS0040-4039%2800%2988103-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Borghese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoine, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hoeck, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mockel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merschaert, A.</span><span> </span><span class="NLM_article-title">Mild and safer preparative method for nonsymmetrical sulfamides via N-sulfamoyloxazolidinone derivatives: Electronic effects affect the transsulfamoylation reactivity</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">770</span><span class="NLM_x">â</span> <span class="NLM_lpage">775</span><span class="refDoi">Â DOI: 10.1021/op0600106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op0600106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=1%3ACAS%3A528%3ADC%252BD28XkslyltLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=770-775&author=A.+Borgheseauthor=L.+Antoineauthor=J.+P.+Van+Hoeckauthor=A.+Mockelauthor=A.+Merschaert&title=Mild+and+safer+preparative+method+for+nonsymmetrical+sulfamides+via+N-sulfamoyloxazolidinone+derivatives%3A+Electronic+effects+affect+the+transsulfamoylation+reactivity&doi=10.1021%2Fop0600106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mild and Safer Preparative Method for Nonsymmetrical Sulfamides via N-Sulfamoyloxazolidinone Derivatives: Electronic Effects Affect the Transsulfamoylation Reactivity</span></div><div class="casAuthors">Borghese, A.; Antoine, L.; Van Hoeck, J. P.; Mockel, A.; Merschaert, A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">770-775</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sulfamides (R1R2N-SO2-NR3R4) are traditionally prepd. by using strong electrophilic and hazardous reagents such as N-sulfamoyl chloride, sulfonyl chloride, phosphorus oxychloride, or phosphorus pentachloride.  We report here a safer and more convenient synthetic methodol. for large-scale prepn. of sulfamides using the N-substituted oxazolidin-2-one derivs. 5 as synthetic equiv. of the corrosive and hazardous N-sulfamoyl chloride.  The scope of the use of N-sulfamoyloxazolidinones to prep. nonsym. sulfamides is explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgy3n1IzRZ57Vg90H21EOLACvtfcHk0lh7F1fEkIeNIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkslyltLw%253D&md5=d81a647f8a79a981be7ff53944a825fc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fop0600106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0600106%26sid%3Dliteratum%253Aachs%26aulast%3DBorghese%26aufirst%3DA.%26aulast%3DAntoine%26aufirst%3DL.%26aulast%3DVan%2BHoeck%26aufirst%3DJ.%2BP.%26aulast%3DMockel%26aufirst%3DA.%26aulast%3DMerschaert%26aufirst%3DA.%26atitle%3DMild%2520and%2520safer%2520preparative%2520method%2520for%2520nonsymmetrical%2520sulfamides%2520via%2520N-sulfamoyloxazolidinone%2520derivatives%253A%2520Electronic%2520effects%2520affect%2520the%2520transsulfamoylation%2520reactivity%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2006%26volume%3D10%26spage%3D770%26epage%3D775%26doi%3D10.1021%2Fop0600106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Mickelson, J. W.; Bhattacharya, S. K.; Brown, M. F.; Dorff, P. H.; LaGreca, S. D.; Maguire, R. J.; Cornicelli, J. A.; Brown, D. L.; Jennings, R.; Walker, J. K.; Huff, R. M.</span><span> </span><span class="NLM_article-title">Preparation of Oxadiazole Cyclobutyl Carboxylic Acid Derivatives as S1P Receptor Modulators for Treating Hyperproliferative and Autoimmune diseases</span>. Patent WO200960278 A1, May 14,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+W.+Mickelson&author=S.+K.+Bhattacharya&author=M.+F.+Brown&author=P.+H.+Dorff&author=S.+D.+LaGreca&author=R.+J.+Maguire&author=J.+A.+Cornicelli&author=D.+L.+Brown&author=R.+Jennings&author=J.+K.+Walker&author=R.+M.+Huff&title=Preparation+of+Oxadiazole+Cyclobutyl+Carboxylic+Acid+Derivatives+as+S1P+Receptor+Modulators+for+Treating+Hyperproliferative+and+Autoimmune+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMickelson%26aufirst%3DJ.%2BW.%26atitle%3DPreparation%2520of%2520Oxadiazole%2520Cyclobutyl%2520Carboxylic%2520Acid%2520Derivatives%2520as%2520S1P%2520Receptor%2520Modulators%2520for%2520Treating%2520Hyperproliferative%2520and%2520Autoimmune%2520diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Schmieder, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draelos, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pariser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfield, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieras, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons-Rich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salganik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeva, E.</span><span> </span><span class="NLM_article-title">Efficacy and safety of the Janus Kinase 1 inhibitor PF-04965842 in patients with moderate to severe psoriasis: phase 2, randomized, double-blind, placebo-controlled study</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi">Â DOI: 10.1111/bjd.16004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=10.1111%2Fbjd.16004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;key=28949012" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Schmiederauthor=Z.+Draelosauthor=D.+Pariserauthor=C.+Banfieldauthor=L.+Coxauthor=M.+Hodgeauthor=E.+Kierasauthor=D.+Parsons-Richauthor=S.+Menonauthor=M.+Salganikauthor=K.+Pageauthor=E.+Peeva&title=Efficacy+and+safety+of+the+Janus+Kinase+1+inhibitor+PF-04965842+in+patients+with+moderate+to+severe+psoriasis%3A+phase+2%2C+randomized%2C+double-blind%2C+placebo-controlled+study&doi=10.1111%2Fbjd.16004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fbjd.16004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.16004%26sid%3Dliteratum%253Aachs%26aulast%3DSchmieder%26aufirst%3DG.%26aulast%3DDraelos%26aufirst%3DZ.%26aulast%3DPariser%26aufirst%3DD.%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DL.%26aulast%3DHodge%26aufirst%3DM.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DParsons-Rich%26aufirst%3DD.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DSalganik%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPeeva%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520the%2520Janus%2520Kinase%25201%2520inhibitor%2520PF-04965842%2520in%2520patients%2520with%2520moderate%2520to%2520severe%2520psoriasis%253A%2520phase%25202%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2017%26doi%3D10.1111%2Fbjd.16004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">Compound <b>25</b>, <i><b>N</b></i>-{<i><b>cis</b></i>-3-[Methyl(7<i><b>H</b></i>-pyrrolo[2,3-<i><b>d</b></i>]pyrimidin-4-yl)amino]cyclobutyl}-propane-1-sulfonamide is available through MilliporeSigma (cat. no. PZ0304).</p></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="note"><p class="first last">NaBH<sub>4</sub> is used to minimize oxidative disulfide formation.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BBU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BBU','PDB','6BBU'); return false;">PDB: 6BBU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BBV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BBV','PDB','6BBV'); return false;">PDB: 6BBV</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i99"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01598">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_55582"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01598">10.1021/acs.jmedchem.7b01598</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Inhibition values for JAK3 and TYK2 and permeability measured using RRCK; fraction unbound compared to logâ¯<i>D</i>; kinase selectivity table for <b>25</b>; initial range finding rAIA study with <b>25</b> at doses of 5, 15, and 50 mpk; cytokine inhibition values in HWB for <b>19</b>, <b>25</b>, <b>35</b>, and <b>36</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_001.pdf">jm7b01598_si_001.pdf (1.41 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01598/suppl_file/jm7b01598_si_002.csv">jm7b01598_si_002.csv (2.41 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structure of compound <b>25</b> in JAK1 and JAK2 can be accessed using PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BBU">6BBU</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BBV">6BBV</a>, respectively, in the RCSB Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">www.rcsb.org</a>). Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-3%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01598%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01598" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797e68288da31e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
